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1 Introduction
1.1 Abstract -- English
With the cost of sequencing continuously dropping and the increased availability of se-
quencing technologies the coming years will bring a wealth of sequencing data that will be
tremendously interesting and challenging to analyse and interpret. It is becoming more and
more clear that both the algorithmic approaches as well as the handling of the data itself will
prove challenging and some of the legacy approaches and file formats that were developed
in the wake of the first large-scale sequencing projects (e.g. the human genome sequencing
project) will prove unsuitable or at least inconvenient to use once projects that aim to analyse
sequencing data from thousands of samples become the norm rather than the exception.
In this thesis I will discuss my work in the field of sequencing analysis during my PhD
studies. I will touch upon some of the challenges and problems researchers are facing in the
field today and will present the approaches and solutions I have developed to deal with those
issues. To this end I will present my work in methods development for sequencing analy-
sis in general and specifically in the context of cancer genomics and give examples of the
application of those methods in projects that I have been involved in. My two main contribu-
tions to availablemethods for sequencing analysis are the HTSeq Python Library and the h5vc
R/Bioconductor package (Anders et al., 2014; Pyl et al., 2014). I co-developed the formerwith
Simon Anders and am the lead developer of the latter. Both pieces of software are available
through public repositories, and are well-documented and -maintained.
The projects in which those methods have found application are the HeLa Kyoto sequenc-
ing project (Landry et al., 2013) and a set of three cancer genomics projects involving cohorts
of up to 18 whole genome sequencing (WGS) samples and up to 21 whole exome sequencing
(WES) samples, respectively. I will discuss my methodological contributions to these projects
as well as relevant biological results in Section 5.
1.2 Abstract -- German
Sowohl die Reduktion der Kosten als auch die immens gesteigerte Verfügbarkeit von Se-
quenziertechnik führt zu einem immer größer werdenden Fundus von Sequenzier-Datensät-
zen. Dies ist ein Trend, welcher sich in den kommenden Jahren noch verstärken wird. Die
konsequente Anwendung der verfügbaren Sequenziertechnologien auf vorhandene biologis-
che Probenwird in naher Zukunft eineMenge an Daten produzieren, die in der Geschichte der
Bioinformatik ihresgleichen sucht. Die Handhabung und Analyse dieser Datenmengen stellt
die Bioinformatik vor eine neue Klasse technischer und algorthmischer Probleme, welche mit
den aktuell verfügbaren Werkzeugen und Dateiformaten schwierig zu bewältigen sein wird.
Es ist schon jetzt offensichtlich, dass einige der algorithmischen Herangehensweisen und tra-
ditionellen Dateiformate dieser Aufgabe nicht gewachsen sind.
In einer Zeit, in der die gleichzeitige Analyse tausender sequenzierter Proben mehr und
mehr zur Norm wird, ist es wichtig die verfügbaren Infrastruktur auf diese herannahende
Datenflut vorzubereiten, bevor große, ambitionierte Projekte, wie zumBeispiel die Re-Analyse
sämtlicher Krebs-Proben aus den ICGC und TCGA Konsortien (mehrere 1000 Datensätze), auf
Grund von technischen Problemen ins Stocken geraten.
In meiner Dissertation werde ich meine Tätigkeit im Feld der Sequenzanalyse im Rah-
men meiner Zeit als Doktorand in der Grupper von Dr. Wolfgang Huber diskutieren. Ich
werde einige der Probleme und Herausforderungen besprechen, denen Wissenschaftler in
der Analyse von Sequenzierdaten begegnen undmeine eigenen Lösungsansätze präsentieren.
Ich werde meine Arbeit auf dem Feld der Sequenzanalyse im Allgemeinen diskutieren und im
Speziellen die Entwicklungmeiner methodischen Ansätze im Feld der Krebsforschungmittels
Sequenzanalyse besprechen.
Meine zwei hauptsächlichen Beiträge verfügbarer Methoden zur Sequenzanalyse sind das
HTSeqModul für die Programmiersprache Python und das R/Bioconductor -Paket h5vc (An-
ders et al., 2014; Pyl et al., 2014). An HTSeq habe ich zusammen mit meinem Kollegen Dr. Si-
mon Anders gearbeitet, während ich der alleinige Hauptentwickler von h5vc bin. Beide Tools
sind öffentlich als wohl-dokumentierte und regelmässig aktualisierte open-source Software
verfügbar.
Ich habe sowohl HTSeq als auch h5vc in diversen Sequenzierprojekten zur Anwendung ge-
bracht, darunter ein Projekt zur genomischen Charakterisierung der weit verbreiteten HeLa-
Kyoto Zellline (Landry et al., 2013). Des Weiteren habe ich an drei Krebssequenzierprojekten
mitgewirkt, welche sich mit der genomischen Analyse von Kohorten von bis zu 21 sequen-
zierten Proben beschäftigen. IchwerdemeinemethodologischenBeiträge zu diesen Projekten
sowie relevante biologische Resultate in Abschnitt 5 diskutieren.
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2 Processing sequencing data with HTSeq
HTSeq is a module for processing sequencing data, written for the Python1 programming
language. I co-developed HTSeq with my colleague Simon Anders and our manuscript has
been accepted for publication and is available online as a pre-print (Anders et al., 2014). Fur-
thermore, we provide extensive online documentation2. In the following sections I will give
a brief overview of HTSeq and its functionality and touch upon some of the fundamental
concepts that make this library a valuable tool for genomics researchers. Since the initial
release of HTSeq in 2010 the package has found considerable use in the research commu-
nity with 5000 downloads per month as reported at https://pypi.python.org/pypi/
HTSeq. We have an application note under review in Bioinformatics and the preprint (available
through biorxiv.org3) has already been cited 15 times according to Google Scholar (reported
on 02.09.2014).
2.1 Introduction
Over the last years high-throughput sequencing (HTS) has seen a rapid technological ad-
vance that lead to the development of amultitude of assays based on short-readHTS technolo-
gies. The large quantities and different kinds of data resulting from the application of those
assays necessitated the development of bioinformatics pipelines suitable to tackling the tasks
at hand. For many of the recurring steps in HTS data analysis, like alignment and assembly
of sequencing reads, a wide range of tools have been developed (e.g. Li and Durbin (2009),
Zerbino and Birney (2008), McKenna et al. (2010)). While most of the standard tasks in HTS
analysis can be achieved using those tools, there is still demand for custom scripts in non-
standard pipelines that explore new types of analysis or diverge from the typical approach
to a task. Usually the need for custom scripts arises after the big common steps in an analy-
sis pipeline have been performed and a set of project-specific questions need to be answered.
Other smaller tasks that need to be tackled in a bioinformatics analysis typically are prepro-
cessing steps such as trimming low-quality ends, demultiplexing and removing adapter se-
quence as well as downstream analyses. Typical downstream analyses are the estimation of
transcript abundance in RNA-Seq experiments by counting read alignments overlapping an-
notated features in gene models, the generation of aggregate coverage profiles around fea-
tures of interest (e.g. transcription start site (TSS)) from ChIP-Seq data and a multitude of
other tasks. Although there exists stand-alone solutions for some of those small tasks they are
usually still focused on answering a very specific question and lack flexibility when questions
1https://www.python.org/
2http://www-huber.embl.de/HTSeq/doc/overview.html
3http://biorxiv.org/content/early/2014/08/19/002824
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are different from the standard work-flow. With the current state of the art in bioinformat-
ics analysis of HTS data only the most common and widely used workflows can be performed
without the need to write custom scripts and a lot of the work of bioinformaticians is to write
scripts to glue together the more commonly established steps of an analysis pipeline. HTSeq
facilitates the writing of those scripts and allows for the implementation of analysis pipelines
dealing with HTS data in a variety of formats. It provides parsers for importing a variety of
types of input data in their most common formats (e.g. SAM and BAM import for read align-
ments). HTSeq comes with extensive documentation, including a tutorial that demonstrates
the use of HTSeq’s core classes and discusses several important use cases in detail. The doc-
umentation, as well as HTSeq’s design, is geared towards allowing users with only moderate
Python knowledge to create their own scripts, while shielding more advanced internals, such
as the use of Cython (Behnel et al., 2011) to enhance performance, from the user.
2.2 Streaming processing of sequencing data
A central design paradigm of HTSeq is the processing of data in a streaming fashion which
does not load a whole dataset into memory in order to process it, but rather iterates through
the raw data (usually read alignments) and collects some form of summary information from
them (e.g. the read coverage overlapping a region of interest in the genome). Using this ap-
proach one can handle the vastly increased size of the raw data generated with HTS assays
when compared to previous technologies, e.g. microarrays, which are typically analysed by
loading the raw data (probe intensity values) intomemory and performing the processing and
analysis on the fully loaded raw data. The size of datasets is a problem that is more apparent
in sequencing assays targeting organisms with comparatively large genomes; e.g. sequencing
data from human samples can easily use hundreds of Gigabytes just for storing read align-
ments. Although the ever increasing affordability and availability of compute resources (CPU
power and available RAM) makes it more feasible to work with HTS data in a similar way as
is typically done in microarrays, currently servers with a Terabyte of RAM are the exception
rather than the rule which makes the in-memory analysis of HTS data from larger genomes
challenging. Furthermore, the increases in available compute resources are offset by the in-
creased availability of ever larger sequencing data-sets through increased depth of coverage
and bigger read-lengths.
As mentioned previously most analyses are likely to focus on some form of summary in-
formation of the raw read alignment data, therefore processing usually happens on a per-
alignment or per-read level. HTSeq provides an implementation of iterators for typical HTS
file types (FASTA, BAM, SAM, GTF, VCF, etc.). In this way even large datasets can be processed
using relatively small amounts of memory, since the results of the processing steps are com-
monly much smaller than the raw data. An example is the per-gene count matrix of a human
RNA-Seq sample, which will fit comfortably into the RAM of a modern computer. The under-
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lying raw data, i.e. the read alignments in BAM format, can be many times larger depending
on sequencing depth. This touches upon another important factor, which is that the depth
to which we can feasibly sequence samples is increasing and compensates for increases in
available compute resources, while most types of summary information will not scale with se-
quencing depth; e.g. the coverage of a specific position in the genomewill, for the foreseeable
future, be a number that can be stored as a 32-bit integer (read depths between 0 and  4
billion reads per position). The nucleotide tally approach to HTS analysis which I introduce in
Section 4.1 is an example of using summary information that is (almost) independent of se-
quencing depth to reduce the memory footprint of the analysis that was necessitated by the
inconvenience of working with the raw data in a larger cohort of sequencing samples. Within
the HTSeq framework the iteration through HTS data files is implemented through a set of
two classes for each file type, a data record class (e.g. the VariantCall class for entries to
a VCF file) and a parser class (e.g. the VCF_Reader class, which streams through a VCF file,
returning VariantCall objects for each of the entries). The parser class handles the file and
performs the iteration which yields an object of the associated data record class for each en-
try (e.g. alignment, variant calls, etc.). For BAM files the parser additionally supports random
access by retrieving all alignments overlapping a specified genomic range.
2.3 Storing position specific genomics data – the GenomicArray
An important task in the analysis of HTS data is the collection of data about read align-
ments that overlap specific genomic positions, i.e. loci of interest like gene annotations, vari-
ant calls or viewports in HiC experiments (see Zhao et al. (2006) and Simonis et al. (2006)).
The ability to efficiently store, manipulate and query data associated with genomic position is
one of the central requirements when developing HTS analysis tools. The genomic positions
provide the coordinate system in which most data is expressed and will be interacted with in
HTS analyses, since most of those analyses focus on read alignments and their locations on
the genome or in relation to other loci of interest. HTSeq provides the GenomicArray class,
which implements an associative container that stores values associated with positions in the
genome. A GenomicArray stores these values in a memory-efficient way and implements fast
random read and write access routines, which allow the user to get and set values associated
with genomic positions. A GenomicArray stores a StepVector for each chromosome and
strand of the genome, where a StepVector is a representation of the vector of values asso-
ciated with positions in the chromosome encoded through their two properties position and
value. In this way the StepVector stores the data as a set of steps that are defined by their
respective starting position and value. This approach of storing a vector of values as a run-
length encoding (i.e. a series of steps) performs lossless data compression. The efficiency of
the compression depends on the sparseness and variability of the data; e.g. a StepVector of
values that are different at each of then bases of a chromosomewill be very inefficient to store
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since a total of n steps are needed and will actually use more memory than a simple array of
values would have (n values and n positions compared to only n values). On the other hand,
the coverage vector of a typical RNA-Seq or whole exome sequencing experiment on a human
sample will be 0 for most of the genome (i.e. in the introns and intergenic regions) and only
the 3% of the genome that are actually coding will have values different from 0. Therefore
the step representation of e.g. an RNA-Seq experiment will store each intergenic region or in-
tron as a single pair of numbers, i.e. the starting position and value (0 in this case), irrespective
of the actual length of the intron or intergenic region. For analyses that do not rely on cover-
age but rather onmismatches (such as calling single nucleotide variants) the read-length does
not influence step size but rather the relative sparsity of SNVs and the expected error rate of
the sequencing machine will guarantee that in most samples the mismatches will be sparsely
distributed along the genome. Many of the standard file formats for storing data associated
with genomic position use some form of run-length encoding, e.g. WIG or BED (Kent et al.,
2010) files usually store data in the form of steps of a given (fixed or variable) length.
In conclusion the usage of run-length encoding to store data associated with genomic po-
sition (as implemented in the GenomicArray and StepVector classes provided by HTSeq) can
be expected to yield favourable compression in many use cases and will allow the user to in-
teract with and analyse such data efficiently and fast within the memory of typical modern
desktop computer. In this way the hard to manage raw data (i.e. potentially hundreds of giga-
bytes of read alignments in BAM format) can be processed to a level of summary information
and stored in a GenomicArray which will then be the basis of further analysis.
An example of a task that can be easily accomplished using this technology (streaming
processing of files and storage of the data in a GenomicArray object) is the loading of a set
of gene models from a GTF file to associate some identifying information for each exon of
each gene to the genomic positions overlapping that exon by using a GenomicArray. This
GenomicArray can then be queried with the genomic positons overlapping read alignments
loaded from a BAM file generated in e.g. an RNA-Seq experiment in order to generate a per-
exon count table (see Section 2.5 and Anders andHuber (2010); Anders et al. (2012) for details).
2.4 Implementation and Availability
HTSeq is implemented in Python and uses SWIG and Cython (Beazley (1996), Behnel et al.
(2011)) to interfacewith high-performance C++ code used to implement the StepVector. I im-
plemented the functionality for reading and writing to BAM files by using the pysam4 Python
module. HTSeq is released as open-source software under the GNUGeneral Public Licence and
available from the Huber group’s web-page5 or from the Python Package Index6.
4https://github.com/pysam-developers/pysam
5http://www-huber.embl.de/HTSeq
6https://pypi.python.org/pypi/HTSeq
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2.4.1 The StepVector data-structure
The StepVector is a class implemented in HTSeq that stores a vector of values encoded
as a series of steps which are defined by their starting position and value. Internally the
StepVector is implemented through the use of the map container that is provided by the
C++ standard template library (STL – Becker (2011)). The map container holds key–value pairs
and is typically implemented as a red-black-tree (Bayer, 1972) which is a form of balanced
binary tree that guarantees O(log(n)) access time for random lookups in a tree that holds n
elements. Such a self-balancing binary tree has routines that make sure that the height of the
tree always stays at approximately log(n) when operations that potentially change the tree
topology occur, e.g. insertion or removal of key-value pairs.
A binary tree is a data-structure that is composed of nodes and leafs. While nodes contain
keys, leafs do not contain keys and are essentially place-holders. For a more mathematically
precise definition of a binary trees, have a look at Garnier and Taylor (2009). Every node must
be connected to exactly two child nodes: one left and one right child. The children of a node
can themselves be nodes or leafs whereas leafs do not have children. An example tree is shown
here:
root node k1
inner node k2
leaf leaf
leaf
Nodes are symbolised as circles and leafs are symbolised as squares and the keys associated
with the nodes (k1 and k2 in this case) are shown inside the nodes. The root node is special,
since it does not have a parent node and all tree operations start there.
A sub-tree is defined as all nodes that lie below a specified node, for example in the tree
shown above the sub-tree rooted in the inner node with the key k2 looks like this:
k2
This sub-tree is called the left sub-tree of the root node, since it is rooted in the left child
node of the root. In order for a binary tree to function as a search tree the nodes in the tree
must fit the following criteria:
1. Each node i is associated with a key ki
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2. The keys of all nodes in its left sub-tree must be smaller or equal to ki
3. The keys of all nodes in its right sub-tree must be larger than ki
To find a given key s in a binary search tree we can implement a simple algorithm called
binary search. For this we set the current node c to the root of the tree and then apply the
following steps:
1. If the current node is a leaf the search ends and the key was not found in the tree. If we
want to insert s into the tree we have to replace the leaf we found with a node that has
s as its key.
2. Compare s to the key of the current node c:
s < kc The key must be in the left subtree of the current node, so we set the current node
to the left child of node c
s = kc We have found the key, it is in node c
s > kc The key must be in the right subtree of the current node, so we set the current
node to the right child of node c
3. Go back to step 1
It should be immediately apparent that this means that the lookup of any key s in a binary
search tree is implemented as a traversal of the tree, starting at the root node.
Figure 2.1 illustrates the effects of balancing a binary search tree. The two trees that are
shown are both binary search trees containing the keys from 1 to 9. While the tree in panel
(a) is unbalanced, the tree in panel (b) is balanced. In both trees the path that needs to be
traversed to find the key 7 is marked in colour. From this example it should be immediately
obvious, that balancing a tree reduces the worst-case run-time needed for lookup of a key.
The function of balanced binary search trees in the implementation of the StepVector is
illustrated in Figure 2.2.
For those cases where the data is very variable from position to positon, i.e. the average
step-size is approaching 1, we implement plain vector storage in RAM or in memory-mapped
files, i.e. an on-disk representation of the vector that is accessible in the same way as a vector
stored in RAMwould be. Note that usingmemorymapped files can reduce the speed of a script
drastically, depending on the performance of the storage solution. The choice of back-end
(balanced binary tree, linear array ormemorymappedfile) does not influence the interface for
programmatic access to the data which allows for reusability of algorithms between different
types of HTS data that each require different storage mechanisms.
Using this type of run-length encoding to store a vector as a series of steps is memory
efficient and offers lossless compression if the vector itself has long stretches of identical val-
ues. An example where this compression is very efficient is the storage of a coverage vector
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(a)
1 2 3 4 5 6 7 8 9
(b)
4
2
1 3
8
6
5 7
9
Figure 2.1: Examples of binary search trees. (a) unbalanced binary search tree. (b) balanced binary
search tree. The search path to key 7 is marked in blue. Note the reduced number of steps needed in
the balanced tree.
of an RNA-Seq experiment. Such a coverage vector will have long stretches of value 0 that
are caused by introns and intergenic regions where no reads map. Assuming a human sample
with  3% of the genome being expressed, this means that 97% of the genome will have a
coverage of zero (bar somemis-mapped reads) and will essentially be represented by a couple
of thousand steps, i.e. the introns and intergenic regions.
2.5 Examples of usage
Probably the most widely used application that utilises HTSeq is the htseq-count script
that is part of HTSeq. This script is heavily relied upon by the DESeq and DEXSeq (Anders and
Huber (2010); Anders et al. (2012)) R/Bioconductor packages which are extensively used for
differential expression analysis of RNA-Seq data. The htseq-count script creates a table of
alignment counts per gene or exon froman input SAMor BAMfile and aGTFfile (gene-models)
by finding overlaps between the read alignments stored in the BAM file and the gene-models
defined in the GTFfile. The script uses the two important coding strategies of HTSeq described
earlier, which are the GenomicArray for storing the gene-models in a memory-efficient way
that can be easily queried with the genomic intervals associated with the read alignments and
the iterative processing of the BAM file, since the read alignments can be read in one by one
and their overlaps with gene models can be determined independently from each other. The
HTSeq and Python functions used to implement such types of HTS data analysis pipelines are
extensively documented online7. Listings 1 and 2 show code snippets that are typically used
in creating customHTS data analysis pipelines (e.g. the htseq-count script) and illustrate that
those typical processing steps (reading alignments from a BAM file etc.) can be implemented
with HTSeq in a few lines of relatively easy to read code.
7http://www-huber.embl.de/HTSeq/doc/overview.html
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Key 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Value 0 0 0 0 3 3 3 17 17 19 19 19 19 5 5 5 9 9
7! 17
4! 3
0! 0
13! 5
9! 19 16! 9
Figure 2.2: Example of the storage of a vector of values as a run-length encoding in a binary search
tree. The table shows the value at each position and the binary search tree shown below illustrates the
translation of the vector of values into a set of steps with keys and associated values. Each node in the
tree is shown as a box and the association between the key k and value v is given as k ! v. Note that
the search tree is defined on the keys only whereas the associated values do not have to comply with
the ordering required of a search tree. Through this layout of the tree we enable fast (O(logn)) access
to the value corresponding to any position via binary search. The steps are colour-coded in the table
and the nodes in the tree have colours matching the steps they correspond to.
1 import HTSeq
2 codingSequence = HTSeq.GenomicArray('auto') #Create an empty GenomicArray
3 for record in HTSeq.GFF_Reader("example.gtf"): #go through 'example.gtf'
4 if record.type == "CDS":
5 codingSequence[record.iv] = record.attr["gene_name"]
Listing 1: Example code demonstrating the iterative processing of a GTF file. This code reads entries
fromaGTFfile and stores gene names in the intervals associatedwith coding sequence of the respective
gene using a GenomicArray.
1 import collections
2 geneCounts = collections.defaultdict(int)
3 for read in HTSeq.BAM_Reader("example.bam"):
4 if read.aligned:
5 matchingGenes = set(list(codingSequence[read.iv].steps()))
6 if len(matchingGenes) == 1: #uniquely mapped to one gene
7 geneCounts[matchingGenes[0]] += 1
Listing 2: Example code demonstrating the iterative processing of a BAMfile for the purpose ofmatch-
ing alignments to the coding intervals generated in Listing 1.
The algorithm used for virus integration site detection in the HeLa genome project (de-
scribed in Section 3.2.3) and the similar algorithm used to detect vector integration sites in
samples from a study into retroviral gene therapy (Section 5.1.2), are both examples of soft-
ware that was easy to develop when using HTSeq to implement the algorithms and might
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otherwise have taken considerably more time and effort to complete.
2.6 Summary
HTSeq provides a framework for the rapid prototyping of HTS analysis software and can
considerably ease the interfacing between differentmonolithic tools in a pipeline since it pro-
vides a wider selection of parsers for many of the commonly used data formats. HTSeq is de-
signed to be useable by researchers with only moderate knowledge of Python programming
and implements concepts that are especially useful in the context of HTS data analysis, like
the streaming processing of data and the ability to efficiently store, look-up and modify data
associatedwith genomic locations implemented through the GenomicArray and StepVector
class.
There are other approaches with the goal of achieving functionality comparable to what
HTSeq provides, e.g. the *Ranges infrastructure included in the Bioconductor framework.
This is implemented in set of packages that provide classes that are designed specifically to
represent data associated with (genomic) intervals. One example is the GenomicRanges class
that holds a set of genomic intervals and associated data (Lawrence et al., 2013). Functions for
manipulation and analysis of data represented as *Ranges is provided through a collection of
Bioconductor packages.
TomeHTSeqwas tremendously helpful in the implementation of analysis pipelines for the
biological projects I describe in Sections 3 and 5, where I had to implement custom analysis
software for specific tasks, e.g. the detection of virus integration sites in the HeLa genome
analysis project, which I will describe in the next section.
3 The HeLa Genome Project
In this chapter I will describe my work on the HeLa-Kyoto genome project which was pub-
lished as a shared co-first-authorship between Jonathan Landry and myself (Landry et al.,
2013). Some of the figures and tables are taken from our publication (Landry et al., 2013) or
its supplementary material.
3.1 Introduction
The HeLa cell line is one of the most widely used model cell lines for studying human
cellular and molecular biology and prior to our publication (Landry et al., 2013) no genomic
reference for this cell line had been available to the research community. As a consequence of
this lack of a high-resolution reference, the experimental design and interpretation of results
from assays using HeLa cells was instead performed in the context of the human reference
genome (e.g. GRCh371).
However accurate genomic information is essential to the design of effectivemolecular ge-
netic studies and the ability to interpret the results of such studies. The aim of our study was
to provide such information for a HeLa Kyoto cell line. We performed DNA and RNA sequenc-
ing of a HeLa Kyoto cell line and analysed the data for different types of genomic mutations,
e.g. single nucleotide variants (SNVs), small insertions or deletions (InDels) as well as large
chromosomal aberrations (i.e. deletion, duplications, inversion and translocation events). We
also characterised the expression profile of the cell line including the analysis for allelic ex-
pression in coding mutations (specifically SNVs).
Our results provided the first detailed account of genomic variants in the HeLa genome,
yielding insight into their impact on gene expression and cellular function as well as their ori-
gins. In addition our analysis piloted workflows that can be used by the research community
to regularly characterise the cell lines they are using.
In the following sections I will highlight major findings from our publication as well as
specific methodological contributions that I made to the project. I will focus on the genomics
analyses, since my contribution to the project was mainly concerned with those. For a com-
plete description including allmethods, results and discussions, please refer to the publication
(Landry et al., 2013) and the supporting material.
1http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/
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3.2 Methods
In the methods section I will focus on analysis steps for which I was the main researcher.
The two concrete examples are the estimation of copy number states and the virus integration
site detection. I implemented the pipeline using stand alone tools and custom scripts using
shell scripting, Python scripting and HTSeq as well as R/Bioconductor for the downstream
analysis.
3.2.1 Estimating copy number states
After fully preprocessing the alignments, I computed the depth of coverage in 10-kb bins
along the genome and applied corrections formappability and GC-dependent biases. The cov-
erage calculation was implemented using Python/HTSeq and R/Bioconductor. Themappabil-
ity correction was based on a custommappability track in which a position in the genomewas
calledmappable if and only if a read of length 101nt (the same length of reads as our libraryhad
generated) originating at that position could be uniquely mapped back to its original position
using our alignment pipeline with the exact same parameters as we used to align the DNA-
Seq library from our HeLa cell line. This means that there exists no alignments with the same
score at other positons for a mappable read. For each 10-kb bin I divided the observed read
count by the proportion of mappable positions and discarded all bins where the mappability
was less than 0.5 (i.e. more than 50% of the positions in the bin were not mappable). Fur-
thermore I performed GC-bias correction to correct for GC-dependent changes in sequencing
depth. To this end I calculated for each 10-kb bin the GC-content (the proportion of refer-
ence bases that are G or C) and used a local robust fit (as implemented in the locfit.robust
function within R) of GC-content and read-count per bin. I picked a desired median coverage
of 60 bp and then used the ratio of the fit and that desired coverage as a correction factor by
which to multiply observed coverages per bin based on the respective bins GC-content. The
effect of the GC correction is illustrated in Figure 3.1. This type of adjustment for GC-content
biases in the coverage is based on the assumption, that the copy number state of a region is
independent of its GC-content. In both panels of Figure 3.1 we can observe a banding in the
plots, representing regions of copy number (CN) 2 and 3, respectively. The majority of the
data in those bands covers the full range of observed values for the GC-content (30% – 60%).
We can conclude that indeed the copy number state of a region does not seem to depend on
its GC-content.
To describe the extent of CN aberrations in our HeLa cell line I created a segmentation of
the genome according to integer CN. This track was generated with the R/Bioconductor pack-
age DNACopy (Seshan and Olshen (2006)) followed by mixture model fitting. Since DNACopy
is designed for working on log2-ratios of samples (e.g. log2 cancercontrol ) I transformed our data by
using the following formula: f(x) = log2 xx0 on the GC-adjusted depth-of-coverage data x,where x0 is the median GC-adjusted coverage of a manually curated region of CN 2 on chro-
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(a) (b)
Figure 3.1: GC-bias correction. The panels show the dependency between GC-content and coverage
in 10-kb bins in panel (a) (the fit is shown as a black line) and the effect of GC bias correction in panel
(b).
mosome 4 (see Figure 3.2). On those log2-ratio values I ran the normal DNACopy workflow for
segmentationwith the parameters undo.splits = "sdundo" (remove break points that split
segments which are less than undo.SD standard deviations apart) and undo.SD = 2 (setting
the cut-off for removal of break points to 2 standard deviations). The result was a segmenta-
tion with segments defined by their start, end and average log2-ratio s, from which I calcu-
lated the respective average copy number as 2s+1. Finally I fitted a mixture model ofm = 8
normal distributions with fixed integer means 1; : : : ;m and weights and standard deviations
estimated from the data. The integer copy number of a segment was then determined by a
Bayes classifier that used the mixture component weights as prior probabilities and required
a posterior probability 0:95 for an integer copy number to be assigned.
3.2.2 Mixture model copy number classifier
The mixture model I used to fit integer copy number states to the observed copy number
in the data consists of m = 8 normal distributions with integer means 1; : : : ;m, standard
deviations 1; : : : ; m and weights w1; : : : ; wm. These distributions were fitted to the copy
number estimates c (where ci is the copy number estimate of the i-th segment) which I cal-
culated from the segmented log2-ratios s (where si corresponds to the log2-ratio of the i-th
segment in the segmentation). I defined ci as a function of si (ci = 2  2si) and the mixture
model was then given as:
X  mj=1wj N(j; j)
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Figure 3.2: Overview plot of chromosome 4 of the HeLa Kyoto cell line. Panels are from top to bottom:
Ideogram with cytogenic bands; Large structural variants; 10-kb binned coverage track normalised to
CN scale (segmentation in black; integer copy number shown as yellow dashed lines); Homozygousity
track, dark purple areas indicate loss of heterozygousity (LoH); SNV allele frequency distribution plot,
darker areas containmore SNVs. Note that along thewhole chromosome the SNVs aremostly observed
at AFs around 50% and 100% indicating a diploid heterozygous region.
and each normal distribution corresponds to a copy number state with a mean that equals
the integer copy number I expect for it (e.g. the second normal distribution corresponds to
copy number 2 and has mean 2). The following parameters define the mixture model:
• m – number of components
• j – standard deviation of the j-th mixture component
• wj – weight of the j-th mixture component (proportion of the genome that is in the
corresponding state) – note thatPmj=1wj = 1
I assigned each segment an integer copy number state based on the probability of observ-
ing the copy number estimate ci in each of them distributions by calculating the log-odds for
each possible state for each segment and assigning the CN state with the highest probability.
Using;(x) as the probability density function of a normal distributionwithmean and
standard deviation  and using k to represent integer CN states, I defined the probability of a
segment with mean coverage value ci in each of them normal distributions in the following
way:
Pr(cijk) = k;k(ci)
The probability of being in state k given the value ci can be calculates using the Bayes-
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Figure 3.3: Example illustration of the log-odds based CN assignment process. In this plot I show the
log-odds ratios of two distributions (centered around 1 and 2 respectively – marked by vertical solid
lines). The color encodes whether a copy number estimate (x-axis) would be assigned a specific CN
state (black) or not (red). There is a region of overlap between the two distributions where both are
marked red and therefore datapoints falling into that region ([1:3; 1:7] – marked by vertical dashed
lines) can not be assigned an integer copy number value because there is not enough confidence in
either of the two possible states. Segments with estimated copy number in [1:3; 1:7]would be assigned
the value NA.
Theorem:
Pr(kjci) = Pr(cijk)  Pr(k)
Pr(ci)
Here Pr(ci) can be omitted since it is constant. Using the weightsw of the mixture model
fit as the prior-probability, I arrived at Pr(kjci) = wk  k;k(ci). I assessed the confidence of
the highest probability call by its log-odds ratio with the sum of probabilities in all other CN
states, which I used as an estimate of the probability of segment i not to be in state k:
Pr(:kjci) =  Pr(kjci) + mj=1Pr(jjci)
logodds(kjci) = log10( Pr(kjci)Pr(:kjci))
I accepted the highest probability CN as the state of segment i if the log-odds ratio was
higher than 1:27, which corresponds to a confidence in the call of at least 0:95; if the log-odds
were lower than this cut-off I assigned NA as the CN state. The process is illustrated in Figure
3.3.
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Figure 3.4: Circos (Krzywinski et al., 2009) plot showing an overview of the genome of a HeLa-Kyoto
cell line. CN, SNV-density, LoH regions and structural variants are shown. Note the chromothripsis-like
pattern on chromosome 11 (see Figure 3.6 for a detailed view of the region). This is the same as panel
A of Figure 1 in our paper – Landry et al. (2013)
3.2.3 Finding virus integration sites
Since the HeLa cell line is based on an human papillomavirus (HPV)-induced ovarian can-
cer (Macville et al., 1999) I mapped potential virus integration sites in the HeLa genome by
aligning the reads of our HeLa library against a composite genome containing the chrom-
somes 1 to 22, X, Y and MT of the human reference (GRCh37) as well as a set of known virus
genomes obtained from the NCBI Entrez viral genomes project2 (Bao et al. (2004)). The algo-
rithm used to find the virus integration sites is described in Section 5.1.2 since I used the same
software that I developed for finding vector integration sites in gene therapy samples. The
resulting list of viral integration sites is shown in Table 3.1.
3.3 Results
3.3.1 Genomic Landscape
We used short-tandem repeat genotyping to confirm the identity of the analysed cell line,
which had a correspondence of more than 80% of the tested markers. This confirmed the
2https://www.ncbi.nlm.nih.gov/genomes/GenomesHome.cgi?taxid=10239
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Chromosome Start End Strand Read support Viral species
1 10002 10118 + 12
Human herpesvirus 6B
Equid herpesvirus 2
Human herpesvirus 6A
Human herpesvirus 7
Gallid herpesvirus 2
Gallid herpesvirus 3
Meleagrid herpesvirus 1
Ovine herpesvirus 2
Cyprinid herpesvirus 3
Saimiriine herpesvirus 1
8 128189764 128190032 - 552 Human papillomavirus 18
and 32 (Alphapapillomavirus
7 and 1)
8 128192272 128192499 + 23 Human papillomavirus 18
(Alphapapillomavirus 7)8 128193167 128193435 + 1748 128200419 128200690 + 163
12 49659073 49659136 - 6 Human herpesvirs 5
12 95467 95567 + 9
Human herpesvirus 6B
Human herpesvirus 6A
Human herpesvirus 7
Gallid herpesvirus 2
Gallid herpesvirus 3
Meleagrid herpesvirus 1
Cyprinid herpesvirus 3
13 19648667 19648780 + 7 Taterapox virus13 19649043 19649209 - 8
X 155185203 155185362 - 8
Human herpesvirus 6B
Equid herpesvirus 2
Human herpesvirus 6A
Human herpesvirus 7
Gallid herpesvirus 2
Gallid herpesvirus 3
Meleagrid herpesvirus 1
Ovine herpesvirus 2
Table 3.1: Table showing an overview of potential virus integration sites that were extracted from the
read alignment to a compound genome of human and virus references.
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identity of the cell line as HeLa and we went on to characterise the genome through read
alignment and subsequent analysis. Of the  1 billion reads of length 101 nt that were pro-
duced in the DNA sequencing assay 86% were successfully aligned to the human reference
genome (GRCh37). Our characterisation of the genomic landscape of the HeLa-Kyoto cell line
was focussed on defining tracks for CN, SNVs, InDels as well as large structural aberrations
(Figure 3.4). These data tracks were intended to provide the research community with tools
to improve their experimental designs and interpretations of results from studies using HeLa-
Kyoto cells. We demonstrated the further interpretation of the data by defining regions of
likely chromothripsis as well as regions of likely LoH which represent important facts that
can inform the design and interpretation of experiments. I will give details on some of those
genomic characterisations in the following sections.
3.3.1.1 Copy Number
The copy number track was defined in 10 kilobase bins along the genome. It revealed
a mostly triploid genome exhibiting a topology that is markedly different from the normal
state of a human genome (i.e. diploid autosomes plus sex chromosomes). The distribution
of copy number calls is shown in Figure 3.5. Additionally, the pattern of copy number calls
contained regions that exhibit patterns commonly associated with catastrophic chromosome
shattering events (so called Chromothripsis events – Stephens et al. (2011)) on chromosome
11, a phenomenon that had previously not been described in HeLa cells. More specifically,
we observed a pattern of many copy number changes between few copy number states con-
centrated in a relatively small region on chromosome 11 (illustrated in Figure 3.6), which is
indicative of a Chromothripsis event. In total we identified potential Chromothripsis regions
on chromosomes 5, 11, 19 and X, with 11 being the most obvious candiate.
3.3.1.2 Variant Calls
We produced calls of SNVs and InDels as well as large structural aberrations. In total we
called 1750535 SNVs and 18411 InDels as homozygous in HeLa. 97:3% of the SNV calls and
95:3% of the InDel calls had been previously reported in The Single Nucleotide Polymorphism
Database (dbSNP) (release 137). A similar overlap was observed with the data from the 1000
Genomes Project (Abecasis et al. (2012)) at 96:9% and 82:6%, respectively (see also Figure 3.7).
For the purpose of generating a HeLa reference sequence we focused on high-confidence vari-
ant calls since we wanted to have good confidence that those will be present in all cells and
are therefore likely to substantially influence genomic assays overlapping their positions. A
total of 53121 previously unreported variant calls remained, which were either specific to the
donor from whose cervical cancer the HeLa cell line is derived, somatic mutations of the tu-
mour, or they were acquired during the transformation and propagation of the cell line in
culture. Since there are no samples from the original cancerous and healthy tissue available
we could not distinguish those variants further into the three possible classes of origin.
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Figure 3.5: Histogram of the distribution of copy number calls amongst the 10-kb bins along the
genome of a HeLa-Kyoto cell line. Colour encodes copy number and matches the color coding used
in Figure 3.4. Note that the majority of bins are called in the triploid state.
Figure 3.6: Overview plot of chromosome 11 of the HeLa Kyoto cell line. See Figure 3.2 for explanations
of the tracks shown. The copy number profile shows patterns typical for chromothripsis events, i.e.
many changes of copy number between relatively few states (CN 2, 3, and 4 in this case).
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Figure 3.7: Overview of the distribution of variant calls (SNVs and small InDels) in HeLa. Stratified by
overlap with previously reported variants in dbSNP and the 1000 Genomes Project data.
In addition to those homozygous variants we called a substantial amount of heterozygous
SNVs and InDels as well. A total of 3026053 heterozygous SNVs and 397969 heterozygous
InDels were called with high overlaps with dbSNP and the 1000 Genomes Project data. There
were 83:1% of heterozygous SNV and 91:8% of heterozygous InDel calls in dbSNP and among
those 91%of SNVs and 44:9%of the InDels were also present in the 1000 Genomes Project data.
The set of HeLa-specific SNVs which were selected to be integrated as part of the HeLa
genome was subjected to an additional quality control step to reduce the number of false-
positives. For this purpose I performed an analysis of themutation signatures (see Alexandrov
et al. (2013)) stratified by the local coverage of the regions. After deciding on the subset of
variant calls with local coverage between 10 and 60 as the high-confidence set we had about
60% (336006 out of 559384) of HeLa specific SNV calls left. Note that this number includes
both homozygous as well as heterozygous SNV calls.
3.3.1.3 Structural Variant Calling – Large Structural Variants (> 50 bp)
We called large structural variants (SVs) (more than 50 base-pairs in length) using the
two tools DELLY (Rausch et al. (2012)) and PINDEL (Ye et al. (2009)). Both tools use aberrantly
mapping read pairs and split reads to detect variants and we used DELLY to call deletions, in-
version, tandem duplications and translocations and PINDEL to call inversions and tandem
duplications. Two sequencing libraries were used: one paired-end library with a target in-
sert size of 300 bp and one mate-pair library with a target insert size of 4 kb. Both libraries
produced pairs of reads from the ends of a fragment of DNA and differ in the average size of
sequenced fragment. In this way the paired-end library with target insert size 300 bp can be
used to detect structural variants as small as 100 bp and the mate-pair library can be used
to detect larger events (> 1 kb) because of the larger target insert size. Of the 2891 break-
point calls for SVs a total of 2277 had support by split-read alignments (a read spanning the
breakpoint with one half of the read mapping upstream of the event and one half mapping
downstream). Those 2277 SV breakpoints could therefore be described at single nucleotide
resolution. Table 3.2 gives an overview of large structural variant calls obtained with DELLY
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DELLY Calls on PE data DELLY Calls on MP data PINDEL Calls on PE data
Type of SV Number of Calls Overlap, % Number of Calls Overlap, % Number of Calls Overlap, %
Deletions 1881 14.89 234 67.09 - -
Duplications 312 38.78 191 69.63 591 22
Inversions 33 60.61 139 56.12 101 24.75
Translocations 51 9.8 50 10 - -
Table 3.2: Overview of the number of SV calls stratified by the type of SV (deletion, duplication, inver-
sion and translocation) as well as the two methods (DELLY and PINDEL) and types of DNA sequencing
library (paired-end (PE) andmate-pair (MP)). The column Overlap,% is calculated as the number of calls
that overlap at least one call from one of the other categories, e.g. 14:89% of the 1881 deletions called
with DELLY on the paired-end library overlap with at least one deletion call from DELLY on mate-pair
data or from PINDEL on paired-end data.
and PINDEL in the paired-end and mate-pair libraries.
3.3.1.4 Loss of heterozygousity
I created a classifier from the allele frequencies observed in our SNVcalls to identifymostly
homozygous regions and applied it to 100-kb bins along the genome. The classifier was based
on a simple cut-off on the proportion of homozygous SNVs (number of homozygous SNVs
divided by total number of SNVs) in each bin and the cut-off was informed by the overall
distribution of the proportion of homozygous SNVs over all bins. I applied the classifier to the
autosomes and the X chromosome (since the tissue that HeLa originates from stems from a
female patient), which allowed us to pinpoint regions that were likely to have undergone LoH,
which means that all copies of a region carry the same allele. In this way I classified 23% of
the genome as homozygous (see also the homozygousity tracks in Figures 3.2, 3.6 and 3.4). The
majority of homozygous regions were present at copy numbers larger than 1 (less than 1% of
theHeLa genomewas called at CN 1), which indicates LoH that could have possibly arisen from
the deletion of one allele and subsequent amplification of the remaining copy. For comparison
I performed the same analysis on individuals from the HapMap3 project, which did not reveal
any homozygous regions larger than 100 kb in their autosomes. Figure 3.6 shows a large LoH
region near the end of chromosome 11 where the copy number is 2. Many of the homozygous
segments in the HeLa genome correspond to regions previously reported as LoH hotspots in
cervical cancer, i.e. chromosomes 3p, 6p, 11q, and 18q (see Rader et al. (1998), Mullokandov
et al. (1996) andMitra et al. (1994)), which suggests that these LoH events might have arisen in
the cervical cancer prior to the cultivation of the HeLa cell line. They could in fact be events
that characterised the tumour genome itself.
3.3.1.5 Building a HeLa genome draft
To generate a first draft of a HeLa genome sequence I selected the set of SNVs, InDels
and large deletions and insertions which were called homozygous and “applied” them to the
3http://hapmap.ncbi.nlm.nih.gov
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Variant Type Number of homozygous calls
SNVs 1; 733; 577
Large Deletions (> 50 bp) 748
Short Deletions 15; 034
Short Insertions 3446
Table 3.3: Overview of the number of homozygous variant calls used in the HeLa genome draft.
human reference genome that the alignments upon which the calls were based were made
against (GRCh37). An overview of the number of events integrated into the HeLa genome
draft can be found in Table 3.3. The overall chromosome structure was kept identical to the
human reference genome (22 autosomes plus sex chromosomes) andwe encoded copynumber
aberrations in a separate file. Both from the DNA-Seq data andmFISH experiments it was clear
that HeLa contains compound chromosomes which might merit a separate nomenclature in
which they would become stand-alone contigs. We decided to stick with the “traditional”
chromosome layout both for ease of usage and because we did not have sufficient data to build
a HeLa genome topology de novo (i.e. running an assembly software like, e.g. Velvet – Zerbino
and Birney (2008)). I implemented the tool to create a HeLa genome sequence draft from an
input FASTA file and a set of variant calls as well as a tools to translate genomic coordinate
between the two genomes (since we integrated deletions and insertions there are shifts and
loci have different coordinates in the two genomes). Both tools were implemented in Python
with the functionality provided by HTSeq (described in Section 2), which facilitated the rapid
development of those scripts.
3.3.2 Transcriptomic Landscape
The gene expression profile of the HeLa-Kyoto cell-line was characterised based on the
sequencing of polyadenylated RNAs. This RNASeq experiment yielded 450million reads of
lengths 76 and 105 nt (two sequencing runs were performed). Of those reads 56% ( 253mil-
lion) were aligned to the HeLa genome sequence draft (see previous section). We analysed the
dependency between copy number and expression level (see Figure 4 of Landry et al. (2013))
and compared the transcriptomic data with reference data from human tissues and cell lines
(Illumina Human BodyMap 2.0 – Schroth (2011); ENCODE – Rosenbloom et al. (2012)).
3.3.3 Data Availability
TheNational Institutes of Health (NIH)mediated discussions with the family of the patient
whose tumour sample eventually became theHeLa cell line (Henrietta Lacks), and a conclusion
was reached, to make our data available through dbGAP in an application-based restricted
access model4.
4http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000640.v1.p1
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3.4 Discussion
3.4.1 Challenges in variant calling
Dealing with a strikingly aberrant genome such as the one of our HeLa cell line poses chal-
lenges in the application of tools that are primarily designed to work well on “normal” diploid
genomes. The tools I used were gsnap (Wu and Nacu (2010)) for alignment and samtools (Li
et al. (2009)), Picard5 and the Genome Analysis Toolkit (GATK) (McKenna et al., 2010) as well
as PINDEL (Ye et al. (2009)) for postprocessing and variant calling. When I processed the DNA-
Seq data from the HeLa sequencing project I followed the best practices at the time, whichwas
alignment followed by a standard GATK workflow of re-aligning around indels, recalibrating
base-call quality scores and removing probable PCR (Saiki et al., 1988) duplicates. The final
step was calling SNVs and InDels with the UnifiedGenotyper walker of the GATK. It is im-
portant to note that the UnifiedGenotyper is a tool primarily designed for calling variants in
diploid genomes. The fact that the HeLa-Kyoto genome is so markedly different from diploid,
with large triploid stretches and even higher copy number in some regions, is likely to have
caused false-negatives in high ploidy regions, e.g. a variant that is present in 1/5th of the
reads in a 5-ploid region looks unlikely to a variant caller that assumes diploidy and therefore
models variants as a two-state model (heterozygous and homozygous). Based on the assump-
tion that the HeLa cell line we used is a genetically stable homogeneous population we could
assume that the observed allelic frequencies of variant calls represent the ploidy state of the
variant (e.g. an allelic frequency of 0:6 would correspond to a location with copy number 5
and 3 out of 5 copies carrying the allele). This approach was likely too optimistic, since HeLa
cells are cancer cells and there is no guarantee that sub-populations will not arise (be that by
internal genomic instability or external influence in culture).
3.4.2 Conclusion
While the HeLa cell line has been widely used in research ever since it was established
in 1951, the substantial amount of studies involving HeLa cells that were conducted prior to
our publication were executed with limited knowledge of the genomic properties of the cell
line. There were efforts to describe the HeLa genome on a lower resolution, e.g. Macville
et al. (1999), but prior to ourwork no single-nucleotide resolution characterisation of theHeLa
genome existed. Our publication provided the first detailed characterisation of the genomic
landscape of a HeLa cell line with respect to differences to the human reference genome. We
provided the research communitywith data tracks describing SNVs, InDels, large SVs, CN, LoH
as well as expression levels for genes. We furthermore integrated a high-confidence set of ho-
mozygous SNVs, InDels and large deletions and insertions into the human reference genome
that the calls were made against, thereby creating a first draft for a genome sequence of the
5http://picard.sourceforge.net
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HeLa-Kyoto cell line that we used. Not only did we provide a useful resource to the com-
munity, which can help to improve experimental designs and interpretation of results (e.g.
in RNA interference screens), but we also described an approach for the characterisation of
model organisms (including tools to implement it) that can be easily transferred to other cell
lines that are in use as a model system.
One of the key findings from combining the copy number data with expression level esti-
mates is that there is little to no dosage compensation as the expression levels can be shown
to correlate with copy number. Given the strikingly aberrant copy number profile of the HeLa
cell line we analysed, this could lead to misregulation of protein complexes where the sto-
chiometry of the different parts that constitute the complex is modified by copy numbers
changes overlapping the genes encoding some of the parts.
In the light of the relatively recent initial description of the phenomenon known as Chro-
mothripsis (Stephens et al., 2011) it is interesting to note that we could identify regions in the
HeLa genome that exhibit the hallmarks of such a catastrophic chromosome shattering event
(many CN changes between few CN states). Chromothripsis has since been described in amul-
titude of different cancer types and has been estimated to be present within the genomes of
2  3% of all cancers. In HeLa it is possible that the original tumour was generated through a
Chromothripsis event, but it is also possible that the Chromothripsis occurred sometime after
the cultivation of the cell line. In the same way in which we cannot distinguish between HeLa
private SNVs stemming from the patient, the tumour or processes during the culture of the
cell line for lack of data, we also cannot discern when the chromothripsis event occurred.
We used shotgun sequencing-based assays for data generation and attained a moderate
sequencing depth (less than 50x). The usage of this type of data imposes specific limitation
on the possible analyses that can be performed. Based on the coverage we obtained with
the 101nt paired-end reads, single nucleotide polymorphism (SNP) phasing by common read
pairs (i.e. phasing adjacent SNPs based on whether they are supported by the same / over-
lapping read pairs) was infeasible. Furthermore repetitive regions pose problems if the reads
cannot be uniquely aligned to those regions. This can be alleviated by moving to a sequenc-
ing technology that produces significantly longer reads (e.g. 10 kilobase reads produced by a
PacBio6 platform), which could eliminate most problems that stem from non-uniquely map-
pable repetitive regions. Amove towards single cell or even single chromosome sequencing as
has been proposed to be implemented on a microfluidics platform (Fan et al., 2011) would be
a tremendous improvement as well, since that would allow for a very precise characterisation
of the topology of the genome (i.e. which sequence is where) up to a point where a reliance on
the default chromosome layout of the reference (as we used) would not be needed anymore.
In summary, our approach generated a very detailed and sometimes surprising picture of
the genomic landscape of the HeLa cell line that we investigated. Our analyses were published
including source codes and tools to repeat essential steps and we expect that similar analyses
6http://www.pacificbiosciences.com/
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will be performed by researchers working on other cell lines as well. This kind of genomic
characterisation can be especially useful in genomically unstable cell lines, i.e. cancer-derived
cell lines like HeLa, in which case a regular check-up might be a good idea to keep track of
eventual changes in the genomic landscape of those cell-lines and adapt the experimental
designs accordingly. We envisage that approaches similar to ours might be useful to ensure
the integrity of cell lines and the quality of the biological insights derived from them.
Our study served to emphasise the importance of accounting for the genomic character-
istics of model cell lines when designing and interpreting experiments. Certainly the genome
of HeLa cells is amongst the more aberrant ones amongst cell lines in use as model organ-
isms, nevertheless it seems a good practice for any researcher to make sure that the genomic
peculiarities of the cell line used are taken into account when analysing their results.
Shortly after our publication another publication characterising the haplotype-resolved
genome and epi-genome of the HeLa CLL-2 strain was published by Adey et al.. Their genomic
characterisation also revealed a mostly triploid genome with a large number of aberrant re-
gions including LoH regions. Adey et al. also detected the HPV integration on chromosome
8 and characterised the affected region with a very detailed structural model. In the analysis
of transcriptomic data Adey et al. find the same lack of dosage compensation that we also re-
ported, which is indicated by a clear correlation between expression levels and copy number
state. The authors do not mention detecting patterns indicative of chromothripsis in their
data.
4 Using HDF5-based nucleotide tallies with 'h5vc'
The challenges researchers face with the advent of massive sequencing efforts aimed at
sequencing RNA and DNA of thousands of samples (e.g. in the context of cancer research: the
TCGA project1) will need to be addressed now, before the flood of data becomes a real prob-
lem. The effects of the infeasibility of handling the sequencing data of large cohorts with the
current standards (BAM, VCF, BCF, GTF, etc. – Danecek et al. (2011); Li et al. (2009)) have be-
come apparent in recent publications that performed population level analyses of mutations
in many cancer samples and work exclusively on the level of preprocessed variant calls stored
in VCF/MAF files simply because there is no way to look at the data itself with reasonable re-
source usage. This can be seen for example in Kandoth et al. (2013). This challenge can be
adressed by augmenting the available legacy formats that are typically used for sequencing
analyses (SAM/BAM files) with an intermediate file format that stores only the most essential
information and provides efficient access to the cohort level data whilst reducing the infor-
mation loss relative to the raw alignments. This file format will store nucleotide tallies rather
than alignments and allow for easy and efficient real-time randomaccess to the data of awhole
cohort of samples.
In this section I will introduce the h5vc R/Bioconductor package. I designed h5vc as a
tool to provide researchers with a more intuitive and effective way of interacting with data
from large cohorts of samples that have been sequenced with current generation sequencing
technologies. It is available for download as part of the Bioconductor package repository
and I published an accompanying application note in Bioinformatics earlier this year (Pyl et al.,
2014). I have given a lecture and accompanying workshop introducing the package at the
CSAMA 2014 conference2. Currently h5vc is being downloaded around  200 times every
month, and an overview of the download statistics can be found in Table 4.5.
4.1 Nucleotide tallies with an HDF5 back-end
The fundamental concept that h5vc is based on, is to use nucleotide tallies as an inter-
mediate data format between raw alignments stored in BAM files and filtered variant calls
stored in VCF files. A nucleotide tally is a table of nucleotide-resolution summary statistics
(e.g. counts of mismatches) at genomic positions augmented by additional dimensions like
strand and sample. In my current implementation I focus on the problem of calling SNVs as
well as small deletions, therefore I tally the mismatch counts, coverages and deletion counts
per nucleotide in the datasets described in Table 4.1. Themismatch count dataset is essentially
1http://cancergenome.nih.gov
2http://www-huber.embl.de/csama/index.html
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a table containing the number of overlapping reads supporting a mismatch for each combi-
nation of nucleotide, genomic position, strand and sample in a cohort. In this way all mis-
matches from aligned reads in a cohort of samples can be expressed in a 4-dimensional array
of nucleotide x sample x strand x position (Table 4.1). Additional data tables contain informa-
tion about the coverage (total number of overlapping reads per position, strand and sample)
and number of deleted bases per position. Possible extension of this concept include the stor-
age of the number of reads supporting an insertion following each position or some type of
phasing-related data, e.g. the mutual information content of one position and its immediate
neighbours with respect to the probability of observing mismatches within read alignments
that overlap both positions.
In my implementation, available in the h5vc package, I use the HDF5 file format (The HDF
Group, 2010) as a back-end to facilitate data storage and access of nucleotide tallies. HDF5
is a fast and mature file format that has already seen production use in fields as diverse as
NASA space missions and big movie special effects (e.g. The Lord Of The Rings3). The fact
that this file format has been used in production environments where a lot of resources and
money rely on its faultless functionality indicates that this is indeed a reliable format that
can be easily adapted in the research community without fear of catastrophic failure. HDF5 is
maintained by the HDFGroup (The HDF Group, 2010), which is a non-profit organisation that
provides updates and fixes and maintains documentation about the format. This adresses
another essential requirement for a file format to find usage with a broad audience, which is
continued and reliable support that is secured for the foreseeable future.
TheHDF5 data format and library are designed specifically for the efficient storage of large
numerical datasets, while allowing for fast and efficient access and providing transparent
compression support, i.e. one can activate compression in HDF5 without having to change
the way that scripts interact with the HDF5 files. HDF5 is available on many platforms in the
form of libraries for different programming languages including C/C++, Java, Python, Matlab
and R. My implementation relies on the rhdf5 R/Bioconductor package (Fischer and Pau,
2012) for low-level access functions to HDF5 files. Mismatch tallies are stored in a dataset
called Counts and further quantities are stored in the datasets Coverages (total number of
overlapping reads per position, sample and strand), Deletions (number of reads supporting
a deletion event for a base at a given position, sample and strand) and Reference (an integer
encoding of the reference sequence, storing for each genomic position the code correspond-
ing to the nucleotide as defined in the reference sequence that the alignments were made
against). These four datasets represent a complete tally and I store a set of 4 datasets for each
chromosome in the reference genome within a tally file. All datasets are essentially large ar-
rays of integers (i.e. numerical data, which HDF5 is especially well equipped to handle) and
are defined in Table 4.1.
Within an HDF5 file the data are stored in a hierarchical structure consisting of groups
3http://www.hdfgroup.org/about/history.html
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Dataset Definition Dimensions
Counts observed mismatches relative
to the reference
[bases x samples x strands x positions]
Coverages number of overlapping reads [samples x strands x positions]
Deletions observed deletions of bases [samples x strands x positions]
Reference vector containing the reference
bases
[positions]
Table 4.1: Overview of the datasets present in an HDF5 tally file giving definitions of their content
and a representation of the dimensions of the datasets.
Study ID
Chromosome 1
Counts Coverages Deletions Reference
: : : Chromosome Y
Counts Coverages Deletions Reference
Figure 4.1: Overview of the internal structure of a tally HDF5 file showing the tree structure with
groups representing studies and chromosomes (contigs) as internal nodes (visualised as green elliptical
nodes) and the 4 datasets defined in Table 4.1 as leafs (visualised as light blue rectangular nodes).
and datasets. This layout is analogous to a file system where groups represent folders and
datasets represent files. Within an HDF5 file the location of an object is represented with a
path notation similar to what a normal file system uses, e.g. /Group/Subgroup/Dataset. In
my implementation I use groups to represent the organisatorial units cohort and chromosome,
which translates to a layout in which a root folder (group) represents a cohort or experiment
and contains subfolders (sub-group) for each of the chromosomes in the reference, which in
turn contain the 4 datasets per chromosome as described above (Table 4.1 and Figure 4.1). In
the filesystem analogy the Counts dataset of e.g. chromosome chr7 of a cohort named Exam-
pleCohort will be stored at the location /ExampleCohort/chr7/Counts within the HDF5 file.
4.1.1 Sample Meta Data
Since HDF5 files are highly optimised towards storing large numerical data-sets we use
multi-dimensional arrays to store the tally data in them. The nucleotide tally representation
of a cohort of samples must also include some sample meta-data, which describes the sample
IDs, which patient IDs they are associated with, whether they are case or control samples and
any other important information that characterises the data-set. One particularly important
piece of information is the location of samples in the sample dimension of the data-sets, i.e.
which index in that dimension corresponds to which sample. The arrays of numerical data
stored in HDF5 files do not provide a formalised way of attaching names to the dimensions
(e.g. the actual genomic positions and the names of the samples, bases or strands). For the
case of the genomic position we avoid having to store the corresponding genomic position for
each entry in the data-set by having the index itself represent the position, which is also the
reason why the tally is stored per chromosome and not as one continuous block of e.g.  3
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billion values for a human sample. The indexes of the nucleotides (“A”, “C”, “G” and “T”) and
strands (“+” and “–”) are well defined and always the same in all nucleotide tally data-sets.
The mapping of samples to their respective indices in the sample dimension of the datasets
on the other hand, is by its very nature specific to a given cohort and not fixed.
To facilitate this mapping and at the same time allow for the storage of other important
data describing the cohort on a per-sample level I implemented a sample meta-data frame-
work that stores a table of sample meta-information alongside each group within an HDF5
tally file. The storage of meta-information can be implemented using either HDF5 attributes,
which are a part of the HDF5 specification and serve the purpose of annotating groups and
data-sets with additional information, or a separate set of data-sets. I implemented an inter-
face that can read the sample meta-data from both the HDF5 attributes as well as a separate
set of data-sets. The default behaviour is now to use separate data-sets (which was not the
case in previous versions of the h5vc package) since HDF5 attributes have a size-limit of 64
kilobytes. This limit is usually not reached in cohorts with less than 100 samples, i.e. the co-
horts I worked on most of the time – Section 5. To be safe for future applications which are
likely to involve larger cohorts I implemented a version without size limitations. The sample
meta-data itself is simply a table containing one row per sample in the cohort. The following 4
columns have to be defined and any amount of additional information can be added in further
columns:
Sample A unique sample identifier
Patient A unique patient identifier (multiple samples can be from the same patient)
Column The index of the sample in the sample dimension of data-sets
Type The type of the sample (e.g. “Case” or “Control”)
An example of what the sample meta-data looks like for one of the cohorts I have been
working on is shown in Table 4.2 (see also Table 5.1). This table contains multiple samples per
patient, some of them re-sequencings of previous runs of unsatisfactory quality as well as re-
lapse andpre-leukaemia samples. Apart from the 4fixed columns that every samplemeta-data
table must contain, one may add any number of additional columns containing for example
descriptions of the samples or patients (e.g. age, sex, time of the sample extraction) or other
relevant clinical variables that can bemeasured on a per-sample level. The combination of nu-
cleotide tallies stored as multi-dimensional numerical data-sets and sample meta-data within
the sameHDF5 file allows the researcher to perform their analyses without the need for exter-
nal sources of information with regard to the cohort itself. Of course there are a lot of useful
external resources that can feed into an analysis, e.g. genemodels or annotations of repetitive
regions to only name a few.
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Sample Patient Column Type
WAS1.AML WAS1 1 Case
WAS1.PreGT WAS1 2 Control
WAS8.AML WAS8 3 Case
WAS8.AMLRelapse WAS8 4 Case
WAS8.PreGT WAS8 5 Control
WAS9.AML WAS9 6 Case
WAS9.PreGT WAS9 7 Control
WAS1PrimaryDNAFirst WAS1First 8 Case
WAS1ControlDNAFirst WAS1First 9 Control
WAS1PrimaryDNASecond WAS1Second 10 Case
WAS1ControlDNASecond WAS1Second 11 Control
WAS5PrimaryDNA WAS5 12 Case
WAS5RelapseDNA WAS5 13 Case
WAS5ControlDNA WAS5 14 Control
WAS6PrimaryDNA WAS6 15 Case
WAS6ControlDNA WAS6 16 Control
WAS7PrimaryDNA WAS7 17 Case
WAS7ControlDNA WAS7 18 Control
WAS7PrimaryDNA_ReSeq WAS7_ReSeq 19 Case
WAS7ControlDNA_ReSeq WAS7_ReSeq 20 Control
WAS8PreLeukemiaDNA WAS8 21 Case
WAS8PrimaryDNA WAS8 22 Case
WAS8ControlDNA WAS8 23 Control
WAS9PrimaryDNA WAS9 24 Case
WAS9ControlDNA WAS9 25 Control
Table 4.2: Example of what sample meta-data is stored in an HDF5 tally file. This data describes the
tallies for two cohorts of paired cancer sample that I have been working on (Section 5).
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4.2 Creating tally files
HDF5-based nucleotide tally files provide an intermediate level of access to high through-
put sequencing data that is more abstract than read alignments stored in BAM files but at the
same time more “raw” than a set of variant calls in a VCF file would be. Essentially the cre-
ation of a nucleotide tally file in HDF5 format is an additional post-processing step that should
be applied to the raw sequencing alignment data. It is important to note that nucleotide tal-
lies offer a lossy compression of read alignment data and they are not a replacement for BAM
files. The transformation of read alignments into tables of nucleotide-level summary statistics
removes any information about the relationship between observations at neighbouring posi-
tions and the tallies of position i are independent of the tallies of position i+1. The advantage
of this is that nucleotide tallies can be created and analysed in parallel since no dependency
between neighbouring positions exist. One negative aspect is the loss of phasing information,
i.e. we can make no assumptions about whether two SNV calls are coming from the same or
different alleles.
Creating nucleotide tally files is a computationally intensive task and for larger cohorts
of e.g. human samples it requires substantial amounts of compute resources. The time and
resources used to create tally files can be seen as an investment which will pay off through
the way in which they allow the user to interact with the data afterwards. The actual amount
of time that is needed depends on the size of the cohort and whether the data is from a WES
or WGS approach as well as the size and power of the computers used for the tally creation,
e.g. the creation of nucleotide tallies of expressed regions for 188 human WES samples in a
highly parallelised fashion takes  2 days to complete. Since nucleotide tallies are storing
only position-specific data and do not contain information about the relation between neigh-
bouring positions their creation can be parallelised. An obvious level of parallelisation is the
creation of tallies per chromosome and it is advisable to create them in blocks along the chro-
mosome (e.g. of size 1 mega-base). Here we have to make a trade-off between speed and file-
size, since HDF5 files can only be written to in parallel if they are not compressed. Since the
compression works in blocks we need to be sure about the content of the block at the time of
compression and with multiple processes writing to the same file at the same time this is not
a guarantee that can be made. Given this limitation of the technology we can choose among
two possible approaches in order to arrive at a highly compressed nucleotide tally file (if we
do not care about hard-disk usagewe can simply switch off compression andwrite in parallel):
1. Create the tally file uncompressed in parallel using a large amount of disk space and
compress it afterwards
2. Create the tallies in parallel in blocks along the genome and write the resulting blocks
into the tally file serially (e.g. one after the other)
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Figure 4.2: Overview of the process layout of partially parallelised nucleotide tally creation. The
chromosome is split into intervals (top) which are each assigned to one sub-job of the master job for
processing. The sub-jobs can run in parallel on amulticore machine or on a compute cluster composed
of multiple machines. The master job waits for sub-jobs to finish and writes the results of finished
sub-jobs to the HDF5 tally file. This writing happens serially, since the usage of compression prohibits
parallel writing into HDF5 files.
In my implementation I have decided to use the second option and h5vc contains func-
tionality to create a nucleotide tally file from a set of input BAM files in this fashion. Essen-
tially a master-process is running, which creates sub-processes that each handle the creation
of a nucleotide tally of the provided BAM files in a given genomic region (e.g. a bin of size 1
mega-base or a single exon or gene). The sub-processes run in parallel and themaster-process
constantly checks for sub-processes that have finished and puts any finished processes into a
queue. The contents of the queue are then serially written to the nucleotide tally file in (com-
pressed) HDF5 format. In this way we can already start writing finished blocks of data into
the nucleotide tally file while other blocks are still being calculated in parallel. The usage of
the BiocParallel and BatchJobs packages allows us to run the sub-processes either on a
multicoremachine or on a compute cluster (Morgan et al., 2013; Bischl et al., 2011). An outline
of the process can be found in Figure 4.2.
4.3 Compression and Chunking in HDF5 files
4.3.1 Compression in HDF5 files
The choice for favouring serial writing with compression over parallel writing without
compression in the creation of the HDF5 tally files is based on the impracticality of storing
nucleotide tallies of large cohorts uncompressed. When working on the EBI compute cluster,
this is actually not really a problem since disk space is abundantly available there. In a more
realistic application scenario where a smaller research group with limited compute resources
attempts to create such a file, this will become a problem. The increased runtime of the tally
creation process when writing serial is feasible and a cohort can usually be processed within
a reasonable timeframe. The exact time it takes to write depends on the size of the cohort
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and the type of experiment, since in a WES sample the tallies actually only need to be created
and written within the coding regions. This approach reduces the amount of data to write by
e.g.  97% in human samples where  3% of nucleotides are coding. The largest cohort I
have worked with so far is a set of 188 human WES samples which can be tallied in less than
a week when covering the whole genome. Tallying only genomic intervals that overlap genes
(including introns) reduces this time consumption to a bit less than two days and a further
reduction to covering only exons (i.e. not covering the intronic regions) is likely to speed this
up even more. In this way whole exome samples are faster to analyse than whole genome
samples.
The way I designed the layouts of the data sets stored in the HDF5 files implies a strong
need for compression, since the genomic position is stored implicitly in the genomic posi-
tion dimension. Therefore the position that a value corresponds to is not explicitly stored but
rather reflected in the location of the value within the data set. The problem with this is very
apparent in the case where a whole exome sample is stored as a nucleotide tally, which will
contain non-trivial values for only about 3% of the genomic positions and therefore the large
majority of the data sets (i.e. the 97% of positions that correspond to introns and intergenic
regions) will contain zeroes. Storing all those zeroes uncompressed creates an HDF5 file that
is equally as big as a corresponding tally file from a whole genome sample. Activating com-
pressionwill remove thememory impact of the large blocks of zeroes. This compression effect
is very similar to the effect of the run-length encoding approach used in HTSeq (Section 2.3)
where one can imagine the compression of large blocks of zeroes through storing only the
information of the size of the block instead of the whole block itself. A dataset containing 100
million zeroes can be stored in a compressed HDF5 dataset using less than 1 mega-byte on the
disk.
4.3.2 Chunking in HDF5 files
Within HDF5 files the data sets are stored in chunks, which are the atomic unit for com-
pression, access and caching of the data. The need for chunking arises from the fact that any
representation of multi-dimensional data (e.g. 4D-arrays of nucleotide counts) on the disk
will have to be serial. Let us consider for example a two-dimensional array of n rows andm
columns that needs to be stored in a file on the hard disk as a serial vector of numbers. There
are two natural approaches that can be taken: one can either concatenate the rows or con-
catenate the columns to form one long vector of length l = m n and store this vector on disk.
This serial storage of multi-dimensional arrays poses some challenges when we are trying to
retrieve sub-sets of the data (e.g. the k-th row where 0 < k < n ). If we store the array by
concatenating the rows we know that the k-th rowwill start at position (k 1) m+1 (all pre-
ceding rows concatenated, which each containm numbers) and the nextm values correspond
to the k-th row. If we however want to extract the k-th column, the corresponding values will
be distributed evenly along the serial representation of the data. This difference can influence
42 Using HDF5-based nucleotide tallies with ’h5vc’
1 2 3 : : : m
m+ 1 m+ 2 m+ 3 : : : 2 m
: : : : : :
l  m+ 1 l  m+ 2 l  m+ 3 : : : l
Table 4.3: This table represents a two-dimensional array of n rows andm columns stored in a row-
concatenated fashion. The numbers in the cells correspond to the positions of the values within the
serialised representation which is a vector of length l = m n. The second column and second row are
marked in red. Note how the second row can be read from the vector representation as one continuous
block of data (spanning the interval [m + 1; 2 m]), while the second column must be read as a series
of single values spacedm positions apart within the vector representation.
the time needed to read data from the file significantly. The example is illustrated in Table
4.3.
To alleviate this effect and allow us to efficiently read from a data-set it is serialised in
chunks within the HDF5 file. This means that a chunk shape is defined, which can be multi-
dimensional and the data is split into chunks of that shape before each chunk separately is
serialised into the HDF5 file. This will reduce the time spent seeking the correct values within
the files since the effects illustrated in Table 4.3 are now localised to the chunkwewant to read
from, instead of affecting the whole data-set. Without such behaviour, extracting the data
corresponding to a single position in the human genome could easily lead to the algorithm
having to jump around theHDF5file by asmuch as 3 billion positions, just to collect the correct
values. If we for example chunk the Counts dataset (which has 4 dimensions) in chunks that
span all nucleotides, samples and strands but are limited to 10000 positions along the genome,
then the function for the retrieval of data will at most have tomove by 10000 positions. This is
to comparewithmoves of up to 250millionpositionswhenweare reading fromanun-chunked
data-set that corresponds to chromosome 1 in a human sample. Because of this layout it can be
helpful to choose a chunk size that suits the way in which one wants to access the data. When
the main way of interaction with the data is in blocks in the range of hundreds of genomic
positions (e.g. SNV positions and a window up- and downstream of them) then using chunks
of a size in the range of mega-bases will create a lot of overhead.
At the moment h5vc implements chunking on the level of genomic position and sample,
therefore the data sets are stored in chunks that correspond to a certain number of samples
(the sampleChunkSize) and a certain number of genomic positions (the chunkSize; named
so for backwards compatibility reasons) as well as both strands and all nucleotides (where ap-
plicable). The default behaviour is for chunks to span all samples and have a length of 50000
in the genomic position dimension. Those values are based on experience with cohorts of
about 20 samples (i.e. the kind of cohorts I usually work on; see also Section 5). Since both
values can be configured by the user through function parameters it should be easy to adapt
them to studies of different dimensions, e.g. containing thousands of samples. The underly-
ing rationale for choosing chunk sizes should always be informed by the way in which a user
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plans to interact with the data-sets in their downstream analyses. For example, a block of data
containing the counts and coverages of 20 samples in a genomic region of width 50000 bases
stored as an array of 32-bit integers uses less than 100Megabytes of space in memory, making
handling the data in chunks of this size easy even on low-end laptop computers. When the
cohort contains e.g. 200 samples the memory usage of a block of 50000 genomic positions is
already almost 1 giga-byte. In the following section I will explain the principles behind the
interface to HDF5 tally files, and it will become more clear that the size of the blocks in which
one interacts with the data is an important thing to consider.
4.4 Interacting with HDF5 nucleotide tallies
The concept of using nucleotide tallies is geared towards reducing the size of the data-
set and making the data more easy to interact with than if one had to work on e.g. a set of
alignments stored in a BAM file. The tallies themselves are large matrices of numerical data
and in fact a lot of the savings in data-set size comes from the compression that the HDF5
library offers (i.e. making the compressed HDF5 file small). If one were to load the mismatch
nucleotide tally representation for the whole genome of a cohort of human samples, e.g. 21
samples, intomemory onewould need to store a total of about 21231094  51011 values in
memory (21 samples times 2 strands times 3 billion positions times 4 bases). If we assume that
we can represent each number by a 32-bit integer (i.e. 4 bytes per number) the total size of this
dataset is somewhere in the range of 2 terabyte. Most people do not have access to machines
with this muchmemory and therefore h5vc implements a similar streaming approach to data
processing as I already introduced in HTSeq (see Section 2).
4.4.0.1 The h5dapply and h5readBlock functions
To facilitate the analysis of nucleotide tally data whilst maintaining a reasonable memory
footprint I implemented two functions in h5vc (h5dapply and h5readBlock) which allow
for the retrieval of data corresponding to a particular genomic region of interest and the ap-
plication of a function (e.g. a variant caller) in blocks along the genome. Nucleotide tallies,
while using comparatively little amounts of disk space when stored in compressed HDF5 files,
can be quite large and usually the nucleotide tally of a set of human samples will not fit into
a computer’s RAM. This is a problem that is typical for HTS data and the reason behind the
streaming approach to processing read alignments used in HTSeq, introduced in Section 2.2.
In the most common use-case we want to do an analysis on a nucleotide tally that works on
the genomic position level, where we want to compute some sort of summary statistic (e.g. a
binned coverage) or we want to find genomic positions that have certain properties (e.g. the
positions of somatic variants in cancer samples). The nucleotide tallies of neighbouring ge-
nomic positions are usually independent of each other and although some correlations might
exist we cannot make any inference about the relations between nucleotide counts at neigh-
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bouring positions once the read alignments have been transformed into tables of mismatches.
In other words, during the translation of read alignments into nucleotide tallies all phasing
information is lost and we can make no assumptions about whether two neighbouring mis-
matches were caused by the same read or two different reads (i.e. whether they are from the
same allele or not).
It is immediately clear that any calculation of the aforementioned type (binned summary
statistics or position specific properties) can be calculated in arbitrarily chosen bins along
the genome and each bin can be calculated without knowledge of the data in any other bin.
This leads to the conclusion that almost any function a researcher might want to apply to a
nucleotide tally can be applied in bins along the genome and for each bin only the tally data
corresponding to it has to be available. In some cases it might be necessary to use overlapping
bins in order to deal with positions at bin boundaries, e.g. when calculating for each position
in the genome the number of mismatches observed in a window of size k centered on the po-
sition (with k being odd), one should choose bins that overlap by k positions. The h5dapply
function implements exactly this behaviour and can be used to apply functions to tallies in
a block-wise fashion (e.g. apply a coverage estimation function in 10 kilobase bins along the
genome as a first step of a segmentation according to copy number). The fact that we can
usually calculate any result of any bin or block independent of the result of any of the other
bins / blocks allows us to process large nucleotide tallies in chunks that fit comfortably into
the memory of a normal laptop. Furthermore the fact that results are independent between
chunks allows for easy parallelisation of any such calculation and h5vc implements such be-
haviour in the h5dapply function, which can use multicore or even multi-machine setups to
parallelise calculations.
The h5dapply function exposes an interface for applying any R function to nucleotide
tally data in blocks along the genome (see Listings 3 and 4 for example code). The concept
is to split the genome (or a genomic region) into bins of a user-chosen size and successively
retrieving the nucleotide tally data corresponding to each bin, applying the user-provided
function to it and returning the result. This process internally uses the bplapply function
from the BiocParallel package, which can be switched from serial processing to multi-core
or multi-machine parallel processing via a simple configuration interface. As a convenience
to the user, h5vc provides the h5readBlock function, which implements essentially the same
behaviour as h5dapply does, if there is only one block to be processed and the function to be
applied is the identity (i.e. function(x) {return(x)} when implemented in R). It basically
reads a block of data from the tally file and returns it directly. In addition to the ability to apply
a function to blocks along the genome or extract specific blocks of data, a further subsetting
by sample is implemented. This subsetting by sample is implemented on the level of the HDF5
library and therefore performed before the data is loaded into memory, this behaviour is cru-
cial when dealing with particularly large cohorts, where even a block of data corresponding
to a region of only 10 kilobases might be too big to fit into the computer’s memory if there are
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e.g. 10000 samples in the cohort.
In summary, the interface that h5vc provides to the user through those two functions
(h5dapply and h5readBlock) allows for the easy retrieval of data corresponding to arbitrary
subsets of genomic positions and samples aswell as the direct application of analysis functions
to this data (e.g. variant calling functionality).
4.5 Implementation and Availability
I implemented the h5vc package using R and C/C++ and made it available as a package in
the Bioconductor project. It is well documented both in a reference of available functions
and a set of vignettes that illustrate common workflows and examples of application. The
Bioconductor repository is regularly tested and well maintained and provides a reliable path
for updates and time-critical bug fixes through its versioning structure. While most of the
functionality is implemented as pure R code some essential parts are implemented in C/C++.
All interactions with HDF5 files are facilitated by exposing the HDF5 C API to R (this was im-
plemented by Bernd Fischer in the rhdf5 package). I implemented the function for creating
nucleotide tallies fromBAMfiles (tallyBAM) in C for increased performance of thismost time-
consuming step in the process. I based the function definition and interface on the bam2R
function provided by the deepSNV package, which was written by Moritz Gerstung (Gerstung
et al., 2012).
4.6 Examples of usage
h5vc is a project that was primarily motivated bymy disappointment and frustration over
using the available tools at the time of its inception. As such I designed the tool with flexibility
in mind and it is more of a framework for analysis of HTS data than just a monolithic tool that
performs one specialised task. This design principle is apparent in the way that the interface
of the h5dapply function is designed to allow the researcher to plug in arbitrary functions as
long as they are callable fromwithin R. This includes both pure R aswell as C functions exposed
through anR interface. Instead ofwriting a package that calculates coverages or SNVpositions
I wrote a package that enables multiple researchers to rapidly prototype ideas and implement
and try them out quickly. In addition h5vc provides functions both for coverage analysis as
well as calling of variants in single samples or pairs of samples. These implementations are
intended as illustrative examples to the users of h5vc andwhile the functionality for coverage
analysis might be called as good as it can get (since the task is so simple), the functions for
calling variants (SNVs and InDels) are not intended as competition to the established variant
calling tools. While I believe the variant calling functionality provided by h5vc to be adequate
for its intended tasks I will not perform a detailed analysis of the sensitivity, specificity and
runtime of the implementations, since themain point of h5vc is not to implement one specific
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variant calling function, but rather to enable the research community to easily experiment
with different approaches to solving the problems at hand. With that inmind I show examples
of the implementation of functions to be usedwith h5dapply in Listing 3 aswell as their actual
application to a specified genomic region of interest in Listing 4.
1 binnedCoverage <- function( data, sampledata ){
2 ret <- rowSums( data$Coverages )
3 names(ret) <- sampledata$Sample[order(sampledata$Column)]
4 ret <- as.data.frame(t(ret))
5 ret$Start <- data$h5dapplyInfo$Blockstart
6 ret
7 }
Listing 3: Example code of the binnedCoverage function provided by the h5vc package.
1 data <- h5dapply(
2 filename = tallyFile,
3 group = "/ExampleStudy/22",
4 names = c( "Coverages" ),
5 blocksize = 500,
6 range = c(38750000,39250000),
7 FUN = binnedCoverage,
8 sampledata = sampleData
9 )
10 data <- do.call(rbind, data)
11 rownames(data) = NULL
12 head(data)
Listing 4: Example code of applying the binnedCoverage function provided by the h5vc package to
region 22:38750000-39250000 of the human genome in bins of size 500bp.
4.6.1 Challenges in comparative variant calling
One of the most fundamental challenges in cancer sequencing analyses is the problem of
comparative variant calling. In most cases the question we are trying to answer is: What are
the differences between two or more samples in terms of the presence and penetrance (allelic
frequency / zygosity state) of variants in those samples. In the setting of comparative cancer
sequencing the most common comparison will be between a cancer sample and its matched
control sample in order to find somatic variants. For population studies one might also be
interested in 1 : N as well as N : M comparisons, e.g. one cancer sample compared to a set
of control samples (1 : N ) or a set of cancer samples compared to a set of control samples
(N : M ).
Up until recently (around 2012) this was a hard problem with few dedicated softwares
available to perform such comparisons. Prior to the development of h5vc I was using the
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GATK (McKenna et al. (2010)) both for processing the BAM files as well as for variant call-
ing. The GATK provides a variant caller that can operate on multiple samples at once (the
UnifiedGenotyper) but the algorithm is based on an assumed diploidy of the samples and
will likely not performwell when confrontedwith polyploidy (as can occur in cancer samples).
There are a number of stand-alone solutions for somatic variant calling available to the re-
search community, e.g. MuTect (Cibulskis et al., 2013), SomaticSniper (Larson et al., 2012) and
Strelka (Saunders et al., 2012). When I was first trying to perform comparative multi-sample
variant calling in one of my cancer sequencing projects, described in Section 5, I realised that
the UnifiedGenotyper was not able to provide calls of sufficient quality for our needs and
using MuTect seemed more promising since the tool was specifically designed to address this
question.
Ultimately I decided to rely on my own implementation using the framework provided by
h5vc which allowed me to have full control over the algorithm and tremendously improved
the way in which I was able to interact with the data. Furthermore it was of great importance
to me, to be able to quickly visualise variant calls in an automated fashion (Section 4.6.5) and
the available tools (e.g. batch programming IGV to generate screenshots – Thorvaldsdottir
et al. (2013)) were too cumbersome and inflexible for my needs.
4.6.2 Variant calling implementations
h5vc contains example implementations of variant calling functions which I developed
during my work on cancer sequencing analysis (Section 5). It should be noted that I do not
intend to compete with any of the stand-alone solutions mentioned in Section 4.6.1, however
most somatic SNV calling algorithms can likely be implemented as a series of operations on
matrixes ofmismatch counts and coverages and can therefore be implemented in R (or Cmade
available as an R function through e.g. Rcpp Eddelbuettel and François (2011)). Since h5vc
provides a framework for the quick implementation of algorithms based on nucleotide tallies
one can therefore implement most somatic SNV calling algorithms as R functions that can be
applied to HDF5-based nucleotide tallies through the h5dapply function provided by h5vc.
4.6.2.1 Principles – Error Profiles
A very usefulmetric for determining the reliability of a given variant call is an error profile
of the position and the surrounding region. This can help to spot error prone regions and
define statistical tests that use amore accurate prior probability formismatches than the error
rate as specified by themanufacturer of the sequencingmachine. That the error rate observed
in sequencing experiments is indeed position dependent is apparent from just looking at the
data and can be nicely visualised using h5vc (see Figure 4.5 for an example). I will explain
the usage of background error frequency data in variant calling in cohorts of samples in the
following sections.
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backgroundFrequencyFwd The averaged frequency of mismatches/deletions
at the position of all samples of type Control on the
forward strand
backgroundFrequencyRev The averaged frequency of mismatches/deletions
at the position of all samples of type Control on the
reverse strand
pValueFwd The p.value of the Binomial test of the sup-
port and coverage in the case sample versus
the estimated background error frequency
backgroundFrequencyFwd (forward strand)
pValueRev The p.value of the Binomial test of the sup-
port and coverage in the case sample versus
the estimated background error frequency
backgroundFrequencyRev (reverse strand)
Table 4.4: Explanation of the values used to annotate variant calls with information about the esti-
mated background mismatch frequencies in the cohort.
An illustration of how the availability of the tally data of a whole cohort in an easily ac-
cessible matrix-like format can be helpful for variant calling approaches can be seen in Figure
4.3.
4.6.3 Paired SNV and deletion calling with h5vc
h5vc provides functions to perform comparative variant calling (CallVariantsPaired)
which calls SNVs and small deletions (i.e. deletions that can be detected form single-read
alignments). The implementation is very basic and relies on absolute cut-offs for the read sup-
port and total coverage of a variant position (the number of reads supporting the variant and
the total number of reads overlapping the position). In addition to the cut-off based decision
to call a position a potential variant a comparison to the background frequency ofmismatches
in the whole cohort may be performed. Table 4.4 contains explanations of 4 values that this
comparison generates for each variant call.
In this way the information about the background mismatch frequencies that is available
from the cohort is integrated as a set of scores for each variant, wich we can apply filters
to in the downstream analysis. For example when calling somatic variants we might want to
exclude positions that show a high allelic frequency over all of the controls in the cohort, even
if the matched control of the cancer sample shows no support for the variant at all.
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Figure 4.3: Illustration of the layout of mismatch tallies for a cohort of two pairs of samples (Case and
Control sample of patients 1 and 2). Tallies are shown for only one strand to reduce the dimension-
ality of the data that has to be plotted (i.e. limiting to three dimensions) and any algorithm designed
to work on nucleotide tallies will likely be implemented to handle the actual 4-dimensional data that
includes information for each strand. (a) General layout of the mismatch tallies of the four samples on
one strand. Colours encode the alternative allele along the horizontal axis and the vertical axis repre-
sents the genomic position. (b) Example of how the data would be subsetted to perform comparative
variant calling in the two samples of patient 2. (c) Example of usage for calculating background mis-
match frequencies from the control samples of all patients. By making the data available as a matrix
we can implement many different algorithms by expressing them through matrix operations, e.g. the
comparative variant calling is implemented through subsetting and comparing two slices (the case and
control sample respectively). The background mismatch frequency estimate is implemented through
subsetting on only the control samples followed by summarising over all controls and dividing by the
sum of coverages in them. The coverage can be obtained as a matrix from the HDF5 file as well.
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In the paired variant calling algorithms implemented in h5vc the basic workflow is using
the following steps:
1. extracting the nucleotide tally data for each pair of samples from the cohort data (that
was provided by a call to h5daply or h5readBlock), this step uses the samplemeta-data
that describes the cohort to find the appropriate indices in the sample dimension of the
datasets.
2. applying the filters defined in the configuration list cl which is generated by a call to
the vcConfParams function. The filters that are applied are hard cut-offs defining min-
imum and maximum allowable values for coverage and support per strand for both the
case andmatching control sample, e.g. aminimumsupport per strand in the case sample
is usually implemented alongside a maximum support per strand in the control sample
in order to call somatic variants. Such filters can be expressed as simple matrix opera-
tions on the nucleotide tally data. An example of this is given in Listing 5.
3. if the returnDataPoints flag is not set we return the list of positions satisfying the
applied filters.
4. if the returnDataPoints flag is set we collect relevant variant specific data for all po-
sitions that passed the filters; this includes the support and coverage values in both the
case and control sample as well as the chromosome, positions and alleles involved.
5. if the annotateWithBackground flag is set we additionally calculate the mismatch fre-
quency that is observed in all control samples of the cohort combined for each of the
strands, i.e. the forward and reverse strand-specific mismatch frequency of all controls
in the cohort; furthermore a p-value is calculated for each strand by applying a Binomial
test against the hypothesis that the true probability of success (i.e. the probability of se-
quencing a readwith the alternative allele) is smaller or equal to the observedmismatch
frequency in the controls of the cohort. Essentially the question is whether it is prob-
able to observe the support we observed for the alternative allele in the case sample if
the underlying probability of seeing a mismatch is equal to that of the control samples.
If we can reject this hypothesis then this position could be a viable variant call and not
just some artefact that could happen in any of the samples (also the controls).
This workflow is essentially identical for both SNVs and small deletions and for the pur-
pose of the calculation the deletion of a single base is actually just treated like another kind
of base, effectively using the following set of possible alternative alleles: A,C,G,T,-, where -
represents a deletion of a single nucleotide.
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1 caseCoverage = data$Coverages[caseColumn,,] #Coverage values of case sample
2 controlCoverage = data$Coverages[controlColumn,,] #Coverage values of control
3 cov_filter = (caseCoverage[1,] >= cl$minStrandCov &
4 caseCoverage[1,] <= cl$maxStrandCov & #Maximum case coverage forward strand
5 caseCoverage[2,] >= cl$minStrandCov & #Minimum case coverage reverse strand
6 caseCoverage[2,] <= cl$maxStrandCov &
7 controlCoverage[1,] >= cl$minStrandCov &
8 controlCoverage[1,] <= cl$maxStrandCov &
9 controlCoverage[2,] >= cl$minStrandCov &
10 controlCoverage[2,] <= cl$maxStrandCov)
Listing 5: Example code showing how to implement a coverage filter of tallies extracted from an HDF5
file (i.e. the data object) based on a configuration list provided to the variant calling function (cl). This
code works on a pair of samples that are defined by caseColumn and controlColumn, respectively.
The mapping of sample pairs to columns (i.e. indices in the sample dimension of tally datasets) is
stored as sample meta-data within the HDF5 files (exemplified Table 4.2 for an example).
4.6.4 Calling single sample variants
For the case where we want to call variants in a single sample without comparing to a
matched sample from the same patient h5vc implements the callVariantsSingle function.
It is important to know that single sample variant calling is significantly more susceptible to
false positives caused by artefacts which would be filtered out in the comparative variant call-
ing setting (i.e. if mismatches are a consequence of sequencing chemistry and local sequence
context they will appear in both the case and control sample and will therefore be discarded).
This ismoreproblematicwhen the single sample that is to be analysed is potentially polyclonal
and carries copy number aberrations, since we can make no assumptions about the expected
frequency with which variants should appear. In a monoclonal diploid sample a strong filter
against allelic frequencies that differ from 50% can be applied, since we assume variants to
either be heterozygous at 50% allelic frequency or homozygous at 100%.
In the implementation that I included in h5vc, variant calls are based on simple cut-offs
for minimum support (total as well as per strand) and allelic frequency. Additionally an error
probability is calculated for each variant call based on an expected error rate (e.g. 1/1000 for
Illumina machines) and the observed percentage of reads carrying mismatches. Furthermore
a statistical test is applied to check for bias in the distribution of reads that carry mismatches
amongst the two strand when compared to the distribution of all reads, i.e. the coverage. This
can be informative when looking for artefacts that are strand specific (see Figure 4.5) since in
those cases the distribution of support for the variant between the two strands is different
from the distribution in the total number of reads and we can test for that. In my implemen-
tation I use Fisher’s exact test as implemented in the R function fisher.test. The selection
of likely variant positions is therefore based on them having at least a certain number of reads
supporting the variant on each strand (the minimum per strand support) as well as at least
a certain total number of supporting reads and an allelic frequency (as estimated from total
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support divided by coverage at the position) larger than a certain minimum. The provided
annotations give the probability of observing the number of supporting reads in the back-
ground error model (e.g. the 1/1000 rate of error that Illumina claims for their machines) as
well as the p-value of the Fisher’s exact test comparing the distribution of support amongst
the two strands with the distribution of all reads amongst the two strands (strongly skewed
distributions of support are indicative of artefacts).
4.6.5 Visualising variant calls
When calling single nucleotide variants or small deletions (but also more generally when
calling any type of variant) it is important to implement reasonable measures for quality con-
trol. Usually the filters that are applied to a set of raw variant calls will rely on properties of
the sample at the variant position itself, e.g. the number of supporting reads or the coverage
at that position. Furthermore, properties of other samples in the cohort or the population in
general (e.g. data from the 1000 genomes project - Abecasis et al. (2012)), such as mismatch
frequency distributions amongst the samples and global minor allele frequency (GMAF) esti-
mates should be used.
In addition to those position specific properties it can also be enlightening to investigate
the immediately surrounding genomic region for unusual patterns of mismatches and likely
artefacts. An example of this is given in Figure 4.4, where two variants are visualised which do
not differ significantly in their position-specific properties but when seen in their genomic
context one might arrive at different levels of confidence in the respective variant calls. In
h5vc the mismatchPlot function is implemented, which generates this type of plots from
the nucleotide tallies.
When processing variant calls from a cohort of sequencing samples I will usually apply
some position specific filters to the variant calls, e.g. on the support, coverage, allelic fre-
quency, GMAF and SIFT conservation score (Kumar et al., 2009) for coding variants to reduce
the number of calls to a more manageable size, e.g. thousands or hundreds of calls. From
this set of calls I will typically create HTML reports in the form of tables of position specific
properties that contain links to additional information (e.g. overlapping genes and existing
variants) as well as mismatch plots of the variant regions in all samples of the associated pa-
tient, i.e. when observing a variant in the primary tumour sample of a patient I will plot
the mismatch plots for all of the samples from that patient, e.g. the control, the primary
and potentially a relapse tumour. I typically use the ReportingTools (Huntley et al., 2013)
R/Bioconductor package to create those reports.
4.6.6 Sequence and strand specific artefacts
During my work on analysing cohorts of sequencing samples I have encountered a variety
of artefacts that can be mistaken for variants when they are more likely to be explained by
specific effects of the library preparation and sequencing technology used. One example is
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Figure 4.4: mismatchPlots of two candidate variant sites. Each sample (Control, Tumour) is shown
in a separate panel, with the genomic position as a common x-axis centered around the position of the
variant. Along the y-axis, alignment statistics of the forward and reverse strand are shown as positive
and negative values, respectively. Grey areas represent coverage by sequences matching the reference,
coloured areas represent mismatches and deletions. (a) Variant present in the tumour sample, but not
in the control. (b) Variant of comparable position-specific statistics as the one shown in (a). Note the
noisyness of the region, which is not immediately obvious from the position-specific values alone.
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the strongly strand-biased accumulation of mismatches that seem to be dependent on the
local sequence and can therefore be observed with comparable intensity in unrelated sample.
Figure 4.5 showsmismatch plots of a region of the genomewhere such artefacts can be ob-
served in multiple control samples of a cohort of paired sequencing samples. I did not further
investigate those artefacts for common sequence context around their positions but think
such analyses could help to better understand artefacts of this sort and help spot regions of
the genome that might be more prone to their occurrence. The existence of highly strand-
specific pile-ups of mismatches in all samples points to a technical rather than a biological
reason. When calling variants in a comparative setting those artefacts are easily removed
simply because they appear everywhere and one of the most basic filters applied in compara-
tive sequencing analysis is for the absence of a tumour variant in thematching control. When
performing single sample variant calling those artefacts are harder to spot. They can be fil-
tered out by requiring support for variants to occur on both strands and annotating potential
variant positions with the observed mismatch frequency of the variant in the rest of the co-
hort if there are more samples available. In certain situations, e.g. when one is looking for
commonalities between a number of samples, the analysis is particularly vulnerable to such
artefacts and it is always advisable to visualise the variants in order to spot problems.
4.7 Summary
In this section I have introduced the h5vc R/Bioconductor package, outlined the chal-
lenges researchers face when handling and analysing large amounts of HTS data and illus-
trated how the usage of h5vc and nucleotide tallies stored in HDF5 files can be used to adress
those challenges. It is important to note that h5vc is essentially a framework that provides in-
frastructure to allow researchers to handle, analyse and (visually) explore large HTS data sets,
which are challenging to handle with the current default suite of file types. It is not designed
as a variant caller, a copy number analysis tool or a solution for any other specialised task one
might encounter during the analysis of HTS data, instead h5vc provides access to a highly
portable, accessible and compressed representation of the HTS data (i.e. the nucleotide tallies
stored in HDF5 files) and comes with functionality that enables the research community to
quickly implement and test new ideas and algorithms on the data. An example of this is the
implemented variant calling functionality, which is simply a collection of pure R functions
which could be written by researchers with limited programming knowledge. In a standalone
application one needs to implement a substantial amount of bureaucracy code, e.g. parsing
read alignments from BAM files, collating the information into a nucleotide tally representa-
tion and subsequent calling of likely variant positions, using h5vc andnucleotide tallies stored
in HDF5 files we can omit the first two steps completely and instead focus on the scientifically
interesting question of how to determine the positions of potential variants.
In the cancer sequencing projects that I am involved in (see next Section) this infrastruc-
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Figure 4.5: Example mismatch plots of a region of the genome with strong strand specific artefacts
that can be found in a set of unrelated control samples (marked by vertical dashed lines). Note also the
general noisiness of the region with a multitude of pileups of mismatches constituting low-frequency
variants or artefacts.
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ture has greatly improved my ability to provide solid analyses and meaningful reports when
dealing with up to 21 samples at the same time. Colleagues in the group use the software on
cohorts of up to 188 samples and I have heard reports fromusers of h5vc that work on cohorts
with more than 300 samples.
Usage statistics for my package are shown in the table below, which contains information
about themonthly number of downloads of h5vc as collected by the Bioconductorwebpage.
Since it was first introduced in the October release of Bioconductor in 2013 the number of
downloads has stabilised around 200 per month.
Month Year Number of distinct IPs Number of downloads
Sep 2013 0 0
Oct 2013 100 157
Nov 2013 129 172
Dec 2013 126 262
Jan 2014 115 174
Feb 2014 121 168
Mar 2014 186 297
Apr 2014 198 378
May 2014 201 422
Jun 2014 269 401
Jul 2014 230 326
Aug 2014 224 346
Total 1376 2930
Table 4.5: Table of the total number of downloads as well as total number of distinct IP address from
which h5vc was downloaded stratified by month. Note that the number of distinct IP address is the
better estimate for the size of the user-base, since it compensates for people that re-download the
package multiple times, e.g. because of an update. This data was taken from http://bioconductor.
org/packages/stats/bioc/h5vc.html on the 3rd of September 2014.
5 Comparative cancer sequencing projects
In this section of my thesis I will provide an overview of the comparative cancer sequenc-
ing projects I am involved in. All of the projects in this section are dealing with cohorts of
paired samples fromcancers andmatched controlwhoseDNAhas been sequencedusingwhole
exomeorWGS technology on Illuminamachines. The challenges I facedwhen I started towork
on those projects promptedme to implement the HDF5 based nucleotide tally framework pro-
vided by h5vc which I described in the previous section.
I will focus on three cancer sequencing projects, of which two projects are related to can-
cer as a side effect of gene therapy and use samples from the same set of patients. Both of
these projects are collaborations with the group of Manfred Schmidt at the National Center
for Tumour Disease in Heidelberg. The third project aims to investigate the genomic makeup
of acute myeloid leukaemia samples sequenced with WES technology and is a collaboration
with the group of Prof. Dr. Anthony Ho from the Universitätsklinikum Heidelberg.
5.1 Cancer as a side effect of retroviral gene therapy ofWiskott-Aldrich
Syndrome
5.1.1 Introduction
Wiskott-Aldrich syndrome (WAS) is an X-linked, complex primary immunodeficiency dis-
order that is caused by a lack of expression of functional product of the WAS gene located at
X:48,534,985-48,549,818 on the forward strand. This disease leads to multiple dysfunc-
tions in parts of the blood system, including defective T and B cell function, disturbed for-
mation of the natural killer cell immunological synapse and impaired migratory responses of
all leukocyte subsets. The symptoms experienced by affected patients include recurrent in-
fections, thrombocytopenia, eczema, autoimmunity and an increased risk of lymphoma. In
severe cases infections and haemorrhaging can lead to an early death and for those cases the
standard therapy is allogeneic haematopoietic stem cell (HSC) transplantation. This kind of
treatment carries a substantial morbidity and mortality risk, especially in cases where no hu-
man leukocyte antigen (HLA)-matched HSC donor is available.
An alternative therapeutic strategy for primary immunodeficiency diseases such as WAS,
is HSC gene therapy (Kay, 2011). With this approach, clinical benefits and corrected function of
immune cells have been shown in several studies, e.g. on patients with X-linked severe com-
bined immunodeficiency disease (c-SCID), adenosine deaminase (ADA)-deficient SCID and
chronic granulomatous disease. In this context there is always a risk that the location of the
vector integrations in the genome can influence gene expression. Both silencing as well as
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induced over-expression occur. If tumour-suppressors or oncogenes are affected the devel-
opment of leukaemia is a possible side-effect of the treatment. For each separate treated cell
the risk of creating such effects is relatively low, but the risk for the patient is substantially
increased by the creation of many millions of modified cells in the course of the treatment.
Our collaborators have performed a study into the feasibility of HSC gene therapy for treat-
ment of WAS on a total of 10 patients (aged between 2 and 14 years). Preliminary results for 2
of those patients have been published (Boztug et al., 2010). A substantial number of patients
developed some form of leukaemia at a later time.
The aim of my work in this project was the genomic characterisation of pairs of matched
tumour and control samples from the patients of this study that had developed leukemia as a
side-effect of the HSC gene therapy applied to treat their WAS. Initially there were 3 patients
that developed T-Cell acute lymphoblastic leukaemias (T-ALLs) and this number has increased
to 6 (out of 10) during the time that I worked on this project. The common factor in those T-
ALLss was that the dominant clone could be determined to carry a vector integration in or
close to the LMO2 oncogene. Furthermore, three patients developed acute myeloid leukaemia
(AML), two of which did so after their initial T-ALL had been treated (the third patient did not
develop a T-ALL previously). Those AMLs were induced by vector integration in or near MDS1
and MN1, respectively.
All patients in this study were closely monitored and therefore control samples and early
time-points of leukaemia are available andhavebeen sequenced (seeTable 5.1 for anoverview).
All samples were sequenced from peripheral blood. In Tables 5.2 I give an overview of the 10
patients involved in the study. This includes the patient ID, their age at the time of gene
therapy as well as the causative mutation to their development of WAS. The columns listing
number of infused cells as well as the estimated average number of vector integrations per cell
are important, since a higher vector-load leads to more integrations and therefore also more
possibilities for adverse effects. Note the difference in the number of days post gene therapy
that the leukaemias were diagnosed (last column). This ranged from 488 to 1812 days post
gene therapy. One of the key questions we were trying to answer was whether there exists a
set of second hits in those leukemias, i.e. if there are specific genetic events necessary that
have to occur in addition to the vector integration, for the cell to become cancerous. This
question arose from the observation of the markedly different timespans until diagnosis of
leukaemia after gene therapy, hinting at a possible second event that has to occur.
For both patient 1 and 7 we performed additional sequencing runs because of insufficient
data quality in the sequencing data of the initial runs. In further analyses I disregarded those
initial samples, with labels WAS1PrimaryDNAFirst, WAS1ControlDNAFirst, WAS7PrimaryDNA and
WAS7ControlDNA. Unless I specify otherwise all statements regarding samples from those pa-
tients are made with respect to the second set of sequencing runs we performed on them. I
explain the reasoning behind requesting additional sequencing runs for patient 7 in Section
5.3.1.2.
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Patient ID Sample ID Library Disease
WAS1 primary tumour WGS T-ALL (LMO2 induced)
WAS1 primary tumour (re-sequencing) WGS T-ALL (LMO2 induced)
WAS1 pre-gene-therapy sample WGS -
WAS1 pre-gene-therapy sample (re-sequencing) WGS -
WAS1 primary tumour WES AML (MN1 induced)
WAS1 pre-gene-therapy samples WES -
WAS5 primary tumour WGS T-ALL (LMO2 induced)
WAS5 relapse tumour WGS T-ALL (LMO2 induced)
WAS5 pre-gene-therapy sample WGS -
WAS6 primary tumour WGS T-ALL (LMO2 induced)
WAS6 pre-gene-therapy sample WGS -
WAS7 primary tumour WGS T-ALL (LMO2 induced)
WAS7 primary tumour (re-sequencing) WGS T-ALL (LMO2 induced)
WAS7 pre-gene-therapy sample WGS -
WAS7 pre-gene-therapy sample (re-sequencing) WGS -
WAS8 primary tumour WGS T-ALL (LMO2 induced)
WAS8 pre-gene-therapy sample WGS -
WAS8 pre-leukaemia / post-gene-therapy sample WGS -
WAS8 primary tumour WES AML (MDS1 induced)
WAS8 pre-gene-therapy samples WES -
WAS9 primary tumour WGS AML (MDS1 induced)
WAS9 pre-gene-therapy samples WGS -
WAS9 primary tumour WES AML (MDS1 induced)
WAS9 pre-gene-therapy samples WES -
Table 5.1: Overview of the sequenced samples in the cancer cohorts relating to the WAS HSC gene
therapy study. The Library column contains abbreviations for WGS and WES. Some samples had to be
re-sequenced due to quality issues.
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Patient Nr Age (at
GT)
WAS muta-
tion
Infused
CD34+
cells
per kg
(106)
Vector
copies
per cell
Clinical Status post gene ther-
apy
1 3 IVS6+1 G>T 18.6 2.4 T-ALL (day 1813), AML during
maintenance therapy
2 3 Arg86His 13.5 2.7 Well
3 3 Glu133Lys 2.9 3.0 Well, status post haploid-
identical haematopoietic stem
cell transplantation (HSCT)
4 4 Arg34X 24.9 3.2 Well
5 12 Glu31Lys 17.9 5.2 T-ALL (day 1073), relapse
shortly after allogeneic HSCT
and death
6 4 IVS8+1_4
delGAGT
20.6 3.0 T-ALL (day 488), nowwell and in
remission after allogeneicHSCT,
but lost to further follow up
7 3 IVS3+1 G>T 13.5 2.7 T-ALL (day 1105), in remission
after allogeneic HSCT
8 3 Ala134Thr 20.9 1.7 T-ALL (day 792), AML during
maintenance therapy
9 2 Val303fsX4 21.1 2.3 AML (day 1165), in remission af-
ter allogeneic HSCT
10 14 His30del 9.7 3.5 Weak vasculitis and residual
proctitis
Table 5.2: Overview of the 10 patients that were part of the original study into gene therapy as a
treatment for WAS. The original (WAS causative) mutations are shown as well as the number of cells
used in for the gene therapy, the average number of vector copies per cell and the clinical status after
gene therapy. Note that the number of vector copies per cell differ quite a lot between the different
patients.
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Patient ID Sample time (days post gene therapy) Peripheral blasts at diagnosis (%)
WAS1 1813 56.5
WAS5 1073 63
WAS6 488 74
WAS7 1105 98
WAS8 792 91
WAS9 1165 20 – 30
Table 5.3: Table showing for each patient the percentage of leukaemic blasts in the peripheral blood
at the time of diagnosis of the initial leukaemia (given in the second column). This percentage can be
used as an estimate of the percentage of tumour cells in the sequenced samples and is therefore our
first approximation of the tumour purity in the sequencing samples.
Table 5.3 lists all samples that were sequenced with WGS technology and gives both the
timepost gene therapy that the leukaemiawas diagnosed aswell as thepercentage of leukaemic
blasts in the peripheral blood at the time of diagnosis.
In totaI I analysed the two cohorts corresponding to the 6 T-ALLswithmatched control and
additional samples (relapses as well as pre-leukaemic samples) and the 3 AMLs with matched
controls, relapse and pre-leukaemic samples.
5.1.2 Vector integration detection
5.1.2.1 Method
Detecting andmapping vector integration sites is an essential step towards understanding
the biology of the leukemias presented in this cohort. We used LAM-PCR (Schmidt et al., 2007)
to identify vector integration sites in the samples. Furthermore I developed an algorithm for
the identification of vector integration sites from WGS data at single nucleotide resolution
and implemented the solution using the HTSeq framework described in Section 2.
The detection of vector integrations relies on an alignment of the sequencing reads to a
compound genome containing the chromosomes of the human reference genome and an addi-
tional contig that contains the vector sequence itself. Using this approach, vector integration
site detection becomes a specialised case of translocation detection. Given that our dataset
was sequenced with a paired-end library, I could exploit the pair information to map the vec-
tor integration sites by searching for pairs of mapped reads where one read mapped to the
vector contig and the other to one of the reference chromosomes (Figure 5.1).
After identification of the set of read pairs that indicate potential integration sites I per-
formed clustering of those pairs and annotated the clusters of read pairs with their mapping
interval (the spanning genomic interval that covers all reads assigned to a cluster) and support
(number of reads in the cluster). Figure 5.2 shows a typical cluster.
I implemented the algorithm for vector integration detection as a Python script that can
be downloaded from the Huber Group EMBL Servers1. The algorithm performs the following
1http://www-huber.embl.de/users/pyl/Tools/VectorIntegrationSiteDetection/vector.
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Figure 5.1: Overview of the typical pattern of read alignments around a vector integration site. (A)
Shows the target chromosome and the vector. (B) Shows the vector as it is integrated into the chromo-
some. Note the sticky ends at the integrations site. (C) Shows the way reads are sequenced from the
construct (colours of reads encode the respective pair) (D) Shows how the reads on the chromosome
side will align to the human reference genome at the integration site. Note how the clusters of reads
from each side of the vector overlap slightly because of the sticky end type cut that is used to facilitate
the integration.
Figure 5.2: Overview plot showing the reads of a typical cluster that indicates a vector integration
site at position 8:130653843. Reads are shown as dark grey blocks with a reference genome track in
between the reads mapping to the forward strand (reads plotted above the reference track) and the
reads mapping to the reverse strand (reads plotted below the reference track). The vertical grey lines
mark the overlap between the two clusters, which is the typical 4 base pairs caused by the usage of
sticky ends for the vector integration.
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steps on an input BAM file:
1. Iterate through the provided input BAM file and store all records that represent aligned
reads with an aligned mate where exactly one of the reads in the pair is mapped to the
vector (the extra contig we added to the genome)
2. for each pair of reads define a pair of genomic intervals representing the regions of the
genome where the reads are mapped
3. cluster the interval pairs by overlap, where two pairs of intervals are clustered together
if both intervals of each of the pairs overlap, i.e. they are likely to originate from the
same event. Note that we relax this requirement on the vector contig since it is repet-
itive and the reads mapping there will have two equally good alignments at either end
of the vector. Therefore overlap is only stringently required on the non-vector side of
the cluster.
4. find pairs of clusters that overlap on opposing strands which are indicative of a vector
integration event (see Figure 5.1) and report them
The two clusters that form around a vector integration site overlap by a number of bases,
which was typically 4 bases in our data-set. The reason behind this overlap is the way in
which the double strand break is created when the vector integrates since it uses sticky ends.
The actual number of observed overlapping bases can vary depending on sequencing depth,
i.e. it depends on whether we have enough reads to cover the breakpoint extensively. Such
variations can also be the effects of local sequence similarity, where the vector sequence that
is inserted and the normal progression of the chromosome (i.e. the sequence that is stored
in the reference genome) are identical for a couple of bases and therefore the reads can align
over the breakpoint.
I defined the properties that a pair of read-pair clusters have to exhibit in order to be a
good indicator of an integration event in the following way:
• each cluster has to be anchored on one end in the vector sequence and on the other end
in the reference genome
• the reference anchors of both clusters must overlap by a few basepairs (with the ex-
pected number being 4 bp) when disregarding the strand that they are mapped to
• the strands of the reference anchors the clusters must be different from each other (i.e.
one maps on the+ and one on the  strand)
integration.latest.py
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Figure 5.3: Overview plot showing the reads of an unmatched cluster that indicates a vector integra-
tion site overlapping an Alu element (AluSx1 - shown in light blue). Note the complete absence of reads
mapping to the reverse strand.
5.1.2.2 Results
The resulting list of identified vector integration events is shown in Table 5.4. In this table
we can see that all of the T-ALL samples carry a vector integration event close to or overlapping
with the LMO2 oncogene (highlighted in red in the table). Those events had been previously
detected by my collaborators by LAM-PCR. Furthermore it is apparent that the number of
vector integrations per clone varies between patients. This is likely the effect of different
virus loads in the initial treatment, i.e. the retroviral gene therapy. Interestingly for some
patients (1, 5, 6 and 7) the number of detected integration sites in the leukaemic clones as
shown in Table 5.4 does correlate with the estimated vector load during gene therapy shown
in Table 5.2 with a correlation of 0:89. Patients 8 and 9 do not show such correlation and have
an estimated vector load of 1:7 and 2:3 copies per cell at gene therapy, respectively, while their
leukaemic clones exhibit 5 and 8 different vector integrations. This is not unexpected though,
since the distribution of vectors amongst treated cells can fluctuate.
Note that there are specific cases where not all of the requirements for a reliable read-pair
cluster defined in the previous section can be fulfilled. An example is the clustermapping near
the LYL1 gene (lymphoblastic leukemia derived sequence 1; located on the reverse strand at
19:13,209,847-13,213,975) in the leukaemia sample of patient 8, which lacks support on
one side, however the very good signal on the other side prompted further investigation. To
be able to find such cases as well as cases where due to low coverage the support on one side
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of the cluster is weak or non-existent the tool I implemented can be configured to relax the
requirements for read-pair clusters. In the case of the vector integration site close to LYL1
I observed a single cluster of very good support on the forward strand but I could not find
a cluster to pair it with. The reason for this can be found by investigating annotated repet-
itive regions in the reference genome which tells us that the insertion point lies close to a
repetitive region in such a way that all reads originating upstream of the insertion site can be
mapped, whereas the reads originating from the insertion site and downstream of it fall fully
into the repetitive element and can therefore not be mapped properly. In this specific case we
are dealing with an Alu (i.e. repetitive) element of the short interspersed element (SINE) class
which lies in the interval 19:13,216,593-13,216,894 and is named AluSx1 as classified by
RepeatMasker (Smit et al., 2007). The forward-strand cluster ends at position 13,216,666 and
therefore overlaps slightly with AluSx1, but since the overlap is 73 bases and the reads are 101
bases long we still have those 38 bases as the front of the reads to anchor their alignments.
The corresponding cluster on the reverse strand would be starting at position 13,216,662
(accounting for the characteristic 4 bp overlap) and reads originating from this cluster will
fall completely into AluSx1 since it has length 302. As a consequence of this, the reads of the
reverse-strand cluster can not be reliably mapped to this region. Either they are not mapped
at all if the aligner was required to only report reads with unique alignments, or they can be
mapped on other copies of the repetitive element, thereby diluting or completely removing
the signal we were looking for. In our dataset multiple alignments were allowed and a post-
processing step removed alignments that were not called primary (the primary alignment of
a read has the best mapping score amongst all reported alignments). Note that the alignment
strategy I employed would not yield a primary alignment for reads that have more than one
optimally scoring alignment available to them, thus removing all reads whose best scoring
alignments map equally well in more than one region of the genome. Figure 5.3 illustrates the
break-point near LYL1 and shows the mapping of reads in that region.
In conclusion, I was able to faithfully detect vector integrations based on Illumina shotgun
sequencing data at single base-pair resolution and corroborate the findings of my collabora-
tors (LAM-PCR based vector integration detection).
5.1.2.3 Vector Integration detection from whole exome sequencing data
When attempting to run my tool on the AML samples that have only been sequenced with
whole exome libraries it became clear that in many cases we lack detection power simply
because most vector integrations do not in fact overlap with coding regions and we simply
do not get reads from those regions. For the 4 samples processed this way (primary AMLs
from patients 1, 8 and 9 as well as a relapse sample from patient 8) only the primary AML
sample of patient 8 contained clusters with at least two reads supports, though all of those
were unpaired (only one side was found). From those results I conclude that whole exome
sequencing data is not a good data source for calling vector integrations, since such data only
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Forward-strand cluster Reverse-strand cluster Common Properties
Chrom From To Support Chrom From To Support Distance Sample
8 80813647 80813794 7 8 80813791 80813972 11 -3 WAS1PrimaryDNAFirst
11 33934228 33934414 12 11 33934411 33934579 15 -3 WAS1PrimaryDNAFirst
X 53311089 53311255 9 X 53311250 53311414 14 -5 WAS1PrimaryDNAFirst
8 80813629 80813794 10 8 80813791 80813948 5 -3 WAS1PrimaryDNASecond
11 33934202 33934406 8 11 33934411 33934599 9 5 WAS1PrimaryDNASecond
X 53311029 53311255 8 X 53311250 53311396 3 -5 WAS1PrimaryDNASecond
1 47703242 47703445 12 1 47703442 47703632 14 -3 WAS5PrimaryDNA
1 208005333 208005617 12 1 208005613 208005809 9 -4 WAS5PrimaryDNA
6 37173972 37174143 14 6 37174140 37174343 11 -3 WAS5PrimaryDNA
10 17496754 17496929 11 10 17496937 17497128 10 8 WAS5PrimaryDNA
11 33945916 33946105 17 11 33946101 33946320 12 -4 WAS5PrimaryDNA
11 38177580 38177776 13 11 38177773 38177973 14 -3 WAS5PrimaryDNA
14 92997399 92997587 12 14 92997578 92997800 15 -9 WAS5PrimaryDNA
17 16299791 16299979 9 17 16299976 16300168 8 -3 WAS5PrimaryDNA
11 33946778 33946851 2 11 33946847 33946931 3 -4 WAS6PrimaryDNA
1 47695816 47696058 38 1 47696055 47696283 38 -3 WAS7PrimaryDNA
11 33915411 33915680 35 11 33915677 33915947 40 -3 WAS7PrimaryDNA
1 47695786 47696058 18 1 47696055 47696300 16 -3 WAS7PrimaryDNAReSeq
11 33915419 33915680 18 11 33915677 33915943 14 -3 WAS7PrimaryDNAReSeq
2 158288046 158288297 16 2 158288294 158288477 14 -3 WAS8PrimaryDNA
7 110779563 110779765 15 7 110779760 110779933 16 -5 WAS8PrimaryDNA
8 130653635 130653845 13 8 130653841 130654040 18 -4 WAS8PrimaryDNA
11 33904947 33905149 16 11 33905144 33905337 15 -5 WAS8PrimaryDNA
19 13216467 13216666 19 NA NA NA NA NA WAS8PrimaryDNA
2 8679211 8679493 12 2 8679489 8679748 8 -4 WAS9PrimaryDNA
2 16618975 16619237 12 2 16619233 16619488 20 -4 WAS9PrimaryDNA
3 13456935 13457178 16 3 13457174 13457384 13 -4 WAS9PrimaryDNA
3 169081857 169082080 13 3 169082075 169082297 13 -5 WAS9PrimaryDNA
7 21395410 21395598 10 7 21395594 21395776 4 -4 WAS9PrimaryDNA
12 46878057 46878328 11 12 46878325 46878547 15 -3 WAS9PrimaryDNA
22 28064024 28064248 17 22 28064244 28064437 11 -4 WAS9PrimaryDNA
22 32534505 32534737 17 22 32534750 32534974 7 13 WAS9PrimaryDNA
Table 5.4: Table listing the detected vector integration in all whole genome sequencing samples from
the WAS T-ALL and AML datasets. Note that WAS9PrimaryDNA is the only AML sample that was se-
quenced with WGS and therefore shows sufficient detection power for vector integrations. Each row
represents one cluster pair indicating a potential vector integration site. The columns shown for each
cluster are the chromosome (Chrom), the starting position (From), the end position (To) and the num-
ber of read pairs supporting the cluster (Support). Additionally the column ’Distance’ indicates the
number of base-pairs that lie in between the end of the forward-strand cluster and the beginning of
the reverse-strand cluster (negative values indicate overlap, which is the expected behaviour). Note
that there are clusters with positive distance, which means that those clusters do not actually overlap.
This can be the case if the local coverage is too low and we lack power to detect the exact breakpoint at
single base-pair resolution, i.e. we simply didn’t sequence a read overlapping the break-point exactly.
The last column indicates the sample that the vector integration was detected in. Cluster pairs located
close to or overlapping with the LMO2 oncogene (LIM domain only 2 – located on the reverse strand
of 11:33,880,122-33,913,836) are highlighted in light red and cluster pairs close to or overlap-
ping with the MDS1 oncogene (MECOMMDS1 and EVI1 complex locus – located in the reverse strand of
3:168,801,287-169,381,406) are highlighted in light blue. The cluster on chromosome 19 in sam-
pleWAS8PrimaryDNA is lacking a partner on the reverse strand because of a repetitive element nearby,
see Section 5.1.2.2 and Figure 5.3 for details.
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has power to detect anything in the 3% of the genome that are sequenced.
5.2 Data Processing Steps for Cancer Sequencing Data
Unless specified in the methods sections for the different projects all samples from all se-
quencing projectswere processed in the sameway up to the generation of theHDF5 nucleotide
tally files. Specifically I treated all WAS related samples as one cohort up until the point of
analysis, therefore both the T-ALL and AML samples were aligned, preprocessed and tallied
with the same commands. The data processing pipeline from raw reads in FASTQ format to
fully processed BAM file and HDF5-based nucleotide tally representation is outlined below.
5.2.1 Read alignment
The reads were aligned using the GSNAP read alignment software (Wu and Nacu, 2010)
version 2013-09-11 using the parameters described in Table 5.5. I left all other options at
their respective default settings.
Parameter Meaning
--nthreads=12 Threaded processing using 12 processes at the
same time
--batch=4 Using batchmode 4which instructs the aligner
to load the genome index into the computers
memory completely to improve speed; smaller
values lead to the genome index being loaded
from disk during usage which reducesmemory
consumption at the cost of increased runtime
--npaths=4 Maximum number of alignments to report for
each read
--quiet-if-excessive Do nor report any alignments for reads which
have more than --npaths valid alignments of
equal quality (in our case this restricts report-
ing to reads with no more than 4 equally well
mapping alignments)
-A sam Output the alignments in SAM format (Li et al.,
2009) instead of the default GSNAP format
Table 5.5: Table listing the parameters used for the alignment of paired-end reads in the cancer se-
quencing projects I have worked on.
The alignment was heavily parallelised using the ability of GSNAP to process FASTQ files
in parts to split each sequencing lane into ten parts which in turn used 12 sub-processes each
as described in Table 5.5. In this way the generation of raw read alignments is sped up sig-
nificantly (using a sufficiently powerful compute cluster; I used the EBI cluster for my calcu-
lations) at the expense of having to add additional post-processing steps for merging of the
output files. Since GSNAP only outputs SAM file format, which is text based and therefore un-
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suited for large data I used samtools to directly convert the outputs to the compressed binary
BAM file format.
5.2.2 Alignment post-processing
After the raw read alignments had been generated several post-processing steps were nec-
essary to prepare the alignments for analysis. Firstly the alignments of each sample (we had
generated 10 parts per lane in the raw alignment step) weremerged into a single file using the
MergeAndSort tool from the Picard2 toolbox for manipulation of SAM/BAM files, followed by
marking of duplicate alignments using the MarkDuplicates tool from the same toolbox. This
step is necessary since read alignment pairs with the exact same starting and end position are
likely to be PCR duplicates of the same fragment of DNA and we want to count each fragment
only once.
The next step is the realignment of reads around InDels which serves to reduce artefacts
when performing SNV calling. Those artefacts occur with reads that span InDels which have
more than one valid and equally scoring alignment. When the alignment program chooses
which possible alignment to report it is not aware of the alignments of any of the other reads
spanning the same InDel and the distribution of reads to those different possible alignments
is essentially random. Figure 5.4 illustrates the kind of artefact that can arise from read align-
ments like this. The InDel-realignment was performed using the Genome Analysis Toolkit
(GATK – McKenna et al. (2010); DePristo et al. (2011)) released by the Broad Institute (version
2.5-2-gf57256b). Specifically two tools were used to perform the InDel-realignment; the
RealignerTargetCreator and the IndelRealigner, both are part of the GATK. In a first
step I defined a set of genomic intervals in which realignment has to occur. This was done us-
ing the RealignerTargetCreator tool, which takes a set of BAM files as input and generates
a text file containing genomic intervals for realignment. Here it was important to use all BAM
files of the whole cohort as input to ensure that the realignment happens in all intervals and
samples. This allows for all samples to be compared to each other in the later analysis, i.e. I
wanted tomake sure that all samples will behave in the sameway around those InDels that the
RealignerTargetCreator has identified for realignment. If each sample is realigned sepa-
rately a situation can occur where there are two valid alignment states around an InDel and
the samples end up in the two different states, which can create artefacts that look like SNVs
as well.
In the second step I used the IndelRealigner tool to perform the actual realignment.
This tool iterates through the previously identified genomic intervals, loads all reads overlap-
ping each of them and aligns all reads together to make sure that eventual ambiguities are
resolved in the same way in all read alignments. To ensure comparability between all samples
I applied this tool to the whole cohort simultaneously so that all reads in all samples of the
cohort will be ensured to behave in the same way when spanning InDels that allow for multi-
2http://picard.sourceforge.net
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Figure 5.4: Example of a small deletion overlapping a SNV where there are two possible alignment
states over the region which each have the same score (1 mismatch and 3 deleted bases). When the
aligner assigns the state randomly for each read we will end up with what looks like two SNVs but can
actually be explained by using just one SNV.
ple equally well scoring alignment states. Note that this requirement could be relaxed to the
patient level (i.e. running the IndelRealigner on all samples from the same patient simulta-
neously) since the most likely scenario of sample comparisons in downstream analyses is that
of comparing different samples from the same patient with each other (e.g. a tumour and a
matched control sample). In larger cohorts of WGS samples (i.e. the WAS-ALL dataset) I used
the patient-level for indel realignment to reduce runtime. At this point the alignments were
fully preprocessed and ready to be used for genomics analysis.
5.2.3 Creating HDF5-based nucleotide tallies
I used the framework provided by h5vc for most of the subsequent analyses. I created
nucleotide tallies stored in HDF5 files using the functionality provided by h5vc, specifically
the batchTallies function which I implemented as part of h5vc to allow me to generate
HDF5 tally files quickly for large cohorts using the EBI compute cluster. This function splits
the genome into bins (1 megabase default size) and calculates the nucleotide tallies and aux-
iliary datasets (i.e. the datasets Counts, Coverages, Deletions and Reference) for each
sample in each bin. The calculations were performed in parallel by using the functionality
for interacting with high performance compute clusters that is provided by the BatchJobs
R/Bioconductor package. A master process handles the collection of computation results per
bin and sample and writes them to the respective HDF5 tally file. See Section 4.2 and Figure
4.2 for details about this process. It is important to note that the nucleotide tallies for theWAS
data were created with a version of h5vc that used slightly different functions than the most
recent version does. This only influences the time consumption of this step and the resulting
tallies are not different from the set created with the most current implementation.
After this introduction to the common steps in the analysis of cancer sequencing cohort,
I will now discuss methods and results for each project separately.
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5.3 Genomic characterization of childhood T-ALLs induced by LMO2
over-expression
I will now discuss my methods and findings in the analysis of the WAS T-ALL dataset, i.e.
the samples from patients that had developed LMO2-induced T-ALLs as a side effect of the HSC
gene therapy used as a treatment of their WAS. The samples are pairs of tumour and matched
controls that were sequenced with a whole genome approach. The aim of this study was to
characterise genomic events in the cancer samples as potential second hits (in addition the
LMO2 over-expression) in the progression towards leukaemia.
5.3.1 Methods
5.3.1.1 Copy number analysis
I performed a copy number analysis of the WGS data of the T-ALL samples. I used the
binnedCoverage function that I implemented as part of the h5vc package in conjunction
with the h5dapply function (see Section 4.4 for details) for the parallel computation of the
coverage in bins of size 10 kilobases. The binnedCoverage function returns a table that con-
tains for each sample the total number of aligned bases per bin and also calculates the number
of G or C bases in the reference sequence in that bin. This data I used to fit a dependency be-
tween coverage and GC-count of each bin, which is used to adjust for the influence of GC-count
on the coverage. It is important to perform this step to make the samples more comparable
for the downstream analysis to identify copy number changes. The algorithm I used here is
essentially identical to the approach I originally developed for use in the HeLa sequencing
project, see also Section 3.2.1 and Figure 3.1. I did not perform a mappability analysis for the
WAS cohort, since I did not expect such a step to improve the overall quality of the CN analy-
sis. The crucial points of the analysis are the calculation of coverage and GC-content in 10-kb
bins and the fitting of the relationship between coverage and GC-content. The fit is used to
estimate a correction factor to adjust for this bias in coverage which can be different from
sample to sample. The adjusted coverages of the samples should all exhibit the same basic
relationship between coverage and GC-count in the bins.
For a given sample s I define the coverage cs (where csi represents the coverage of the
i-th bin in sample s) and the GC-content gc (gci for the i-th bin). A local regression is fit
using the locfit.robust function proved by R, which implements a robust local regression
similar to the lowess method (Cleveland, 1981). Here a low-degree polynomial is fitted to a
neighbourhood of each point in the data where the influence of the neighbours is weighted
by their distance to the point the fit is being calculated for. Additionally the fit is made robust
by down-weighting neighbours of the point based on their distance to the fitted polynomial in
an iterative fashion. The result is the value of the fitted polynomial at each of the datapoints.
The fit f is performed on the relationship between cs and gc. I used the default parameters
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for the R function to perform the fit. The adjustment factor ai for the i-th bin is defined as
the ratio between the predicted coverage and a desired coverage dcs chosen by the user. Since
all downstream analysis of adjusted coverage values is always done by comparing the values
of different regions or different samples (when searching for gains and losses) it is in fact not
necessary to base the choice of desired coverage on the input data. I chose a desired coverage
of 50 since that roughly reflects the coverage that the sequencing experiments were aiming
for, although arbitrary other choices would be equally as valid. Another effect of choosing the
same fixed desired coverage for all samples is that the values become directly comparable and
library size effects are eliminated. This works well if the samples largely have the same copy
number, i.e. if they are mostly diploid. If one of the samples were largely triploid then the fit
(which detects the biggest population of datapoints) will still make sure the median adjusted
coverage is 50 but that would then correspond to the triploid state in the sample. I assumed
that the samples I analysed here were still mostly diploid and there should be no problems
with the approach.
The adjusted coverage ac is then given as acsi = csi ai and the effect of this adjustment is il-
lustrated in Figure 5.5 which shows the relationship between coverage and GC-count (number
of G or C bases within each 10KB bin) using a smoothed scatter plot.
A similar approach to GC-content correction is also implemented in the HMMCopy package,
which is available through Bioconductor (Lai et al., 2012).
5.3.1.2 GC-bias as quality control
Creating smoothed scatter plots of the relation between coverage and GC-content for all
samples can help with spotting problems that might not have been apparent in the preceding
quality control steps. A good example of this is the behaviour of the primary tumour sample
of patient 7 (labelled WAS7PrimaryDNA). In the smoothed scatter plot (shown in Panel (a) of
Figure 5.6) we can see a very strong correlation between coverage and GC-count of the bins
which is coupled with a noisiness of the data that leads to a complete lack of the features
typically associated with haploid regions in those plots, i.e. two parallel clouds of points cor-
responding to diploid and haploid regions, respectively. In this severe case the fitting and the
adjustment algorithm do not work and are unable to remove the GC-bias in the data. Based
on my observation of the noisiness and generally bad quality of the data, this specific sample
was sequenced a second time. The smoothed scatter plots of that sequencing run are shown
in Panel (b) of Figure 5.6. The re-sequencing of the sample fixed the problem to some extent
and did not exhibit such an extreme GC-bias as the initial sequencing run. However, it is still
a bit more noisy than other samples in the cohort.
Similar observations of noisiness in the initial sequencing runs of the samples frompatient
1 lead to the decision to re-sequence those samples as well.
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Figure 5.5: Smoothed scatter-plots illustrating the effect of adjusting the coverage for GC-bias. The
input data is shown on the left, the result of the adjustment on the right. Note that in the input data
the coverage is defined as total number of aligned bases in a bin of size 10KB leading to significantly
larger numbers. The adjustment is made with a target value of 50 which can essentially be chosen
freely. If it is chosen too low there might be issues with discretisation when comparing values between
samples or regions. Note that each of the plots shows two clouds of points, corresponding to the diploid
(autosomes) and haploid (allosome) regions of the genome. All samples in this cohort exhibit such
patterns since all patients are male.
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(a)
(b)
Figure 5.6: Smoothed scatter plots of the initial and re-sequencing run for the tumour sample of
patient 7. (a) Initial sequencing run with the left plot showing the raw data and the right plot showing
the adjusted data. (b) Plots for the re-sequencing of the sample. Note the extreme GC-bias in the
raw data of the initial sequencing run, which can not be adjusted for through the applied algorithm.
The re-sequencing alleviates the problems slightly, allowing for a better removal of GC-bias while still
remaining slightly more noisy than other samples in the cohort (compare Figure 5.5)
74 Comparative cancer sequencing projects
5.3.1.3 Calculation of log2-ratios between paired samples
The next step was the calculation of the log2-ratios of adjusted coverages in the 10kb bins
for each pair of samples. This was performed for all pairs of case and control samples, e.g. for
patient 5 the two pairs primary vs. control and relapse vs. control were analysed (see Table
5.1). The log2-ratios were used to estimate gains and losses in the case samples relative to
their matched controls. For this purpose the log2-ratio (rct) of adjusted coverages of two sam-
ples c (the control sample) and t (the tumour sample) is calculated according to the following
formula:
rcti = log2(ac
t
i
acci
)
where rcti is the log2-ratio of adjusted coverages of samples c and t in the i-th bin and acti
is the adjusted coverage of sample t in the i-th bin. To compensate for differences in library
size rct is centered on 0 by subtraction of the median of rct from the ratios of all the bins.
When using a fixed desired coverage for all samples as I did, this step is not necessary, since
the median of the log2-ratios should be 0 anyway.
rct = rct   ~rct
The resulting track of GC-adjusted log2-ratios was segmented using the DNAcopy pack-
age in the same way as I implemented for the HeLa genome project (see Section 3.2.1). The
adjusted coverage data was first smoothed using the smooth.CNA function provided by the
DNAcopy package, which implements outlier detection and smoothing using circular binary
segmentation (CBS; Olshen et al. (2004)). TheDNAcopypackagewas originally developed in the
microarray era and works on probe intensities from e.g. tiling arrays (Mockler et al. (2005)).
The algorithmic approach itself is not dependent on the data source and therefore coverage
estimates from aligned reads per bin can be easily substituted as inputs. Figure 5.7 shows the
log2-ratios for chromosome 6 of three sample-pairs from the cohort. We can see a large (po-
tentially polyclonal) deletion in the tumour sample of patient 6 and the difference between
the initial and re-sequencing of the tumour sample of patient 7 which does not carry large
structural aberrations on this chromosome.
When performing a copy number analysis it is important to consider potential contami-
nation of the tumour sample with control material as well as the possibility of a polyclonal
population of cells in the cancer sample. Table 5.3 lists the tumour purity for the samples in
this cohort as determined prior to sequencing.
5.3.1.4 Comparative SNV calling
I called somatic SNVs in the samples from the WAS T-ALL cohort on the HDF5-based nu-
cleotide tallies I created for this cohort. I used the callVariantsPaired function to perform
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Figure 5.7: Overview plot of chromosome 6 showing the log2-ratios of GC-adjusted coverages in 10kilobase bins for 3 sample pairs from the WAS T-ALL cohort. The x-axis shows the genomic position
and the y-axis the log2-ratio where a value of e.g.  1 corresponds to a reduction of coverage by 50%, i.ea loss of one copy of the respective chromosomal region. The three panels are labeled with the sample
identifiers of their respective tumour sample. The top panel (labeledWAS6PrimaryDNA) shows the log2-ratio of tumour and control of patient 6, where a large deletion is present at a frequency of  50% in
the tumour sample. The two lower panels serve to illustrate the effect of the extreme GC-bias observed
in the initial sequencing run of patient 7 (see also Figure 5.6). The results of the copy number analysis
of this cohort are discussed in detail in Section 5.3.2.1.
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somatic variant calling on tumour-normal pairs. See Section 4.6.3 for a description of the
variant calling algorithm. I used the default settings for the variant caller, which require the
following properties for a position to be called a variants:
Sample Property Limits Description
Case Coverage (c) 5  c  200 Total number of reads overlapping the position
Case Support (s) s  2 Number of reads supporting the alternative allele
Control Coverage (c) 5  c  200 Total number of reads overlapping the position
Control Support (s) s = 0 Number of reads supporting the alternative allele
Note that these requirements need to be fulfilled on both strands separately. The default
values make sure that a variant has at least 2 reads supporting it on each strand of the tumour
sample (the Case sample) and no supporting reads in the matched control sample. Further-
more I limit the range of coverages in which to attempt calling to have at least 5 reads on each
strand so we have enough power to even detect a variant and no more than 200 reads per
strand to exclude repetitive regions such as pseudogenes or transposons. The upper limit on
the coverage serves to reduce the number of artefacts caused by reads from a similar but not
exactly equal genomic region being falsely mapped (with a fewmismatches) to a homologous
region of their origin. This can happen if the alignment program is ill-equipped to deal with
sequence homology or if the reference sequence actually does not contain the homologous
region.
I generated a set of raw somatic variant calls for each pair of samples using the function
and parameters described above. I implemented the calling with the use of the BatchJobs R
package to heavily parallelise the computations on a compute cluster, using one compute node
permega-base and effectively running 3000 processes at the same time. This parallelisation
allows for the genome-wide calling of somatic variants in thewhole cohort in only a fewhours.
The rawvariant callswere thenfilteredmore stringently to extract a set of high-confidence
calls and further limited to such variants that were predicted to overlap with coding regions
and therefore constitute non-synonymous coding SNVs. I used the Ensembl Variant Effect
Predictor (EVP) tool (McLaren et al., 2010) to make those predictions.
5.3.1.5 Single Sample Variant Calling
I used the callVariantsSingle function from h5vc on the HDF5-based nucleotide tallies
of the WAS T-ALL cohort to create a set of single sample variant calls. I configured the variant
calling function to require at least 6 reads supporting a variant (at least 3 on each strand) as
well as a minimum allelic frequency of more than 15% to generate a first (raw) set of single
sample variant calls. From this raw set of SNV calls I created a filtered set of variant calls,
requiring an allelic frequency of at least 20% and a coverage of at least 20 reads. This filtered
call-set was used in further analyses of the single sample variant calls.
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Figure 5.8: Histogramof the observed allelic frequencies in single sample variant calls fromall samples
in the cohort. The cut-off for defining a variant as homozygous was chosen at 80% (vertical black line).
Note that one cannot simply define homozygous variants by their allelic frequency being 100% since
the purity of the tumour sample can not be guaranteed (see also Table 5.3).
5.3.1.6 Allele frequency profile analysis
In order to detect regions of abnormal copy number as well as CN-neutral structural vari-
ants that cause LoH I profiled the distributions of observable allelic frequencies in bins along
the genome. I performed single sample variant calling on all the samples in the cohort using
relatively stringent filters to avoid noise (i.e. low-frequency artefacts and sequencing errors)
to influence the signal. I required an allelic frequency of at least 20% and a coverage of at least
20 reads for a position to be considered a variant (see Section 5.3.1.5). I visualised the variant
calls by plotting the observed allele frequencies along the genome by subsampling the variant
calls down to 1 call per ten kilo-bases to reduce plot density (i.e to avoid over-plotting) and
improve performance of the plotting function. This allowed for visual inspection for large re-
gions of interest. I also developed a classifier analogous to the LoH classifier used in the HeLa
genome sequencing project, by first defining all variants with allelic frequencies larger than
80% as potentially homozygous (informed by the distribution of allelic frequencies, see Figure
5.8) and then calculating the proportion of potentially homozygous variant calls over all vari-
ant calls permega-base along the genome. Since all patients aremale I focused this analysis on
the autosomes only. I used the segmentation algorithm for LoH data provided by the DNAcopy
package to define a segmentation of those 1 mega-base bins according to the percentage of
homozygous calls. The histogram of the mean percentages of homozygous calls per segment
is shown in Figure 5.9 and a cut-off for defining a segment as mostly homozygous is derived
from this histogram. I defined any segment with a mean percentage of homozygous calls
larger than 60% to be a homozygous segment. Based in this classifier I could detect homozy-
gous regions at a resolution of 1mega-base in the cohort. This helped to identify copy-number
neutral LoH events.
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Figure 5.9: Histogram of the percentage of homozygous variant calls per 1 mega-base bin along the
genome. Data is shown pooled from all samples in the cohort. Guided by this histogram a cut-off for
defining mostly homozygous regions was chosen at 60% (dashed black vertical line).
5.3.2 Results
5.3.2.1 Results of copy number analysis
The copynumber analysis (Section 5.3.1.1)was performed onbins of size 10 kilobases along
the genome for all samples thatwere analysedwithwhole genome sequencing. After adjusting
the coverage for GC-bias I calculated pairwise log2-ratios for all pairs of samples (tumour and
matched control) and segmented this signal using DNAcopy (R/Bioconductor package). The
sample pairs will always be identified by the sample identifier of the tumour sample, since for
some patients multiple tumour samples were compared to the same control sample, e.g. in
patient 5 I compared primary tumour and relapse tumour each with the same control sample.
Figure 5.10 shows histogram of the mean log2-ratios of the segments for all tumour sam-
ples. We can see for both cases where re-sequencing was done, how the signal was more noisy
in the initial sequencing run, much more so in the initial sample of patient 7 than patient 1
(labeled asWAS1PrimaryDNAFirst).
I observed large structural variants in this cohort which were present in samples from
multiple patients. One of those is a gain on the long arm of chromosome 17 in the samples
of patient 1 and 5, which is shown in Figure 5.11. This copy number gain on chromosome 17
has been previously described, e.g. in Strefford et al. (2007) and can therefore be considered
a typical event in T-ALLs and not a specific symptom of the vector-integrations caused by the
retroviral gene therapy that the patients were treated with.
5.3.2.2 Comparative SNV calling – Results
In total I called 270829 raw SNV calls with the somatic variant calling approach described
Section 5.3.1.4. After filtering out variant calls with allelic frequencies smaller than 10%a total
of 89608 variants remained, that were distributed among the tumour samples. An overview
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Figure 5.10: Histograms of the segmentations of log2-ratios in all samples from the WAS cohort thatwere sequenced with WGS. (Note that WAS9PrimaryDNA is an AML sample, while all others are T-ALL
samples). The x-axis shows the mean log2-ratios of the segments and the y-axis the total amount ofbases on the genomewith that log2-ratio. It is apparent that the initial sequencing runs of both patient7 (WAS7PrimaryDNA) and patient 1 (WAS1PrimaryDNAFirst) are much more noisy than their respective
re-sequencings (WAS7PrimaryDNA_ReSeq and WAS1PrimaryDNASecond). Apart from this noisiness in the
initial sequencing runs of low-quality most samples seem rather quiet and do not show extreme copy
number aberrations (compared to e.g. the HeLa data shown in Figure 3.5)
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Figure 5.11: Overview plot of chromosome 17 showing the segmented log2-ratios of the tumour sam-ples of patient 1 and 5 (primary tumour and relapse sample). Genomic position is shown on the x-axis
and log2-ratios on the y-axis. Black dots represent 10kb bins and red lines show the segmentationof those bins according to their log2-ratios. The primary and relapse tumour sample of patient 5 areshown in the two top panels and the primary tumour sample of patient 1 is shown below. Note the
common gain of one copy of the long arm of chromosome 17. The different purities of the tumour
samples lead to different values for the segmentation which are slightly smaller than the expected
log2(3/2) = 0:58. Given the observed purity of the tumour samples (56% for patient 1 and 63% for pa-tient 5 – see Table 5.3) the expected values for heterozygous events can be calculated and are shown as
grey horizontal lines in the plots. In patient 1 the observed segment very closely follows this expected
value whereas in the primary tumour of patient 5 the signal is more noisy and generally a bit higher.
This can be the result of imprecise measurements of peripheral blast percentage or an effect of the
noise. Additionally it seems that the gain is polyclonal in the relapse sample of patient 5 which could
be explained by the gain being present in the primary tumour sample and the relapse sample being
composed of a small fraction of resistant primary tumour cells and a larger fraction of a new clone.
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Sample Raw Filtered Coding
WAS1PrimaryDNAFirst 89807 21363 126
WAS1PrimaryDNASecond 45655 14456 58
WAS5PrimaryDNA 23677 7108 30
WAS5RelapseDNA 5289 3726 9
WAS6PrimaryDNA 34628 17091 48
WAS7PrimaryDNA 17174 7285 25
WAS7PrimaryDNA_ReSeq 23523 6462 24
WAS8PreLeukemiaDNA 5896 4205 20
WAS8PrimaryDNA 25180 7912 42
270829 89608 382
Table 5.6: Table showing the number of somatic SNVs called in the T-ALL samples from the WAS
cohort. The raw, filtered (AF 10%) as well as coding SNV call counts are shown. Note that this table
includes the initial (low quality) sequencing runs of patients 1 and 7.
of the distribution of somatic SNV calls among the samples is shown in Table 5.6. For further
analysis I excluded the initial sequencing runs of the tumour samples from patients 1 and 7,
further reducing the total number of variant calls to 163848 raw and 60960 filtered variant
calls, respectively. After filtering and exclusion of initial (low quality) sequencing runs a total
of 231 coding somatic variants were left.
To answer the question of possible second hits after the initial vector integration and sub-
sequent over-expression of LMO2 I focused on early events in the analysis of the SNV calls.
To this end I filtered the variant calls further to exclude events with less than 30% allelic fre-
quency. A total of 59 coding somatic variants with sufficiently high allelic frequency to be
likely early events and therefore likely driver mutations of the respective cancer samples re-
mained after this filtering step. Amongst the genes affected by those 59 variant calls where
FBXW7 (Park et al., 2009), PTEN and LEF1, which have been implicated in the context of cancer
development or progression. I will discuss these findings in more detail in Section 5.3.3.1.
5.3.2.3 Single Sample Variant Calling – Results
After the filtering of the raw variant calls a total of  40 million positions remained (ex-
cluding the initial sequencing runs of samples from patients 1 and 7).
This set of variant calls was generated to enable the analysis of profiles of allelic frequen-
cies along the genome. I did not investigate the single variant calls separately, but rather used
them to make high-level predictions about shifts in the distributions of observable allelic fre-
quencies in genomic regions. Such shifts occur as a side effect of structural variants and can
helpwith the identification of structural variants, especiallywhen they are copy-number neu-
tral and would not be detected by analysis of e.g. the log2-ratios of coverages between tumour
and control samples.
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Sample Homozygous Regions (Mb)
WAS1PrimaryDNAFirst 27
WAS1PrimaryDNASecond 27
WAS5ControlDNA 180
WAS5PrimaryDNA 218
WAS5RelapseDNA 172
WAS6ControlDNA 7
WAS6PrimaryDNA 7
WAS8PrimaryDNA 35
Table 5.7: Table showing for those samples that have at least one bin (of size 1mega-base) classified as
homozygous the total length of homozygous regions in mega-bases. Note that for the tumour sample
of patient 1 two entries exist because this sample was sequenced twice. The common LoH event on
chromosome 9 has an approximate length between 27 (patient 1) and 35 (patient 8) mega-bases. Note
that all samples of patient 5 show a remarkably high number of homozygous regions, indicating that
this patients germ-line genome is homozygous in regions of about 180mega-bases length.
5.3.2.4 Allele frequency profile analysis – Results
Analysis of the patterns of observable allelic frequencies revealed a common copy-number
neutral LoH event on the short arm of chromosome 9 in the primary tumour samples of pa-
tients 1, 5 and 8. The segmented log2-ratios of Chromosome 9 do not show indications of large
structural aberrations on that chromosome and are shown in Figure 5.14. The common LoH
event is visualised in Figure 5.15 where I plot the observed allelic frequencies of single nu-
cleotide variant calls in the tumour samples of patients 1, 5, 6, 7, 8 and 9. The results of the
binary classifier applied to bins of size 1 mega-base is shown in Figure 5.12, where I plot the
percentage of homozygous calls for each of the bins on chromosome 9 as well as an overlay
of the segmentation into homozygous and heterozygous regions. Table 5.7 shows the total
length of genomic regions that were classified as homozygous for sample where at least one
bin was classified as homozygous (samples not present in this table have no large homozy-
gous regions). It is apparent that patient 5 has large homozygous regions present on chro-
mosome 9 in his germ-line sample; whether this fact influenced the progression of his cancer
is unknown (Figures 5.15 and 5.12). The copy-number neutral LoH event on the short arm of
chromosome 9 however has been described previously (Takeuchi et al., 1997), as well as the
homozygous deletion at 9p21 in the tumour sample of patient 8, visualised in panel (b) of Fig-
ure 5.14). The fact that Takeuchi et al. described those events at 57% and 43% prevalence,
respectively, indicates that those features of our cohort are typical aberrations in childhood
acute lymphoblastic leukaemia and likely not linked to the fact that the T-ALLs we analysed
were caused by vector integrations from retroviral gene therapy. Although a number of large
homozygous regions are apparent throughout the genome of the control sample of patient 5,
the LoH on the short arm of chromosome 9 is specific to the tumour sample of this patient
and likely unrelated to the presence of those germ-line homozygous regions.
Through visual inspection of the observed allelic frequencies of called variants I could also
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Figure 5.12: Overviewof percentage of homozygous variant calls on chromosome 9 for cancer samples
from patients 1, 5, 6, 7 and 8 as well as the control sample of patient 5. The x-axis is the genomic
position and the y-axis is the percentage of homozygous calls. The dots represent the 1Mb bins along
the chromosome and the lines show their segmentation. The colour encodes the classification into
heterozygous and homozygous regions and the size of dots shows the number of variant calls in that
bin and serves as ameasure of the confidencewe canhave in the classifier. Note the commonLoHon the
short arm of chromosome 9 shared between the primary tumour samples of patients 1, 5 and 8. Three
samples are shown from patient 5 and it is clear that the LoH is only present in the primary tumour
sample but not in the relapse tumour or the control. Furthermore, large regions of homozygousity are
apparent near the end of the chromosome in all samples from patient 5, including the control sample.
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Figure 5.13: Overview plot showing the GC-adjusted coverages of the control and tumour sample of
patient 6 in the top two panels. The third panel shows the log2-ratio and segmentation of those twosamples. The region shown lies on the short arm of chromosome 16. A germ-line duplication event
spanning from around 15 up to 18mega-bases is apparent in the top two panels. In the log2-ratio plotas well as the coverage of the tumour sample two somatic deletion events located some mega-bases
up- and down-stream of the duplicated region can be seen. The log2-ratio overlapping the duplicationevent does not show the event, however. Note that the ratios and segmentation are a bit offset from 0
(the expected value). This is likely due to noise in the data, since the samples of patient 6were amongst
the more noisy ones in this cohort (see also Figure 5.10).
detect a germ-line duplication of about 5 kilo-base size on chromosome 16 in patient 6. This
event was also not apparent from the log2-ratio plots, since the duplication is already present
in the control sample. Figure 5.13 shows the log2-ratio as well as the GC-count adjusted cover-
age vectors for the control and tumour sample of that patient which indicate the duplication
event.
The set of aberrations I could detect by analysis of allelic frequency distributions illustrates
well the usefulness of this approach, since some of those events are silent in the coverage
tracks, e.g. the copy number neutral LoH could not be detected by absolute coverage or log2-
ratio of coverages. Furthermore the essentially comparative approach to analysis of cancer
genomes fails to detect germ-line events. The analysis of log2-ratios of coverages between
tumour samples and their matched controls as well as the analysis of SNVs based on evidence
for their presence in the tumour and absence in the control samples can not spot such copy-
number neutral events as the LoH of chromosome 9p or the duplication on chromosome 16
of patient 6 (shown in Figure 5.13). Therefore the genome-level analysis of the distributions
of allelic frequencies and the GC-adjusted coverage for each sample can help to understand
large-scale events of this type. For the calling of SNVs however the comparative approach is
vastly superior, since the control samples provide a filter against biologically uninteresting
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SNVs as well as technical artefacts that occur in all samples independent of their biology.
5.3.3 Discussion
5.3.3.1 Comparative SNV calling – Discussion
When investigating the 59 filtered coding somatic variant calls I could not determine any
genes that were affected within more than one of the cancer samples that are relevant to the
cancer progression. The only gene mutated in at least two cancer samples is DUX4L5 (dou-
ble homeobox 4 like 5 [ Homo sapiens (human) ] – GeneID: 653545). This gene has not been
previously implicated in childhood leukaemia. Despite this I am convinced that this hit is not
relevant to the cancer since I have seen hits in multiple other genes of the same family (dou-
ble homeobox 4) in another set of cancer samples I analysed in a project which deals with
the analysis of multiple myeloma sequencing samples (not reported on in this thesis). Fur-
thermore, those two variants have relatively low support and coverage and are present in a
region of severe background noise (i.e. the DUX4L5 gene). A mismatch plot of the region in
question is shown in Figure 5.16, which makes it apparent that the region itself does not yield
reliable variant calls since the noise levels are very high (probably as a consequence of the
large number of homologous genes in the DUX family).
Amongst the remaining somatic variants that are likely early events there are some that
affect genes that have been strongly implicated in cancer, such as FBXW7 (Park et al., 2009),
PTEN and LEF1. When relaxing the requirement for allelic frequency to allow for lower fre-
quency variants (i.e. at least 10%) we can furthermore pick up TMP53, TP53RK, PTPN11 and
NOTCH1 (Park et al., 2009). However, those variants are not likely drivers due to their low
allelic frequency.
5.3.3.2 Conclusion
The general picture in this cohort is one of an unspecific cancer-like behaviour of the sam-
ples without any clear hints at a common second event that occurred after the initial hit (i.e.
the vector integration). This second hit was speculated since the time-frames are so vastly
different between the patients (between 488 and 1813 days post gene therapy – Table 5.3) and
no patient developed their leukaemia straight after gene therapy.
The only common events I could identify were the LoH on the short arm of chromosome
9 (Figure 5.14) and the duplication of the long arm of chromosome 17 (Figure 5.11), while no
commonly mutated positions, commonly mutated genes or even commonly mutated path-
ways could be detected with the set of high-frequency coding somatic variants. While the
common large structural aberrations are typical of childhood leukaemia and have been previ-
ously described (Strefford et al., 2007; Takeuchi et al., 1997), I do not believe them to be related
to the induced LMO2 over-expression that is a common factor between the T-ALLs analysed in
this cohort.
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(a)
(b)
Figure 5.14: Overview of log2-ratios for tumours with LoH events on chromosome 9. (a) Overview oflog2-ratios for all samples affected by the LoH event on chromosome 9. Note that none of the samplesshow indications of copy number changes (except for a small region in the tumour sample of patient
8). The sample from patient 1 is more noisy than e.g. the samples of patients 5 and 8. (b) Tumour
sample of patient 8, showing a wider range of log2-ratios to illustrate a small deletion around 20 to 25mega-bases. Note that a log2-ratio of  3:5 (tumour / control) would indicate that the control samplehad about 10 times as many copies of that region as the tumour. Considering that this is an extremely
unlikely scenario it is clear that this segment is actually completely lost in the tumour sample and the
reads that we observe stem from contamination of the tumour sample with the control. This lines up
well with the expected tumour purity of 91% (see Table 5.3), since a mixture of 91% tumour with a
homozygous deletion and 9% diploid control sample would lead to a theoretical log2-ratio of  3:47,which is exactly what we observe here (log2(0:091:00) =  3:47).
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Figure 5.15: Plots showing observed allele frequencies in the tumour samples of patients from the
WAS T-ALL cohort. Chromosome 9 is shown with the genomic position on the x-axis and the observed
allelic frequency of single nucleotide variant calls on the y-axis. Each dot represents a variant call and
is colour coded by the alternative allele (A, C, G and T). In normal diploid human samples most variants
will fall either into a band around an allelic frequency of 0:5 or 1:0, representing the heterozygous
and homozygous case, respectively. The tumour sample of patient 7 (WAS7PrimaryDNA_ReSeq) is a good
example where the whole chromosome exhibits the typical pattern of a mixture of homozygous and
heterozygous variants. The tumour samples of patients 1, 5 and 8 show a common pattern of LoH on
the short arm of chromosome 9, where themiddle band (the one around 0:5 representing heterozygous
events) is absent. Note that the relapse sample of patient 5 does not show the common LoH, indicating
that this relapse is indeed from a different clone than the original tumour. However, we can identify
another large region that shows very fewhomozygous events in samples from this patient (downstream
of 125mega-bases). There are in fact multiple regions like this spread around the genome of patient 5
that can be detected in the germ-line sample as well.
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Figure 5.16: Mismatch plot of the region containing the two somatic variant calls overlapping the
DUX4L5 gene in the relapse sample of patient 5 and the primary tumour sample of patient 1, respec-
tively. The left panel shows the region around a somatic variant in the relapse sample of patient 5
located at position 190,999,052 on chromosome 4 and the right panel shows the region around a
variant in the tumour sample of patient 1 that is located at position 190,999,460 on the same chro-
mosome. All samples from both patients 1 and 5 are shown and the somatic variant calls are marked
with vertical dashed lines. In each panel the samples that are involved in the variant call are marked
with a light blue border. To illustrate the general nature of the regions in question a set of unrelated
control samples (from patients 7 and 8) are shown. It is apparent that the whole region is very active in
terms of mismatches. Furthermore the positions in which somatic variants are detected in the cancer
samples from patients 1 and 5 carry a lot of mismatched in the unrelated control samples of patients
7 and 8. Taking all those properties of the regions and variant positions into account leads me to the
conclusion that they are biologically not relevant and likely artefacts.
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5.4 Genomic characterization of childhood AMLs induced by MDS1 /
MN1 over-expression
I will now discussmymethods and findings in the analysis of theWAS AML dataset, i.e. the
samples from three patients that had developed MDS1 or MN1-induced AMLs as a side effect of
the HSC gene therapy used as a treatment of their WAS. Two of those AMLs were developed
after an initial LMO2-induced T-ALL had been treated. For one patient the AML was the first
leukaemia. The samples are pairs of tumour and matched controls that were sequenced with
a whole exome approach. Analogous to the analysis of the T-ALLs, the aim of this study was
to characterise genomic events in the cancer samples as potential second hits (in addition the
MN1 / MDS1 over-expression) in the progression towards leukaemia.
5.4.1 Methods
5.4.1.1 Copy number analysis
Since all AML samples except for the one from patient 9 were sequenced with WES I could
not use the same pipeline as I implemented for the copy number analysis in the T-ALL samples
of the WAS cohort. When dealing with WES data it is not possible to define fixed-size bins
along the genome and determine the coverage and GC-bias in this way (like the 10Kb bins I
used for the T-ALL samples; Section 5.3.1.1). This is because the read alignments will only fall
onto the coding regions of the genome. As a consequence of the alignments mapping only to
coding regions it is non-trivial to determine and adjust for a possible GC-bias in the coverage.
There are tools that attempt this and I have experimented with e.g. the exomeCopy package
(Love, 2013), but in general a relationship between coverage and GC-count is hard to establish
if the data-points stem from genomic intervals of varying sizes (i.e. the annotated exons in the
human reference genome). It is still possible to determine log2-ratios of coverage and since
all samples in this cohort were sequenced on the same flow-cell at the same time and using
the same library preparation it is a reasonable assumption that if a GC-bias exists, it will likely
affect all samples equally. For comparative analyses, like the detection of gains and losses
through log2-ratios of coverage, the GC-bias would then have a negligible effect.
Therefore, the copy number analysis of the AML samples sequenced with WES is based on
the coverage per annotated exon. I used the h5dapply and binnedCoverage functions since
h5dapply can work on a list of specific genomic intervals and the list of annotated exons can
be easily retrieved using R/Bioconductor through annotation packages. An example is the
TxDb.Hsapiens.UCSC.hg19.knownGene annotation package (Carlson, 2011). I computed
the log2-ratios for the tumour samples on the raw (unadjusted) coverages directly, followed
by segmentation with DNAcopy and visualisation as chromosome overview plots.
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5.4.1.2 Comparative SNV calling
I called somatic SNVs in the samples from WAS patients that developed AMLs using the
HDF5-based nucleotide tallies that I created for this cohort. I used the callVariantsPaired
function to perform somatic variant calling on tumour-normal pairs and the same set-up as for
the WAS T-ALL cohort as described in Section 5.3.1.4 The raw variant calls were then filtered
more stringently to extract a set of high-confidence calls and further limited to such variants
that were predicted to overlap with coding regions using EVP – (McLaren et al., 2010).
5.4.1.3 Homozygousity Classification
In order to detect abnormalities that could hint at copy-number neutral LoH events or
other irregularities, I applied the same classifier that I developed for the analysis of the WAS
T-ALL samples (described in Section 5.3.1.6) to the AML samples. In order to identify homozy-
gous regions on a mega-base scale I used the same cut-offs as for the T-ALL cohort.
5.4.2 Results
5.4.2.1 Copy number analysis
Since I could not adjust the WES-based coverages for GC-bias it was important to check
whether such a bias was evident in the log2-ratios. To this end I created smoothed scatter
plots of the relationship between the log2-ratios (per exon) of the AML samples (the tumour
samples compared to their respective controls) and the GC-content of the respective exons.
The plots are shown in Figure 5.17. It is apparent that indeed a tendency exists for those
samples to have higher (positive) log2-ratios in exons with higher GC-content. The effects
do not seem to be the same amongst the different sample pairs. Whether this effect is indeed
negligible is hard to estimate. Therefore, as an additional precautionwhen analysing the log2-
ratios, I chose to visualise for all exons the percentage of GC, in order to be able to detect copy
number aberrations that show suspicious patterns of GC-content in their affected exons.
The only samples showing large copy number aberrations were the primary and relapse
samples of patient 8. There are obvious large copy number variations on chromosomes 9 and
17 in those samples. Coincidentally those are the same chromosomes that carry recurrent
large aberrations in a number of the T-ALL tumour samples. Those recurrent events are de-
scribed in Sections 5.3.1.6 and 5.3.2.1 and the corresponding Figures 5.15 and 5.11. The large
aberrations in the AML samples are shown in Figures 5.18 and 5.19. I coloured the data ac-
cording to GC-content in the plots of the AML samples to see whether a correlation between
high GC and gain or between low GC and loss could be established. Such a correlation could
explain the pattern seen in Figure 5.17 that indicates a dependency between GC content and
log2-ratio of the exons.
When comparing the distribution of GC-percentage per exon of the affected regions visu-
alised in Figures 5.18 and 5.19 (i.e. on the short arms of chromosomes 9 and 17) I could not
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Sample Raw Filtered Coding
WAS1.AML 8751 1483 26
WAS8.AML 15911 1911 26
WAS8.AMLRelapse 5400 754 37
WAS9.AML 5127 729 33
WAS9PrimaryDNA 28394 11302 30
63483 16179 152
Table 5.8: Table showing the number of somatic SNVs called in the AML samples from theWAS cohort.
The raw, filtered (AF 10%) as well as coding SNV call counts are shown. Note that this table contains
two sequencing runs of the same biological samples (WAS9PrimaryDNA and WAS9.AML) and for further
analysis the latter one was used exclusively.
detect any biases towards higher GC-percentage in the region affected by a CN gain and lower
GC in the region affected by a CN loss. Therefore it appears that the GC-dependency of the
log2-ratios in samples from patient 8 is not just an effect of the large copy number variations
overlapping with particularly GC-rich or GC-poor regions of the genome, but rather a more
global effect that could be caused by different GC dependencies in the tumour and the control
sample.
5.4.2.2 Comparative SNV calling
In total I called 63483 raw SNV calls with the somatic variant calling approach described
in Section 5.4.1.2. After filtering out variant calls with allelic frequencies smaller than 10% a
total of 16179 variants remained. An overview of the distribution of somatic SNV calls among
the tumour samples is shown in Table 5.8. Note that the sample WAS9PrimaryDNA is a WGS
sample of the same biological material as the sample labelled WAS9.AML. The number of cod-
ing variants in both is very similar – 30 and 33, respectively. Since I am limitingmy analysis of
somatic variants to coding variants the sample labelled WAS9PrimaryDNA was excluded from
further analyses and I limited my analysis to the AML samples sequenced with WES. Those
samples are all processed on the same flow-cell of the sequencing machine and should there-
fore have similar artefacts and mismatch profiles, allowing for easier comparative analyses.
After filtering and exclusion of initial (low quality) sequencing runs, a total of 122 coding so-
matic variants were left in the whole exome AML samples.
To detect likely early mutations (i.e. likely driver mutations) I limited the variant calls
further to those that were predicted to be non-synonymous and were present at an allelic
frequency of at least 30%, leaving 15 variant calls. Each sample contained between 2 and 5
of those 15 driver candidates. No genes were found to be mutated in more than one of the
tumour samples (not even between the primary and relapse AMLs of patient 8).
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Figure 5.17: Smoothed scatter plots of the relationship between log2-ratios and GC-content (per exon)of sample pairs in the WAS AML cohort. The x-axis shows the percent GC bases per exon and the y-axis
shows the observed log2-ratios in the exons. The majority of the data lies around a log2-ratio of 0indicating that the copy number of most exons is unaffected in the cancer. It is important to note that
in some sample pairs (notably the initial AML of patient 8) a clear dependency of the log2-ratio on theGC-content can be observed.
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Figure 5.18: Overview plot of chromosome 9 showing the log2-ratios of AML samples sequenced withwhole exome sequencing technologies. The genomic position is shown on the x-axis and the log2-ratioon the y-axis. Dots represent exons (coloured by GC-content) and red lines show the segmentation of
those per-exon log2-ratios. This plot shows one of the few large-scale copy-number aberrations, whichis a gain on the short arm of chromosome 9 in the AML and relapse sample of patient 8. Seeing this
in contrast to the structure of this chromosome in the T-ALL samples of the same patient (panel (b) of
Figure 5.14) we can corroborate the observation that this AML is indeed based in a different clone than
the T-ALL, which is entirely expected, given that the location of the vector integrations in the AML
samples as determined by LAM-PCR are different than in the T-ALL sample from the same patient.
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Figure 5.19: Overview plot of chromosome 17 showing the log2-ratios of AML samples sequencedwithwhole exome sequencing technologies. The genomic position is shown on the x-axis and the log2-ratioon the y-axis. Dots represent exons (coloured by GC-content) and red lines show the segmentation
of those per-exon log2-ratios. This plot shows one of the few large-scale copy-number aberrations,which is a loss on the short arm of chromosome 17 in the AML and relapse sample of patient 8. The
same chromosome was affected by a recurrent gain on the long arm in the T-ALL cohort (Figure5.11).
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5.4.2.3 Homozygousity Classification
There weremega-base bins in the AML samples classified as homozygous, e.g. on the short
arm of chromosome 17 where a deletion was apparent in the primary AML sample of patient
8 (Figure 5.19). Apart from those regions overlapping deletion events (i.e. those that are ho-
mozygous because there is only one copy left) the segmentation algorithm did not yield any
large regions of homozygousity in the AML samples, in contrast to the copy-number-neutral
LoH on chromosome 9 and the large stretches of homozygous regions in samples from patient
5 as I have described in the T-ALL samples (Figure 5.15).
5.4.3 Discussion
5.4.3.1 Copy number analysis
The type of deletion affecting the short arm of chromosome 17 as observed in the primary
tumour and relapse sample of patient 8 is one of the more severe chromosomal abnormalities
that had been reported in AML (Battiwalla, 2014). The important tumour suppressor gene
TP53 is located in this region (17:7:57–-7:59Mb) and the deletion therefore constitutes a loss
of one copy of TP53 in the AML samples of this patient. Such a deletion is known to have
severe consequences when it happens in the germ-line (see Li-Fraumeni Syndrome – Li and
Fraumeni (1969)). As described by Battiwalla, such a cytogenetic aberration has a generally
poor outcome in AML and recurrence is observed in almost 50% of AMLs that were treated
with HSC transplantation. In light of this observation it is not surprising that the only AML
patient that had a relapse (patient 8) was the one in whose cancer samples a loss of one copy
of TP53 was found.
It should be noted that both CN events found in the tumour samples of patient 8 (Figures
5.18 and 5.19) seem to be present at high, but sub 100% frequency in the cells sequenced in the
sample. Whether this stems from subclonality of the tumour population or contamination of
the tumour sample with normal cells is hard to establish. If we assume no subclonality but
rather contamination, we can estimate the proportion of cells carrying the events in the pri-
mary AML sample at 67:5% and 74:5%, in the duplication on chromosome 9 and the deletion
on chromosome 17, respectively. For the relapse sample the estimated purities are 46:8% and
43:7% for each of those events. Although we cannot exclude subclonality playing a role, the
numbers support the theory that the primary AML sample has a tumour purity of about 70%
(67:5%   74:5%). In the relapse sample about 45% of cells carry the event. Whether or not
the remaining 55% of cells represent clonal populations of tumour cells or normal contami-
nation can not be easily tested with the available data. However, the numbers point towards
two aberrations being carried by the same population of tumour cells, since the estimated
percentages of affected cells are so similar between the two events.
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Sample Affected Genes
WAS1.AML ZSCAN10
WAS8.AML NRAS, IKZF1
WAS8.AMLRelapse NRAS, IKZF1
WAS9.AML TP53RK, HK2, CSMD3
Table 5.9: Table showing the genes affected by high frequency somatic mutations in AML samples
from WAS patients. Those genes can be considered driver candidates and some of them hint at an
obvious cancer background, e.g. NRAS and TP53RK.
5.4.3.2 Comparative SNV calling
After visual inspection of the mismatch plots of the 15 likely driver mutations I could ex-
clude some of thembased on noisiness of the region or presence of the variant in other control
samples, leaving a total of 11 likely early mutations distributed amongst the 4 AML samples
as shown in Table 5.9
Amongst those driver candidate mutations some affect genes with obvious connections to
cancer, like NRAS and TP53RK (TP53 Regulating Kinase), others are implicated in AML suscep-
tibility, like IKZF1 (Ross et al., 2013). These results verify that my variant calling approach
is working well, and I can reliably detect somatic coding mutation that are potential drivers
of cancer. In patient 1 the only remaining candidate mutation in the AML sample affects the
gene ZSCAN10 (Zinc Finger And SCAN Domain Containing 10), which encodes for a zink-finger
protein. I could not find literature describing mutations in this gene in the context of AML.
Whether this mutation is a novel driver of leukaemia or a passenger mutation of a different
event that can not be detected using WES, is hard to distinguish.
Similarly to the results of the WAS T-ALL analysis of coding somatic SNVs, I cannot point
out a single position, gene or pathway that is commonly affected between all the samples.
Therefore the hypothesis that a second hit in addition to the vector integrations in or near
MDS1 and MN1 occurred, can not be substantiated by the results of my analysis.
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5.5 Identification of metastasis drivers and predisposing mutations in
AML
5.5.1 Introduction
This project is a collaboration with the group of Prof. Dr. Anthony Ho from the Univer-
sitätsklinikum Heidelberg. It is based on the whole exome sequencing analysis of pairs of
AML and control samples from 10 patients and one auxiliary set of samples of breast cancer
and matched control from a relative of one of the patients. An overview of the samples in this
cohort is given in Table 5.10.
My objectives in working with this data were to establish a variant calling approach that
provides high-quality variant calls that can be reliably verified using PCR methods. Further-
more, my analysis was geared towards identifying somatic mutations that could be candidate
drivers for metastasis as well as pre-leukaemic mutations present in the germ-line samples
of patients. A third aspect was the search for likely predisposing mutations in the germ-line
samples of some of the AML patients. However, this part of the project is still ongoing and I
will not present results on it in this thesis.
Note that the patients with the IDs KM89, KM891 and KM892 are two brothers who both
developed an AML and their sister, who developed a breast cancer.
5.5.2 Methods
5.5.2.1 Sequencing
The sequencing library preparation was done by my collaborators according to the fol-
lowing protocol. The library preparation for capturing of selected DNA regions (Agilent Hu-
man All Exon 51Mb v4) was performed according to Agilent’s SureSelect protocol for Illumina
paired-end sequencing. In brief, 3:0g of genomic DNAwas sheared on a Covaris™ E220 instru-
ment. The fragment size (150-300 bp) and the quantity was confirmed with the Agilent 2100
Bioanalyzer 7500 chip. Fragmented DNA was end-repaired, adenylated and ligated to Agilent
indexing-specific paired-end adaptors. The DNA with adaptor-modified ends was PCR am-
plified (6 cycles, Herculase II fusion DNA polymerase) with SureSelect Primer and SureSelect
Pre-capture Reverse PCR primers, quality controlled on the DNA 7500 assay for the library size
range of 250 to 450 bp and hybridized for 24 hrs on 65 C (Applied Biosystems 2720 Thermal
Cycler). The hybridization mix was washed in the presence of magnetic beads (Dynabeads
MyOne Streptavidin T1, Life Technologies) and the eluate was PCR amplified (16 cycles) in
order to add the index tags using SureSelectXT Indexes for Illumina. The final library size
and concentration was determined on Agilent 2100 Bioanalyzer 7500 chip. Each library was
sequenced on an Illumina HiSeq 2000 platform following the manufacturer’s protocol, with
a paired end sequencing run of 2  76 bp to at least 70 mean coverage. Images from the
instrument were processed using the manufacturer’s software to generate FASTQ sequence
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Sample Patient Type Notes Molecular Biol-
ogy
KM103AML KM103 Case - FLT-3-ITD
KM103Control KM103 Control - -
KM115Control KM115 Control The samples from patient
KM115 were mis-labeled
(sample swap in
sequencing); see Section
5.5.3.2 for details
no screening per-
formed
KM115AML1 KM115 Case no screening per-
formed
KM115AML2 KM115 Case no screening per-
formed
KM80AML KM80 Case - FLT-3 ITD, NPM1
KM80Control KM80 Control - -
KM87AML KM87 Case - FLT-3-LM, NPM1
KM87Control KM87 Control - -
KM88AML KM88 Case - CBFb-MYH11
(inv16)
KM88Control KM88 Control - -
KM891AML KM891 Case AML sample of older brother no mutation
found
KM891Control KM891 Control control sample of older
brother
-
KM891PreAML KM891 Case pre-leukaemic sample of the
older brother
-
KM892Control KM892 Control control sample of sister -
KM892Primary KM892 Case breast cancer sample of sister no screening per-
formed
KM89AML KM89 Case AML sample of older brother no mutation
found
KM89Control KM89 Control control sample of younger
brother
-
KM89PreAML KM89 Case donated bone marrow sam-
ple from younger to older
brother
-
KM90AML KM90 Case - FLT-3 ITD
KM90Control KM90 Control - -
KM93AML KM93 Case - CEBPA
KM93Control KM93 Control - -
KM95AML KM95 Case - no mutation
found
KM95Control KM95 Control - -
Table 5.10: Tabular overview of the samples in the AML cohort from the collaboration with Prof. Dr.
Anthony Ho. Columns are in order: the sample ID, the patient ID the type of sample (Case or Control), a
short description and a list of mutations known from molecular biology analysis in the in-house anal-
ysis lab of our collaborators at the Universitätsklinikum Heidelberg.
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Parameter Meaning
--nthreads=12 Threaded processing using 12 processes at the
same time
--batch=4 Using batchmode 4which instructs the aligner
to load the genome index into the computers
memory completely to improve speed; smaller
values lead to the genome index being loaded
from disk during usage which reducesmemory
consumption at the cost of increased runtime
-A sam Output the alignments in SAM format (Li et al.,
2009) instead of the default GSNAP format
Table 5.11: Table listing the parameters used for the alignment of paired-end reads.
files.
5.5.2.2 Common AML Mutation Screening
The samples were subjected to PCR-based screening for typical AMLmutations by our col-
laborators at an external diagnostics lab. The results of this screening are shown in the last
column of Table 5.10.
5.5.2.3 Read alignment
The reads were aligned using the GSNAP read alignment software (Wu and Nacu, 2010)
version 2013-07-20 with the parameters described in Table 5.11. I left all other options at
their respective default settings.
The alignment was heavily parallelised using the ability of GSNAP to process FASTQ files
in parts to split each sequencing lane into ten parts which in turn used 12 sub-processes each
(Table 5.11). In this way the generation of raw read alignments is sped up significantly (us-
ing a sufficiently powerful compute cluster; I used the EBI cluster for my calculations) at the
expense of having to add additional post-processing steps for merging of the output files.
5.5.2.4 Alignment post-processing
The alignments were post-processed with the same pipeline as I implemented for the AML
and ALL samples from the WAS cohort. The details are described in Section 5.2.2
5.5.2.5 Creating HDF5-based Nucleotide Tallies
I created a set of HDF5-based nucleotide tallies from the alignment data of this cohort
using the same approach as for the WAS data (described in Section 5.2.3), with some modifi-
cations. In the WAS cohort I was dealing with a mixture of whole exome and whole genome
sequencing samples and decided to tally in 1 mega-base bins along the genome to keep the
pipeline simple. In this cohort there are only WES samples and therefore I ran the tallying
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functions on a set of genomic intervals representing the annotated genes in the human refer-
ence genome. I extracted those intervals from the TxDb.Hsapiens.UCSC.hg19.knownGene
R/Bioconductor annotation package using the genes function. This allowed for a faster cre-
ation of the tallies, since I only had to process 3%of the genome. I did not expect significant
loss of information since the WES library is designed to only yield reads overlapping coding
regions and I would not expect alignments that fall outside of coding regions to be reliable
data.
5.5.2.6 Copy number analysis
As described in Section 5.4.1.1, WES data is challenging to deal with when trying to ad-
just for GC-bias in the coverage and I therefore treated the AML samples in this cohort in the
same way as I treated the AML samples in the WAS cohort, i.e. not adjusting for GC count
and analysing copy number aberrations based on the log2-ratios of coverage per exon. I used
the h5dapply and binnedCoverage functions working on a list of specific genomic inter-
vals I retrieved from the same source as the intervals in which I created the tallies, i.e. the
TxDb.Hsapiens.UCSC.hg19.knownGene annotation package (Carlson, 2011). I computed
the log2-ratios for the tumour samples on the raw (unadjusted) coverages directly, followed
by segmentationwith DNAcopy and visualisation as chromosome overview plots. This process
was identical to the way I implemented the copy number analysis of the WAS AML samples
(Section 5.4.1.1).
5.5.2.7 Calling SNVs
For this cohort I created two sets of SNV calls to find both single sample and somatic vari-
ants. Somatic variantswere called using the callVariantsPaired function provided byh5vc
(see section 4.6.3 for a description of the variant calling algorithm). I used the same param-
eters to call somatic variants as in the WAS T-ALL cohort (described in Section 5.3.1.4). The
single sample variant calls were also obtained in the same way as for the WAS T-ALL cohort
and used for the purpose of identifying homozygous regions (see Sections 5.3.1.5 and 5.3.1.6).
5.5.2.8 Allelic frequency distribution analysis
In order to spot homozygous regions, I performed the same analysis as for the two WAS
cohorts (T-ALL and AML) where I ran a classifier on the track of percentage of homozygous
SNV calls per mega-base bin ( Sections 5.3.1.6 and 5.4.2.3). This helped with the identification
of copy-number neutral events, like LoH. In this way I could identify the copy number losses
which lead to single-copy states, since those regions are homozygous as well.
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5.5.2.9 PCR Validation of SNV calls
From the somatic variant calls I selected a high-confidence sub-set for PCR validation. The
variants were selected from the top of the list of calls, when sorted by both coverage and
allelic frequency. Each variant was manually checked for suspicious mismatch patterns in the
immediate surrounding region (i.e. mismatch plots were created and evaluated).
The PCR validations were performed by my collaborators. Forward and reverse primers
were designed mapping roughly 250 bp up- and down-stream of the variant to amplify a sec-
tion of the genome of approximately 500 bp length with the variant centered in it. One third
(8l) of the obtained 25l PCR product was tested in 1:7% agarose gel for the detection of the
amplification band. Based on the thickness of the band (which indicated successful amplifica-
tion) between 6 and 12l of PCR product was diluted with water to prepare 13:5l of diluted
PCR product to which 1:5l of forward primer was added. The well mixed 15l of diluted
PCR product and forward primer was then sent to an external service provider (Eurofins Ge-
nomics3) for direct PCR product sequencing. The result of the direct PCR product sequencing
was sent back by the company as chromatogramfiles in which the presence of the called SNVs
was manually checked.
5.5.2.10 Metastasis-driver detection in series of mouse xenografts
Our collaborators set up a series ofmouse xenograftswherein the primary tumour samples
of the patients in this cohort are transferred into immunocompromisedmice. This is followed
by a series of xenografts from the engrafted cells of one mouse into another mouse. Based
on the assumption that there is a genetic basis for the ability to metastasise or engraft in an
immunocompromisedmouse we can expect this process to exert a selective pressure on those
mutations that enable cells to engraft or improve their engraftment efficiency. After having
established the SNVcalling pipeline and the ability to verify the presence of SNVs throughPCR
the next step was to use targeted sequencing on those genes that carry somatic mutations (as
detected by my analysis pipeline) in order to generate profiles of the allelic frequencies of
the mutation in the time-series. This is ongoing work and the samples are currently being
sequenced. I expect the data to be available by the end of the year.
5.5.3 Results
5.5.3.1 Copy number analysis
As a quality control step before analysing the segmented log2-ratios of the AML samples
in this cohort I created smoothed scatter plots of the dependency between log2-ratios and
GC-content of the exons for each of the sample pairs I analysed. Figure 5.20 shows the plots,
that are of the same type as those I created for the WAS AML samples (Figure 5.17). Notably
there are a number of samples exhibiting unusual patterns which hint at severe problems
3http://www.eurofinsgenomics.eu/
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with data quality. Most of those samples are concentrated within the subset of samples that
come from the two brothers that both developed AMLs as well as the breast cancer sample
from their sister. We can see that we will have to consider the observed log2-ratios in the
sample pairs for KM891PreAML, KM89PreAML and KM891AML to be potentially unreliable and
we should take extra precautions when analysing them. This assertion is corroborated by
the histograms of observed log2-ratios shown in Figure 5.21, which show far more noisy and
spread-out log2-ratios for the samples in question, whenwe compare them to the distributions
observed in other samples from the same cohort. Essentially the only samples between the
three siblings showing log2-ratio to GC-content dependencies suitable for further analysis are
the AML sample of the younger brother (KM89AML) and the breast cancer sample from the
sister (KM892Primary) and I have therefore focused on those samples and disregarded the other
samples from this set of siblings.
It is not surprising that the AML sample of the older brother is unusable, since this sam-
ple was stored for 5 years before the sequencing and the noisy data indicates that the sample
apparently deteriorated during that time. We were not able to reconstruct a history of the
storage facility to check for problems like power outages that might have occurred during the
5 years and could have lead to thawing and accelerated degradation of the sample. Investigat-
ing the samples labelled KM891PreAML and KM89PreAML, which are actually one pre-leukaemic
sample and one sample that is taken from an initial bone marrow transplant performed be-
tween the younger and the older brother, we can see a clear dependency of log2-ratio to GC-
content. An explanation for this lies in the fact that a subset of the samples was sequenced
on a different flow-cell and lane than the rest of the cohort. Specifically both case and con-
trol samples from the sister (KM892) as well as the control sample from the younger brother
(KM89) and the pre-leukaemic sample from the older brother (KM891) were sequenced together
and separate from the rest. This means that in addition to any noise from the sample itself,
the comparisons of KM891AML and KM891Control can be affected by a difference in sequencing
chemistry leading to a difference in the way the coverage depends on the GC-content. Such a
difference will then of course also affect the log2-ratio (Figure 5.22).
Whenwe compare samples from the same flow cell, which therefore should have the same
dependency of coverage to GC-content, the usage of ratios removes this bias and the depen-
dency between log2-ratio and GC-content becomes essentially flat, as can be seen for e.g. sam-
ple KM89AML or KM87AML in Figure 5.20. Apart from the problematic samples discussed above,
all samples looked reasonable and were used for further analyses.
After segmenting the log2-ratios of all samples some large chromosomal aberrations be-
came apparent. Among those are such events that have been previously reported to play a role
in the occurrence or progression of AMLs. One such example is the occurrence of large dele-
tions or even the total loss of one copy of chromosome 7 (Figure 5.23). Such deletion events
have been shown to affect specifically the MLL3 gene (Histone-lysine N-methyltransferase
MLL3), which is a haploinsufficient tumour suppressor located on chromosome 7 in the region
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Figure 5.20: Smoothed scatter plots of the relationship between log2-ratios and GC-content (per exon)of sample pairs in the cohort. The x-axis shows the percent GC bases per exon and the y-axis shows
the observed log2-ratios in the exons. The majority of the data lies around a log2-ratio of 0 indicatingthat the copy number of most exons is unaffected. It is important to note that in some samples a clear
dependency between log2-ratio and GC-content can be established. Furthermore, some samples (e.g.KM115AML1, KM115AML2 and KM95AML) show a banding in the plot that hints at the presence of large
single-copy regions within the genomes of those samples, i.e. they are likely affected by large deletion
events. There are samples that show severe effects, such as KM891AML (very noisy) and KM891PreAML
(non-linear GC-dependency).
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Figure 5.21: Histograms illustrating the distributions of segmented log2-ratios in the samples fromthis cohort. Note how we can see indications of large deletions in the samples KM115AML1 and
KM115AML2 as well as KM95AML through peaks near a log2-ratio of  1, which correspond to losses ofone copy in a diploid region. We already saw indications of such events through banding observed in
the smoothed scatter plots shown in Figure 5.20. Furthermore a general noisiness is apparent in sam-
ples KM891PreAML and KM89PreAML, as was also apparent from the smoothed scatter plots shown in
Figure 5.20
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Figure 5.22: Smoothed scatter plots of the relationship between coverage and GC-content for samples
from the two brothers (Patients KM89 and KM891). The left plots are showing the case samples and the
right plots show their matched controls. Each pair of plots exhibits the same non-linear dependency
between log2-ratio and GC-content (see Figure 5.20, panels KM89PreAML and KM891PreAML). Lookingat the relationships between the coverage and the GC-content as shown here we can immediately see
how each case sample differs from their respective matched control sample in a similar way and both
controls and both case samples behave similarly. This explains why their respective log2-ratios showsimilar non-linear dependency on the GC-content as shown in Figure 5.20.
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Figure 5.23: Overview plot of chromosome 7 showing the log2-ratios and their segmentation for asubset of the samples (i.e. those with large deletions on chromosome 7). The genomic position is
shown on the x-axis and the log2-ratios are shown on the y-axis. The dots represent exons and arecoloured according to their respective GC-content to visualise eventual biases. Red lines represent the
segmentation of the log2-ratios. The genomic interval corresponding to MLL3 is marked with verticalgrey lines. Note how the deletion events in KM115AML1 and KM115AML2 lie upstream of MLL3, whereas
in the other samples a loss of one copy of MLL3 can be observed.
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7:151832010-152133090 (Chen et al., 2014), frequently leading to AML. Figure 5.23 shows an
overview of the region containing MLL3 in samples with deletions on chromosome 7. Here
we can see deletions overlapping MLL3 in samples KM95AML, KM89AML, KM891AML. The log2-
ratios of those events are exactly at or extremely close to 1, indicating that the events affect
all or most of the cells in the respective sample, i.e. they are early events in the tumour pro-
gression and therefore potential drivers of the cancer. In the two tumour samples of patient
KM115 there are large deletions upstream of the MLL3 locus. It seems that MLL3 is not affected
by those deletions directly. Furthermore, a close investigation of other copy number aberra-
tions in those samples revealed that those samples are affected by deletions events overlap-
ping the genes PURA and PURB (Homo sapiens purine-rich element binding protein A and B).
The locations of the genes are shown in the following table:
Gene Chromosome Start End
PURA 5 139493708 139499001
PURB 7 44915892 44924960
Interestingly the two samples in question (KM115AML1 andKM115AML2) showdeletion events
overlapping the location of both these genes as is illustrated in Figure 5.24. Those events are
at log2-ratios of around 1, indicating presence of the events in almost all cells in the samples,
i.e. they are likely early events and therefore potential drivers of the cancer. Simultaneous
deletion of both of these genes has been implicated in the development of AML as a progres-
sion of myelodysplastic syndrome (MDS) as reported by Lezon-Geyda et al..
5.5.3.2 Sample Swap in Patient KM115
Early in my analysis I discovered a sample swap in the cohort in the samples from patient
KM115, where there were a surprisingly high number of somatic variant calls (millions) while a
typical sample has a couple of hundred somatic variant calls at most. In addition to this SNV-
level evidence, the copy number analysis further substantiated the sample swap as illustrated
in Figure 5.25. The following table shows the original and fixed sample labels:
Old Label New Label
KM115Control KM115AML1
KM115Relapse KM115AML2
KM115AML KM115Control
Knowing that the original control and AML samples were swapped lead to my decision
to label the two AML samples simply KM115AML1 and KM115AML2 since it is not quite clear
whether even more mistakes were made and I did not feel confident to make a data-based
ordering of the AML samples into primary and relapse, respectively.
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(a)
(b)
Figure 5.24: Overviewplots showing the log2-ratios of exons (blue) and their segmentations (red lines)for the two samples KM115AML1 and KM115AML2 in the regions surrounding the PURA and PURB genes,
respectively. The genomic position is shown on the x-axis and the log2-ratio on the y-axis. Verticalgrey lines mark the respective start and end of the two genes. (a) region surrounding PURA; (b) region
surrounding PURB. Note how both genes are at a log2-ratio of  1 indicating loss in all (or almost) allcells in the samples, i.e. they are likely early events.
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Figure 5.25: Overview plot of chromosome 11 showing the log2-ratios observed with the fixed (i.e.new) sample labels. Genomic position is shown on the x-axis and log2-ratio of case and control sampleon the y-axis. The dots represent exons and are coloured according to their respective GC-content. Red
lines represent the segmentation of the log2-ratios of exons. This is the same type of plot as shown forthe WAS AML cohort in Figures 5.19 and 5.18. Given the obvious similarity between the behaviour of
the two AML samples (same pattern of gains and losses) it is apparent, that the labelling used here (i.e.
the new/fixed sample labelling) correctly identifies the control and cancer samples.
5.5.3.3 Variant Calling
I created a total of 3901 somatic variant calls of which 1065 had an allelic frequency larger
than 10%and 446had an allelic frequency higher than 20%. After filtering for variants that are
coding and non-synonymous, 144 variants with allelic frequency higher than 20% remained.
A per-tumour sample overview of the somatic variants is shown in Figure 5.26 and Table 5.12
shows the distribution of variants amongst the samples.
From the 144 somatic coding non-synonymous variant calls with allelic frequencies larger
than 20% we selected 33 somatic SNVs and one somatic small deletion to be validated by PCR
as well as one variant with only 18:5% allelic frequency. This was done to verify that the
variant calling pipeline works and that we could track those variants for the later analysis of
xenografts in series. The validation of a further 12 SNVs was delayed due to a lack of available
DNA from their corresponding samples and my collaborators are working to obtain the DNA
in order to verify those variants as well. Of the 34 variants that were already subjected to PCR
validation we could reliably detect 33 that were present at allelic frequencies between 20:5%
and 50:5%. One variant could not be confirmed, which was the variant with the lowest allelic
frequency of only 18:5%. This variant is located on chromosome 19 (19:55250979) and was
detected in the tumour sample of patient KM90. The mismatch plot showing the region for
both samples of the patient is given in Figure 5.27. From visual inspection the variant call
seems justified and it is likely that the relatively low allelic frequency is the reason for the
failed PCR validation, since the PCR protocols for variant detection have lower limits for the
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Figure 5.26: Overview plot of somatic coding variants in AML samples. The x-axis shows allelic fre-
quency and the y-axis shows the coverage. Each dot represents a variant call and is coloured black if
it passed the basic filters (AF > 20%) and grey otherwise. Circles represent synonymous mutations
and triangles represent non-synonymous mutations. The expected allelic frequency for a heterozy-
gous early event (50%) is marked with a dashed vertical line. Note that some samples do not carry
any variants that passed the filters (KM89AML) or do so at very low frequency (KM891PreAML). Sample
KM89AML carries only one coding mutation and it is a non-synonymous one. In principle we can group
the samples into active and non-active ones, based on how many variant calls are present. KM87AML
and KM88AML are examples of active samples with many variant calls, this points to a more instable
genome and the potential for sub-clonality, but could also be the effect of noise in the data. The samples
KM90AML, KM115AML1 and KM115AML2 are of the non-active variety and show relatively few variants.
Those samples are likely more stable and less likely to contain many sub-clones.
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Sample Raw Filtered (AF > 20%) Coding (AF > 20%)
KM80AML 20 4 0
KM87AML 96 73 34
KM88AML 42 27 10
KM89PreAML 92 21 1
KM89AML 21 5 0
KM891PreAML 1440 85 1
KM891AML 302 117 8
KM892Primary 1369 529 47
KM90AML 44 16 4
KM93AML 32 19 8
KM95AML 86 36 6
KM103AML 113 57 14
KM115AML1 41 21 6
KM115AML2 203 55 5
3901 1065 144
Table 5.12: Tabular overview of the distribution of variant calls among the samples. The second
column shows the number of raw variant calls, i.e. output of the variant calling function. The column
labelled Filtered shows howmany of those raw calls have allelic frequencies larger than 20% and the last
column shows how many of the filtered variants are actually coding (and non-synonymous).
detectable allele frequency in the range of 20%. However, my collaborators work on estab-
lishing protocols that should allow for the detection of variants with allelic frequencies as low
as 10%. This work is still ongoing.
To identify earlymutations thatmight be drivers of the cancer I further filtered the variant
calls to have allelic frequencies higher than 30% and be predicted to be deleterious by SIFT,
as obtained through the application of the EVP Software on the variant call set (Kumar et al.,
2009). This revealed mutations in typical cancer genes such as DNMT3A and NRAS.
Through annotation of the variant calls with overlapping previously reported variants
from dbSNP (Smigielski et al., 2000) and the Catalogue Of Somatic Mutations In Cancer (COS-
MIC) database (Forbes et al., 2011), I could further narrowdown the list of candidatemutations.
If a variant was overlapping with a dbSNP variant and had a significant population frequency
(more than 1%) I excluded it as a likely cancer driver mutation, since it is described as being
present in the general population at frequencies at which I would expect an obvious cancer
relation of the variant to have been detected already. Amongst the deleterious coding somatic
variant calls that I created for this cohort, I found 13 with associated dbSNP accession num-
bers, i.e. there is an annotated variant in dbSNP at the same position. Note that the EVP tool
only checks for overlap of position, not of alternative allele, when reporting existing variants
overlapping with the input set of calls. Therefore each variant overlapping a known site was
investigated separately because it might have a different and not previously described alter-
native allele at this position.
The COSMIC database contains curated variant calls from many different analyses of can-
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Figure 5.27: Somatic coding variant in the AML sample of patient KM90 overlapping the KIR2DL3 gene.
This SNV is called at an allelic frequency of 18:5% and was not detectable by PCR validation. However,
from the mismatch plot and local context it seems to be a good variant call.
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cer sequencing data. An overlap in COSMIC is indicative of a true cancer variant and the fre-
quency at which the variant was observed in different tissues and cancer types can be investi-
gated on the COSMIC webpage. It should be noted that sometimes a COSMIC variant overlaps
a variant call with matching alternative allele, but the COSMIC entry describes the variant in
a completely different tissue/tumour context. Although it can certainly happen, that can-
cer mutations occur in different cancer types (e.g. in genes like TP53), when the variant had
only been described in one or two experiments I still investigated the variant stringently for
any signs of the presence of an artefact. Looking into the overlap of my likely early events
(AF > 30%) with the COSMIC database, I found 4 mutations to overlap with positions that
have been previously reported to contain cancer mutations. The following table shows the
samples and affected genes:
Sample Gene ID
KM87AML ETV6 COSM158691
KM87AML DNMT3A COSM442676
KM103AML U2AF1 COSM1318797
KM115AML1 KRT77 COSM162063
Notably the mutations affecting DNMT3A, U2AF1 and ETV6 have been reported in as can-
cerous mutations in haematopoietic and lymphoid tissues (Ding et al. (2012) and Neumann
et al. (2013)) according to COSMIC. Moreover DNMT3Amutations are of particular interest be-
cause they have been implicated to exist in pre-leukaemic states at lower frequencies which
turn into fully developed leukaemias through the acquisition of additional driver mutations
(Corces-Zimmerman et al., 2014). In their paper Corces-Zimmerman et al. describe amodel for
AML progression inwhichHSCs acquire a subset of themutations that constitute themutation
profile of the fully developed AML. This acquisition of mutations occurs in a serial fashion and
somaticmutations in e.g. IDH2 or DNMT3A can spontaneously occur in single HSCs, which then
start to expand and acquire furthermutations, before the cell population transfers to a tumour
state. Notably it is possible that the pre-leukaemic HSCs remain a population in the patient
after the AML is fully developed. The pre-leukaemic HSCs are implicated to form a reservoir
for remission post-chemotherapy, in case some of them are able to survive the treatment. In
addition to this somatic mutation in DNMT3A I specifically searched for evidence of the pres-
ence of such pre-leukaemic mutations in the control samples of our patients, extending the
search range to both DNMT3A as well as IDH1 and IDH2 based on the information presented by
Corces-Zimmerman et al. (2014). I was able to identify pre-leukaemic mutations of DNMT3A in
the control samples of patients KM80, KM89 and KM90 (Table 5.13). Note that there are some
mutations in the control samples of patients KM115 and KM93, that look heterozygous in the
control samples and are therefore not likely to be pre-leukaemic mutation. They are proba-
bly normal population variants. In IDH2 I identified a variant (15:90631838 C->T) that was
present at 11% AF in the control sample of patient KM89 and 45% in the matched AML sample.
This profile of allelic frequency development fits the model proposed by Corces-Zimmerman
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Position Ref Alt Sample AF
25457242 C T KM80AML 0.38
25457242 C T KM80Control 0.21
25457242 C T KM87AML 0.51
25457242 C T KM89PreAML 0.01
25457242 C T KM90AML 0.50
25457242 C T KM90Control 0.05
25457242 C T KM95Control 0.02
25467448 C A KM89AML 0.94
25467448 C A KM89Control 0.19
25467448 C A KM89PreAML 0.02
25469502 C T KM115Control 0.57
25469502 C T KM115AML1 0.50
25469502 C T KM115AML2 0.41
25469502 C T KM90AML 0.01
25469502 C T KM93AML 0.49
25469502 C T KM93Control 0.48
Table 5.13: Tabular overview of DNMT3Amutations in AML andmatched control samples. The columns
show the genomic position (on chromosome 2), the reference allele, alternative allele, affected sample
and observed allelic frequency. Horizontal lines divide the table based on the location of the variant.
Mismatch plots of those variants are shown in Figure 5.32.
et al. very well and the variant is therefore a likely pre-leukaemic mutation of the type de-
scribed above.
5.5.3.4 Allelic frequency distribution analysis
The analysis of the distributions of allelic frequencies along the genome using the clas-
sifier described in Section 5.3.1.6 yielded evidence of the copy-number losses that were also
evident from the analysis of the log2-ratios. No patients with significant homozygous regions
in their control samples were identified, except for a small (less than 10 kilo-bases) region on
chromosome 17 in the control sample of patient KM80. Figure 5.28 illustrates the samples and
genomic regions that have been identified as homozygous in this cohort. Therewas significant
overlap between the regions classified as homozygous and regions in which the log2-ratios in-
dicated copy-number losses, i.e. the majority of homozygous regions were simple the result
of deletion events that remove one of the two alleles in the affected region completely.
In Figures 5.29, 5.30 and 5.31 I showa visualisation of the homozygousity classifier for chro-
mosomes containing homozygous regions alongside their log2-ratio plots. Here it is apparent
that the homozygous regions on chromosomes 5, 7 and 18 in the AML samples of patientKM115
are the results of deletion events leading to single copy regions which are then obviously ho-
mozygous (see Figure 5.29). In Figure 5.30 (showing data from the samples of patient KM89)
it is apparent that the homozygous region on chromosome 7 is the result of a deletion event
with a log2-ratio of  1, i.e. a deletion that affects almost all cancer cells and is therefore a
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Figure 5.28: Overview plot showing chromosomes 2, 4, 5, 7, 17 and 18 in horizontal panels and a
selection of samples that show large homozygous regions on those chromosomes in the vertical panels.
The plot is essentially a multi-chromosome version of Figure 5.12, where dots represent 1 mega-base
bins. The genomic position is shown on the x-axis and the percentage of homozygous variant calls
on the y-axis. Red dots and their respective red segmentations (shown as horizontal lines) indicate
homozygous region in the respective sample and chromosome.
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Figure 5.29: Plot showing homozygousity classifier results (top three panels) and log2-ratios (twolower panels) of samples from patient KM115. Genomic position is shown on the x-axis and the percent-
age of homozygous variants, and the log2-ratio of the matching tumour-normal comparison is shownon the y-axis in the respective tracks. Note how the homozygous regions (reg coloured segments in the
upper tracks), correspond to deletion events as identified by the log2-ratios dropping to around 1 inthe bottom panels. Here we show three chromosomes with large homozygous regions in the samples
of patient KM115. Those are caused by large deletion events on chromosomes 5 and 7 and a complete
loss of one copy of chromosome 18.
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Figure 5.30: Overview plot of a copy-number neutral LoH event on chromosome 2 in sample KM89AML
as well as a large deletion event on chromosome 7. Note also the large deletion near the end of chro-
mosome 2, which does not cause a homozygous region because it is only present in a subclone of the
population. The plot is of the same type as the one shown in Figure 5.29.
likely early event and potential driver of the cancer. The result of this deletion is a single-copy
region of the genome which is homoyzgous near the end of chromosome 7. On chromosome
2 a homozygous region corresponding to roughly the first 75mega-bases of the chromosome,
with no corresponding change in log2-ratio, can be observed. This is the typical pattern of
a copy-number neutral LoH event. Also note that the deletion near the end of chromosome
2 has no corresponding homozygous region, which is due to the fact that the event is only
present in about half of the sequenced cells (log2-ratio of   0:5) and the variant calling al-
gorithm (which works on the combined data of the bulk sequencing of all the cells) can not
detect homozygous events there. Figure 5.31 shows clear indications of a copy-number neu-
tral LoH event on the long arm of chromosome 4 that affects the AML sample of patient KM90.
5.5.4 Discussion
5.5.4.1 Causative mutations
Looking at the molecular biology results shown in the last column of Table 5.10 we can
conclude that amongst theAML samples a likely causativemutation has been found in patients
KM103, KM80, KM87, KM88, KM90 and KM93.
Amongst the AML samples in which a causative mutation could not be detected, deletions
on chromosomes 5 and 7 that overlap with the genes MLL3, PURA and PURB were found. Tak-
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Figure 5.31: Copy-number neutral LoH event on the long arm of chromosome 4 in sample KM90AML.
The plot is of the same type as the one shown in Figures 5.29 and 5.29.
ing into account the findings of Chen et al. and Lezon-Geyda et al. and the results shown in
Figures 5.23 and 5.24 it is apparent that those deletion events constitute likely causative mu-
tation for those AMLs. Furthermore, the events affecting MLL3, PURA and PURB are present in
themajority of sequenced cells and are therefore likely early events in the cancer progression.
Through this simple analysis of common AMLmutations by PCR and the identification of copy
number changes through the analysis of log2-ratioswe could identify for each of the AML sam-
ples a good candidate causative mutation, providing insights into the drivers of those AMLs.
This kind of analysis, if implemented as a clinical assay, can help inform treatment decisions
in newly admitted AML patients.
5.5.4.2 Pre-Leukaemic mutations in DNMT3A and IDH1/2
Prompted by previous reports by Corces-Zimmerman et al. I investigated the presence
of pre-leukaemic mutations in DNMT3A in the control samples of this cohort. Such muta-
tions can increase the ability for self-renewal and inhibit the differentiation of haematopoi-
etic stem cells. Such properties are beneficial to a prospective cancer cell and the acquisition
of a DNMT3A mutation can therefore be seen as a first step in the progression of a normal
haematopoietic stem cell on the path to a leukaemia. When a cell starts acquiring such muta-
tions this can lead to its clonal expansion which creates a population of pre-leukaemic stem
cells (pre-LSCs). The DNMT3A mutations in such populations will show up with less than 50%
allelic frequency in the control samples of the affected patients and will be present in the ma-
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jority of cancer cells since they are essential for the development of the cancer. An overview
of all DNMT3Amutations I found is shown in Table 5.13. Figure 5.32 showsmismatch plots of the
mutations I found to be present in the pre-leukaemic state in control samples of patients in the
cohort. In some cases one can observe the progression from a low frequency pre-leukaemic
state to a high-frequency cancer state representing a fully developed leukaemia with the mu-
tation present in the majority (if not all of the) cells.
There are some patients where the mutations exist in the AML samples but there is no
indication at all that they were present in the control sample at significant proportions. This
is the case in the samples from patients KM87 (Figure 5.32 and Table 5.13). Such behaviour is
not a problematic result, since it is entirely possible that the cancer cells acquired the DNMT3A
mutations and the other necessary driver mutations within a very short timeframe, and the
time spent in the pre-leukaemic state was therefore too short for the mutations to be observ-
able at significant proportions in the control sample. In principle the samemutations that are
beneficial for a cancer cell in the sequential progression model can also beneficial to a cancer
cell if they are acquired all at once.
For patientKM90 a very small amount of support (2 reads only) for a variant canbeobserved
on the AML sample. Given the extremely small allelic frequency of this mutation it stands to
reason, that it is not significantly involved in the development and progression of this specific
cancer.
In the samples of patient KM80 one can observe themutation at about 21% frequency in the
control and closer to 40% in the AML, representing a very typical example of the expansion of
a pre-leukaemicmutation. Here the 21% of cells in the control sample that carry themutation
are likely pre-LSCs of the leukaemia the patient developed later on.
In the AML sample of patient KM89 the pre-leukaemicmutation from the control is actually
present in a homouzygous state with allele frequency 94%
5.5.4.3 Copy-number neutral loss of heterozygousity events
Through the analysis of the allelic frequency distribution in single sample variant calls
combined with the copy-number analysis based on log2-ratios of coverage I could identify
copy-number neutral LoH events on chromosome 4 in sample KM90AML and chromosome 2
in sample KM89AML (Figures 5.31 and 5.30). Their importance to the development of the can-
cers remains unclear and one might speculate that if cancer-driving mutations were to exist
in the affected regions, then a copy-number neutral LoH event could eliminate the second
(healthy) copy of an affected gene and replace it with a mutated copy, making the locus ho-
mozygous for the mutated genotype. Such behaviour has been described previously in AMLs
with FLT3 internal tandem duplications, where the region containing FLT3 undergoes copy-
number neutral LoH which yields two mutated copies of FLT3, resulting in an unfavourable
clinical prognosis (Whitman et al., 2001). In our data we can see such an effect for the DNMT3A
mutation in patient KM89. DNMT3A overlapswith the copy-number-neutral LoH event on chro-
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(a) (b)
(c)
Figure 5.32: The DNMT3A mutations found as germ-line as well as somatic mutations in this cohort.
Mismatch plots are shown for the threemutated positions listed in 5.13 showing all samples of patients
that carry each mutation in at least one of their samples. (a) 2:25457242 C->T; (b) 2:25467448
C->A; (c) 2:25469502 C->T;
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mosome 2 in this patient, and the mutation 2:25467448 C -> A is observed in the control
sample at allelic frequency 19% and in the AML sample at 95%. In this case the LoH event has
made a pre-leukaemic mutation homozygous in the AML.
5.5.4.4 Tracking drivers of metastasis through mouse xenografts
The part of the project that deals with tracking the progression of allelic frequencies of
mutations through a series of xenografts is still ongoing and I expect arrival of the targeted
sequencing data for the xenograft series by the end of the year. So far I have established
a pipeline for somatic variant calling in the samples from this project and my collaborators
have established an accompanying PCR protocol to experimentally validate the somatic vari-
ant calls. We are therefore in a position where we can properly call and validate somatic vari-
ants once the data arrives.
Furthermore all the parts of the analysis pipeline to quickly generate allele frequency pro-
files for somatic variants in the time series of xenografts are in place. This will allow us to dis-
tinguish variants that convey selective advantages to the cancer cells in the xenograft setting,
which is a good model for the formation of metastases.
6 Conclusion
Duringmy time as a PhD student I haveworkedonvarious projects related to the analysis of
sequencing data. Usually this involved human samples of cancers and their matched controls.
I have encountered a number of shortcomings of the available software infrastructure when
dealing with larger datasets from sequencing multiple human samples and published some of
my attempts at improving the way such data is analysed in two papers describing the HTSeq
Python Module (Anders et al., 2014) and the h5vc R/Bioconductor package (Pyl et al., 2014).
I have also been a shared first author with Jonathan Landry on the HeLa Genome sequencing
project (Landry et al., 2013), which was one of the earlier sequencing projects I worked on. I
have developed methods for analysing large cohorts of cancer samples in an efficient and in-
tuitive way andmade those methods available through public open-source software packages
that can be easily used and vetted by the research community. I am committed to keeping
those software packages updated (specifically h5vc, which is part of the Bioconductor repos-
itory) and I was engaged in teaching their usage at the CSAMA1 conference 2014 in Brixen,
Italy. I am working on improving h5vc with every release cycle of R/Bioconductor (every 6
months). So far I have used the software for cohorts up to 198 samples of WES in 98 pairs
of human cancer samples and their respective controls. This work was a collaboration in a
project of my colleagueMałgorzata Oleś who is working on the analysis of this dataset. I know
of users of the h5vc package that are analysing up to 300 human whole exomes with it and in
the context of the Huber group’s involvement with the ICGC Pan-Cancer project I will test out
my software on an initial cohort of 50 tumour-normal sample pairs that have been sequenced
with WGS technology. Ultimately I am aiming at generating HDF5-based nucleotide tallies for
the complete Pan-Cancer dataset, whichwill encompass thousands of samples from the TCGA2
and ICGC3 projects.
In collaborations with groups at the National Center for Tumour Disease and the Univer-
sitätsklinikum Heidelberg I have worked on different cohorts of paired cancer samples, fo-
cussing on blood cancers (AMLs and T-ALLs). We have not published any of the results of
those projects yet, as some analyses are still ongoing. However, the results of my analysis so
far yielded a wealth of interesting biological findings, including, for example, the presence of
pre-leukaemic mutations in matched control samples of AMLs.
I am convinced, that my contributions to the set of available computational tools in the
field of cancer sequencing analysis will enable more researchers to analyse their data in a
more intuitive fashion. The advantages of using HDF5-based nucleotide tallies and h5vc will
1http://www-huber.embl.de/csama/index.html
2http://cancergenome.nih.gov/
3https://icgc.org/
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become even more apparent as the size of sequencing data-sets increases.
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